



## 2025 Prior Authorization (PA) Criteria

Certain drugs require prior authorization from ConnectiCare Medicare Advantage Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and provide information describing the use and administration of the drug so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for or click this [\[SEARCH\]](#) button and enter the name of your drug in the pop-up task pane.

# ACTEMRA

## Products Affected

- ACTEMRA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial - approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Orencia, Rinvoq or Xeljanz/XR (Note: if the patient does not meet this requirement, previous trial(s) with the following drugs will be counted towards meeting the try TWO requirement: Cimzia, infliximab, golimumab SC/IV, or a non-preferred adalimumab product will also count.). OR B) patient has heart failure or a previously treated lymphoproliferative disorder. PJIA, initial-approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, Orencia, Rinvoq, Xeljanz or a preferred adalimumab product. (Note: if the patient does not meet this requirement, a previous trial with the drug infliximab or a non-preferred adalimumab product will be counted towards meeting the try TWO requirement.), OR B) patient has heart failure or a previously treated lymphoproliferative disorder. Systemic-onset JIA, approve for patients who have tried one other systemic agent for SJIA (eg, a corticosteroid [oral, IV], a conventional synthetic DMARD [eg, MTX, leflunomide, sulfasalazine], Kineret (anakinra), or Ilaris (canakinumab for SC injection), or a 1-month trial of a nonsteroidal anti-inflammatory drug [NSAID]). Giant cell

PA Criteria	Criteria Details
	arteritis, initial-approve if the patient has tried one systemic corticosteroid. Cont tx, RA/PJIA/SJIA/GCA - approve if the pt had a response as determined by the prescriber. Cytokine release syndrome associated with chimeric antigen receptor (CAR) T-Cell therapy-approve. Please Note: preferred adalimumab products include Humira (NDCs starting with - 00074), Cyltezo, Yuflyma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ACTEMRA SQ

## Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS
- TYENNE AUTOINJECTOR
- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	Interstitial lung disease-18 years and older (initial and continuation)
<b>Prescriber Restrictions</b>	RA/GCA/PJIA/SJIA - Prescribed by or in consultation with a rheumatologist (initial therapy only). Lung disease-presc/consult-pulmonologist or rheum (initial and cont)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA) [A or B]: A) tried two of the following: Enbrel, preferred adalimumab product (see Example 1), Orencia, Rinvoq or Xeljanz/XR (Note: trials with the following will also count towards meeting the try two requirement: Cimzia, infliximab, golimumab SC/IV, non-preferred adalimumab product), or B) heart failure or a previously treated lymphoproliferative disorder.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A or B]: A) tried two of the following: Enbrel, Orencia, Rinvoq, Xeljanz, preferred adalimumab product. (Note: trials with infliximab or a non-preferred adalimumab product will also count towards meeting the try two requirement), or B) heart failure or a previously treated lymphoproliferative disorder.</p> <p>SYSTEMIC-ONSET JIA (SJIA) [one of A, B, or C]: A) tried one other systemic agent (e.g., corticosteroid [CS], conventional synthetic DMARD [e.g., MTX, leflunomide, sulfasalazine], or B) tried Kineret (anakinra) or Ilaris (canakinumab for SC injection), or C) one-month trial of an NSAID.</p> <p>GIANT CELL ARTERITIS: tried one systemic CS.</p> <p>INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (A and B): A) elevated acute phase reactants and B) diagnosis confirmed by high-resolution computed tomography.</p> <p>CONTINUATION THERAPY: ALL INDICATIONS: patient had a</p>

PA Criteria	Criteria Details
	response to therapy. Example 1: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ACTIMMUNE

---

## Products Affected

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## ACYCLOVIR (TOPICAL)

---

### Products Affected

- *acyclovir topical ointment*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ADALIMUMAB

## Products Affected

- CYLTEZO(CF) PEN
- CYLTEZO(CF) PEN CROHN'S-UC-HS
- CYLTEZO(CF) PEN PSORIASIS-UV
- CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML
- HUMIRA (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA PEN (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML
- HUMIRA(CF) PEN (PREFERRED NDCS STARTING WITH 00074)
- SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- HUMIRA(CF) PEN CROHNS-UC-HS (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN PEDIATRIC UC (PREFERRED NDCS STARTING WITH 00074)
- HUMIRA(CF) PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074)
- YUFLYMA(CF) AI CROHN'S-UC-HS
- YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another biologic DMARD or targeted synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried
<b>Age Restrictions</b>	Crohn's disease (CD), 6 or older (initial therapy only). Ulcerative colitis (UC), 5 or older (initial therapy only), PP-18 years and older (initial therapy only)
<b>Prescriber Restrictions</b>	Initial therapy only for all dx-RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist.UV-ophthalmologist



PA Criteria	Criteria Details
Coverage Duration	Approve through end of plan year
Other Criteria	<p>INITIAL THERAPY: CROHN'S DISEASE (CD) [one of A, B, C, or D]: A) tried or currently taking corticosteroid (CS) or CS is contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine [6-MP], methotrexate [MTX], certolizumab, infliximab, ustekinumab, vedolizumab), C) had ileocolonic resection, or D) enterocutaneous (perianal or abdominal) or rectovaginal fistulas.</p> <p>JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA (one of A, B, C, D, or E): A) tried one other systemic therapy (e.g., MTX, sulfasalazine, leflunomide, NSAID), B) tried a biologic (e.g., etanercept, abatacept, infliximab, anakinra, tocilizumab), C) will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide, D) patient has absolute contraindication to MTX, sulfasalazine, or leflunomide, or E) patient has aggressive disease.</p> <p>HIDRADENITIS SUPPURATIVA (HS): tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics, isotretinoin).</p> <p>PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of a biologic will also count) or B) contraindication to MTX.</p> <p>RHEUMATOID ARTHRITIS (RA): tried one conventional synthetic DMARD for at least 3 months (Note: a 3-month trial of a biologic will also count).</p> <p>ULCERATIVE COLITIS (A or B): A) tried a systemic therapy (e.g., 6-MP, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a CS) or B) has pouchitis and tried therapy with an antibiotic, probiotic, CS enema, or mesalamine (Rowasa) enema.</p> <p>CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.</p>
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## ADBRY

### Products Affected

- ADBRY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy (i.e., Dupixent, Cinqair, Fasenra, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical].
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	AD-12 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	Atopic Dermatitis-prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
<b>Coverage Duration</b>	Initial-Atopic Dermatitis-4 months, Continuation-1 year
<b>Other Criteria</b>	Atopic Dermatitis, initial-patient has atopic dermatitis involvement estimated to be greater than or equal to 10 percent of the body surface area and patient meets a and b: a. Patient has tried at least one medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroid AND b. Inadequate efficacy was demonstrated with the previously tried topical corticosteroid therapy. Continuation- Approve if the patient has been receiving Adbry for at least 4 months and patient has responded to therapy. Note: A patient who has received less than 4 months of therapy or who is restarting therapy with Adbry should be considered under initial therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ADEMPAS

---

### Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Phosphodiesterase Inhibitors Used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ADSTILADRIN

### Products Affected

- ADSTILADRIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a urologist or an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Muscle Invasive Bladder Cancer, approve initial therapy if the patient meets (A and B): A) patient has high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive disease, and B) the patient has carcinoma in situ (CIS) with or without high-grade papillary Ta/T1 tumors OR the patient has high-grade papillary Ta/T1 tumors without CIS. Non-Muscle Invasive Bladder Cancer, continuation of therapy - approve.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# AIMOVIG

## Products Affected

- AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination therapy with another cGRP inhibitor for migraine headache prevention
<b>Required Medical Information</b>	Diagnosis, number of migraine headaches per month
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) If pt is currently taking Aimovig, the pt has had significant clinical benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# AKEEGA

## Products Affected

- AKEEGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer- Approve if the patient meets the following (A, B, C, and D): A)Patient has metastatic castration-resistant prostate cancer, AND B)Patient has a BReast CAncer (BRCA) mutation, AND C)The medication is used in combination with prednisone, AND D)Patient meets one of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog, Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), and Orgovyx (relugolix tablets).OR ii. Patient has had a bilateral orchiectomy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ALDURAZYME

## Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic alpha-L-iduronidase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ALECENSA

### Products Affected

- ALECENSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Non-small cell lung cancer-approve if the patient has both (A and B): A) either (i or ii): i) medication is used as adjuvant treatment following tumor resection (note: for tumors greater than or equal to 4 cm or node positive) or ii) advanced or metastatic disease and B) anaplastic lymphoma kinase (ALK)-positive disease as detected by an approved test. Anaplastic large cell lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease and (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease.</p> <p>Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory Myofibroblastic Tumor- pt has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) pt has advanced, recurrent or metastatic disease, or (ii) tumor is inoperable. Large B-Cell Lymphoma- pt has ALK-positive disease AND pt has relapsed or refractory disease.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anaplastic large cell lymphoma, Erdheim Chester disease, Inflammatory Myofibroblastic Tumor, Large B-Cell Lymphoma
<b>Part B Prerequisite</b>	No



# ALOSETRON

---

## Products Affected

- *alosetron*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No



## ALPHA 1 PROTEINASE INHIBITORS

---

### Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Alpha1-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease)-approve if the patient has a baseline (pretreatment) AAT serum concentration of less than 80 mg/dL or 11 micromol/L.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ALUNBRIG

## Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	ALK status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has ALK positive disease and has advanced, recurrent or metastatic disease or the tumor is inoperable. NSCLC, must be ALK-positive, as detected by an approved test, have advanced or metastatic disease and patients new to therapy must have a trial of Alecensa prior to approval of Alunbrig.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Erdheim-Chester disease, Inflammatory myofibroblastic tumor (IMT)
<b>Part B Prerequisite</b>	No

# ANKTIVA

## Products Affected

- ANKTIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or urologist (initial/maintenance therapy)
<b>Coverage Duration</b>	Initial-6 months, Maintenance-3 months
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL-NON-MUSCLE INVASIVE BLADDER CANCER-all of (i, ii, iii): i) Patient has Bacillus Calmette-Guerin (BCG) unresponsive disease, AND ii) Patient has carcinoma in situ with or without papillary tumors, AND iii) Medication is used in combination with BCG. MAINTENANCE THERAPY-NON-MUSCLE INVASIVE BLADDER CANCER-all of (i and ii): i) Patient has an ongoing complete response defined as ONE of the following (a or b): a) Patient has negative cystoscopy and meets ONE of the following [(1) or (2)]: 1. Negative urine cytology, OR 2. Malignant urine cytology if cancer found in the upper tract or prostatic urethra and random bladder biopsies are negative, OR b) Patient has positive cystoscopy with biopsy-proven benign or low-grade Ta non-muscle invasive bladder cancer and negative urine cytology, AND ii) Medication is used in combination with BCG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ANTIBIOTICS (IV)

### Products Affected

- *amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml*
- *ampicillin sodium*
- *ampicillin-sulbactam*
- *azithromycin intravenous*
- *aztreonam*
- **BICILLIN L-A**
- *cefoxitin*
- *cefoxitin in dextrose (iso-osm)*
- *ceftazidime*
- *cefuroxime sodium injection recon soln 750 mg*
- *cefuroxime sodium intravenous*
- *ciprofloxacin in 5 % dextrose*
- *clindamycin in 5 % dextrose*
- *clindamycin phosphate injection*
- *colistin (colistimethate na)*
- *doxy-100*
- *doxycycline hyclate intravenous*
- *ertapenem*
- *gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml*
- *gentamicin injection solution 40 mg/ml*
- *gentamicin sulfate (ped) (pf)*
- *imipenem-cilastatin*
- *levofloxacin in d5w*
- *levofloxacin intravenous*
- *lincomycin*
- *linezolid in dextrose 5%*
- *linezolid-0.9% sodium chloride*
- *meropenem intravenous recon soln 1 gram, 500 mg*
- *metro i.v.*
- *metronidazole in nacl (iso-osm)*
- *moxifloxacin-sod.chloride(iso)*
- *nafcillin in dextrose (iso-osm) intravenous piggyback 2 gram/100 ml*
- *nafcillin injection*
- *oxacillin*
- *oxacillin in dextrose(iso-osm)*
- **PENICILLIN G POT IN DEXTROSE INTRAVENOUS PIGGYBACK 2 MILLION UNIT/50 ML, 3 MILLION UNIT/50 ML**
- *penicillin g potassium*
- *penicillin g sodium*
- *pfizerpen-g*
- **STREPTOMYCIN**
- *sulfamethoxazole-trimethoprim intravenous*
- *tazicef*
- **TEFLARO**
- *tigecycline*
- *tobramycin sulfate injection recon soln*
- *tobramycin sulfate injection solution*
- **VANCOMYCIN IN 0.9 % SODIUM CHL INTRAVENOUS PIGGYBACK 1 GRAM/200 ML, 500 MG/100 ML, 750 MG/150 ML**
- *vancomycin intravenous recon soln 1,000 mg, 10 gram, 5 gram, 500 mg, 750 mg*
- **VIBATIV INTRAVENOUS RECON SOLN 750 MG**

PA Criteria	Criteria Details
Exclusion Criteria	N/A

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ANTIFUNGALS (IV)

---

### Products Affected

- *fluconazole in nacl (iso-osm)*
- *voriconazole*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ARCALYST

---

## Products Affected

- ARCALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## ARIKAYCE

---

### Products Affected

- ARIKAYCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## ASPARLAS

---

### Products Affected

- ASPARLAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	1 month to 21 years
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## AUBAGIO

---

### Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of teriflunomide with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of MS, to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## AUGTYRO

---

### Products Affected

- AUGTYRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# AVONEX

## Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of other disease-modifying agent used for multiple sclerosis
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or after consultation with a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# AYVAKIT

## Products Affected

- AYVAKIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	GIST-approve if the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation or if the patient has tried two of the following: Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib) or Qinlock (ripretinib). Myeloid/Lymphoid Neoplasms with eosinophilia-approve if the tumor is positive for PDGFRA D842V mutation. Systemic mastocytosis-Approve if the patient has a platelet count greater than or equal to 50,000/mcL and patient has either indolent systemic mastocytosis or one of the following subtypes of advanced systemic mastocytosis-aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid/Lymphoid neoplasms with Eosinophilia
<b>Part B Prerequisite</b>	No

## BALVERSA

---

### Products Affected

- BALVERSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies, test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Urothelial Carcinoma, locally advanced or metastatic-approve if the patient has susceptible fibroblast growth factor receptor 3 genetic alterations AND the patient has progressed during or following prior platinum-containing chemotherapy, other chemotherapy or checkpoint inhibitor therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# BENLYSTA

---

## Products Affected

- BENLYSTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## BENLYSTA IV

### Products Affected

- BENLYSTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	5 years and older (initial).
<b>Prescriber Restrictions</b>	SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont)
<b>Coverage Duration</b>	SLE-Initial-4 months, cont-1 year, Lupus Nephritis-6 mo initial, 1 year cont
<b>Other Criteria</b>	Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to Benlysta subcutaneous or intravenous. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA [anti-dsDNA] antibody AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to

<b>PA Criteria</b>	<b>Criteria Details</b>
	be intolerant due to a significant toxicity AND The patient has responded to Benlysta subcutaneous or intravenous.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## BESREMI

---

### Products Affected

- BESREMI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other interferon products
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## BETASERON/EXTAVIA

---

### Products Affected

- BETASERON SUBCUTANEOUS KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agent used for multiple sclerosis
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or after consultation with a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## BEXAROTENE (ORAL)

---

### Products Affected

- *bexarotene*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## BEXAROTENE (TOPICAL)

---

### Products Affected

- *bexarotene*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Adult T-Cell Leukemia/Lymphoma- approve if the patient has chronic/smoldering subtype and this medication is used as first-line therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Adult T-Cell Leukemia/Lymphoma
<b>Part B Prerequisite</b>	No

## BONIVA INJECTION

### Products Affected

- *ibandronate intravenous*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other medications for Osteoporosis
<b>Required Medical Information</b>	Diagnosis, test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Treatment of postmenopausal osteoporosis, must meet ONE of the following 1. T-score (current or at any time in the past) at or below -2.5 at the lumbar spine, femoral neck, or total hip, 2. has had osteoporotic fracture or fragility fracture, 3. had a T-score (current or at any time in the past) between 1.0 and -2.5 at the lumbar spine, femoral neck, or total hip and the physician determines the patient is at high risk for fracture AND has had an inadequate response to oral bisphosphonate therapy after a trial duration of 12 months as determined by the prescribing physician (e.g., ongoing and significant loss of bone mineral density (BMD), lack of BMD increase), had an osteoporotic fracture or fragility fracture while receiving oral bisphosphonate therapy, or experienced intolerability to an oral bisphosphonate (e.g., severe GI-related adverse effects) OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid) OR the patient has had an osteoporotic fracture or a fragility fracture.
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## BOSENTAN/AMBRISENTAN

### Products Affected

- *ambrisentan*
- *bosentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	For treatment of pulmonary arterial hypertension, ambrisentan or bosentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. CTEPH - prescribed by or in consultation with a cardiologist or pulmonologist
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	CTEPH - pt must have tried Adempas, has a contraindication to Adempas, or is currently receiving bosentan for CTEPH. Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chronic thromboembolic pulmonary hypertension (CTEPH) (bosentan)
<b>Part B Prerequisite</b>	No



# BOSULIF

## Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# BRAFTOVI

## Products Affected

- BRAFTOVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, BRAF V600 status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation. In addition, patients new to therapy must have a trial of Zelboraf or Tafinlar prior to approval of Braftovi. Colon or Rectal cancer-approve if the patient meets the following (A, B, and C): A) The patient has BRAF V600E mutation-positive disease AND B) The patient has previously received a chemotherapy regimen for colon or rectal cancer AND C) The agent is prescribed as part of a combination regimen for colon or rectal cancer. NSCLC- approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Mektovi (binimetinib tablets).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## BRIUMVI

---

### Products Affected

- BRIUMVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of MS, to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## BRUKINSA

### Products Affected

- BRUKINSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Follicular Lymphoma - approve if pt tried at least two other systemic regimens and will use this in combination with Gazyva (obinutuzumab intravenous infusion). Mantle Cell Lymphoma/CLL/SLL - for patients new to therapy, approve if the patient has tried Calquence. Marginal zone lymphoma-approve if the patient has tried at least one systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma-approve. Hairy Cell Leukemia - approve if pt has received therapy for relapsed or refractory disease AND pt has progressive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Hairy Cell Leukemia
<b>Part B Prerequisite</b>	No

## C1 ESTERASE INHIBITORS

### Products Affected

- CINRYZE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Cinryze for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Cinryze as prophylactic therapy compared with baseline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## CABLIVI

### Products Affected

- CABLIVI INJECTION KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, concurrent medications
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	Approve for 12 months
<b>Other Criteria</b>	aTTP-approve if the requested medication was initiated in the inpatient setting in combination with plasma exchange therapy AND patient is currently receiving at least one immunosuppressive therapy AND if the patient has previously received Cablivi, he/she has not had more than two recurrences of aTTP while on Cablivi.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# CABOMETYX

## Products Affected

- CABOMETYX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, histology, RET gene rearrangement status for NSCLC
<b>Age Restrictions</b>	Thyroid carcinoma-12 years and older, other dx (except bone cancer)-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Renal Cell Carcinoma-Approve if the patient has relapsed or stage IV disease. Hepatocellular Carcinoma-approve if the patient has been previously treated with at least one other systemic therapy (e.g., Nexavar, Lenvima). Bone cancer-approve if the patient has Ewing sarcoma or osteosarcoma and has tried at least one previous systemic regimen. Thyroid carcinoma-approve if the patient has differentiated thyroid carcinoma, patient is refractory to radioactive iodine therapy and the patient has tried Lenvima or sorafenib. Endometrial carcinoma-approve if the patient has tried one systemic regimen. GIST-approve if the patient has tried two of the following-imatinib, Ayvakit, sunitinib, dasatinib, Stivarga or Qinlock. NSCLC-approve if the patient has RET rearrangement psotivie tumor.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Non-Small Cell Lung Cancer, Gastrointestinal stromal tumors (GIST), Bone cancer, Endometrial Carcinoma
<b>Part B Prerequisite</b>	No



# CALQUENCE

## Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>CLL and SLL-approve. Mantle Cell Lymphoma- approve if the patient has tried at least one systemic regimen or is not a candidate for a systemic regimen (e.g., rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, bortezomib, or lenalidomide). Marginal Zone Lymphoma-approve if patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide, or chlorambucil). Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen (e.g., Brukinsa [zanubrutinib capsules], Imbruvica [ibrutinib tablets and capsules], rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, fludarabine, or cladribine)</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Marginal zone lymphoma.
<b>Part B Prerequisite</b>	No

# CAPRELSA

---

## Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	MTC - approve. DTC - approve if refractory to radioactive iodine therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma.
<b>Part B Prerequisite</b>	No

## CARGLUMIC ACID

### Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases
<b>Coverage Duration</b>	NAGS-Pt meets criteria no genetic test - 3mo. Pt had genetic test - 12mo, other-approve 7 days
<b>Other Criteria</b>	N-Acetylglutamate synthase deficiency with hyperammonemia-Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia or Methylmalonic Acidemia with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater then or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (generic carglumic acid)
<b>Part B Prerequisite</b>	No

# CAYSTON

---

## Products Affected

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# CEPROTIN

## Products Affected

- CEPROTIN (BLUE BAR)
- CEPROTIN (GREEN BAR)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Protein C Deficiency, Severe-approve if the patient meets the following criteria A, B and C: A) The diagnosis of protein C deficiency is confirmed by at least one of the following (i, ii, or iii): i. Plasma protein C activity below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR ii. Plasma protein C antigen below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR iii. Genetic testing demonstrating biallelic mutations in the PROC gene AND B) Acquired causes of protein C deficiency have been excluded AND C) Patient has a current or prior history of symptoms associated with severe protein C deficiency (e.g., purpura fulminans, thromboembolism).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## CHEMET

---

### Products Affected

- CHEMET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Blood lead level
<b>Age Restrictions</b>	Approve in patients between the age of 12 months and 18 years
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist)
<b>Coverage Duration</b>	Approve for 2 months
<b>Other Criteria</b>	Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## CIBINQO

### Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD). Concurrent use with an Anti-Interleukin Monoclonal Antibody. Concurrent use with other Janus Kinase Inhibitors. Concurrent use with a biologic immunomodulator. Concurrent use with other potent immunosuppressants.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	AD-12 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	Atopic Dermatitis-prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
<b>Coverage Duration</b>	Initial-Atopic Dermatitis-3 months, Continuation-1 year
<b>Other Criteria</b>	Atopic Dermatitis, initial-approve if the patient has had a 4-month trial of at least one systemic therapy OR patient has tried at least one systemic therapy but was unable to tolerate a 4-month trial. Note: Examples of systemic therapies include Dupixent (dupilumab subcutaneous injection) or Adbry (tralokinumab-ldrm subcutaneous injection). Methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil also count towards a trial of one systemic therapy. Continuation-Approve if the patient has been receiving Cibinqo for at least 90 days AND patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Cibinqo) in at least one of the following: estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, and/or a decreased requirement for other topical or systemic therapies for atopic dermatitis AND compared with baseline (prior to receiving Cibinqo), patient experienced an improvement in at least one symptom, such as decreased itching. Note: A patient who has received less than 3 months of therapy or who is restarting therapy with Cibinqo should be considered under initial therapy.
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## CIMERLI

---

### Products Affected

- CIMERLI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Administered by or under the supervision of an ophthalmologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Retinopathy of prematurity
<b>Part B Prerequisite</b>	No

## CIMZIA

### Products Affected

- CIMZIA POWDER FOR RECONST
- CIMZIA STARTER KIT
- CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried
<b>Age Restrictions</b>	18 years and older for CD and PP (initial therapy).
<b>Prescriber Restrictions</b>	All dx initial therapy only. RA/AS, prescribed by or in consultation with a rheumatologist. Crohn's disease, prescribed by or in consultation with a gastroenterologist. PsA prescribed by or in consultation with a rheumatologist or dermatologist. PP, prescribed by or in consultation with a dermatologist. nr-axSpA-prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	AS initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Xeljanz/XR, Cosentyx. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. PsA initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Cosentyx, Tremfya, Stelara, Otezla, Orencia, Rinvoq, Skyrizi or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. RA initial tx, approve if the patient has tried two of the following drugs in the past: Enbrel, a preferred adalimumab product, Orencia, Rinvoq or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. CD initial tx, approve if patient has previously tried TWO of the following drugs in the past: a preferred adalimumab product, a preferred infliximab product, Stelara, Skyrizi or Rinvoq. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab/infliximab product will also count.

PA Criteria	Criteria Details
	<p>Plaque Psoriasis (PP), initial tx-approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Skyrizi, Stelara SC, Otezla, Cosentyx, Tremfya, Sotyktu. A trial of a non-preferred adalimumab also counts. Cont tx, AS/PsA/RA/CD/PP - approve if the pt had a response as determined by the prescriber. Non-radiographic axial spondylitis (nr-axSpA), initial tx-approve if the patient has objective signs of inflammation, defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroilitis reported on MRI. nr-axSpA continuation tx-approve if the patient has had a response as determined by the prescriber. Please Note: preferred adalimumab products include Humira (NDCs starting with -00074), Cyltezo, Yuflyma. Preferred infliximab products include Remicade, Zymfentra.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# CINACALCET

## Products Affected

- *cinacalcet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Hypercalcemia d/t parathyroid CA-prescr/consult w/onco or endo. Hypercalcemia w/primary hyperparathyroidism-prescr/consult w/nephro or endo. Hyperparathyroidism in post-renal transplant-prescr/consult w/transplant physician/nephro/endo.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Hypercalcemia due to parathyroid carcinoma-approve. Hypercalcemia in patients with primary hyperparathyroidism-approve if the patient has failed or is unable to undergo a parathyroidectomy due to a contraindication. Secondary Hyperparathyroidism in patients with chronic kidney disease on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundles payment benefit). Hyperparathyroidism in Post-Renal Transplant Patients-approve if the baseline (prior to starting cinacalcet therapy) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	hyperparathyroidism in post-renal transplant patients
<b>Part B Prerequisite</b>	No

# CLOBAZAM

## Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other medications tried
<b>Age Restrictions</b>	2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Lennox-Gastaut Syndrome, initial therapy-patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex or valproic acid. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Dravet Syndrome and treatment-refractory seizures/epilepsy
<b>Part B Prerequisite</b>	No

# CLOMIPHENE

## Products Affected

- *clomid*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Use in patients for infertility
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Woman (a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Male hypogonadism
<b>Part B Prerequisite</b>	No

## COLUMVI

### Products Affected

- COLUMVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma- approve if the patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: Examples of diffuse large B-cell lymphoma (DLBCL) include DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from indolent lymphoma. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) +/- rituximab. Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma- approve if the patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Post-transplant lymphoproliferative disorders- approve if the</p>

PA Criteria	Criteria Details
	<p>patient has received two or more lines of systemic therapy, the medication will be given as a single agent and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine).</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma. Post-transplant lymphoproliferative disorders.
<b>Part B Prerequisite</b>	No



# COMETRIQ

## Products Affected

- COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	MTC - approve. Non-Small Cell Lung Cancer with RET Gene Rearrangements - approve. Differentiated (i.e., papillary, follicular, and oncocyctic) Thyroid Carcinoma-approve if the patient's carcinoma is refractory to radioactive iodine therapy and patient has tried a Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-Small Cell Lung Cancer with RET Gene Rearrangements, Differentiated (i.e., papillary, follicular, and oncocyctic) Thyroid Carcinoma
<b>Part B Prerequisite</b>	No

## COPIKTRA

### Products Affected

- COPIKTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma - approve if the patient has tried one systemic regimen (e.g., Imbruvica (ibrutinib capsules, tablets and oral solution), Venclexta (venetoclax tablets), rituximab, Gazyva (obinutuzumab intravenous infusion), chlorambucil, fludarabine, cyclophosphamide, bendamustine, high-dose methylprednisolone, Campath (alemtuzumab intravenous infusion), Calquence (acalabrutinib capsules), Brukinsa (zanubrutinib capsules), or Arzerra (ofatumumab intravenous infusion). T-cell lymphoma- For peripheral T-cell lymphoma, approve. For breast implant-associated anaplastic large cell lymphoma, or hepatosplenic T-cell lymphoma, approve if the patient has relapsed or refractory disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	T-cell Lymphoma
<b>Part B Prerequisite</b>	No

# COSENTYX

## Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis and previous medications use
<b>Age Restrictions</b>	PP-6 yr and older. AS/Spondy/HS initial - 18 years of age and older. PsA-2 years and older. Enthesitis-4 years and older
<b>Prescriber Restrictions</b>	PP initial-presc/consult derm. PsA initial - prescribed by or in consultation with a dermatologist or rheumatologist. AS/spondylo/enthesitis initial- by or in consultation with rheumatologist. HS initial - by or in consult w/ dermatologist
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: HIDRADENITIS SUPPURATIVA (HS): tried at least one other therapy (e.g. systemic antibiotics, isotretinoin). NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: objective signs of inflammation and meets a or b: a) C-reactive protein elevated beyond the upper limit of normal or b) sacroiliitis reported on MRI. PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of at least one biologic that is not Cosentyx or a Cosentyx biosimilar also counts) or B) contraindication to MTX. CONTINUATION THERAPY: ALL INDICATIONS: patient has experienced benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## COSENTYX IV

### Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	PsA initial - Prescribed by or in consultation with a dermatologist or rheumatologist. AS/Non-radio Axial Spondy-Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	Non-Radiographic Axial Spondyloarthritis, initial therapy- approve if pt has objective signs of inflammation defined as (a or b): a) C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or b) sacroiliitis reported on magnetic resonance imaging. For continuation of therapy for all covered indications - approve if the pt has benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# COTELLIC

---

## Products Affected

- COTELLIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## CRESEMBA (ORAL)

---

### Products Affected

- CRESEMBA ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Candidiasis of the esophagus - HIV infection, sepsis
<b>Part B Prerequisite</b>	No

# CRYSVITA

## Products Affected

- CRYSVITA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Chronic Kidney Disease (CKD), Severe Renal Impairment or End Stage Renal Disease
<b>Required Medical Information</b>	Diagnosis, lab values
<b>Age Restrictions</b>	TIO-2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or nephrologist (initial therapy)
<b>Coverage Duration</b>	XLH-1 year (initial/cont), TIO-initial-6 months, cont-1 year
<b>Other Criteria</b>	<p>XLH-Initial therapy-Approve if the patient has had a baseline (prior to any XLH treatment serum phosphorus level that was below the normal range for age and patient meets ONE of the following (a or b): a) The patient has had a baseline (i.e., prior to any XLH treatment tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender OR b) The patient has had a genetic test confirming the diagnosis of X-linked hypophosphatemia via identification of a PHEX pathogenic variant AND if the patient is greater than or equal to 18 years of age, the patient is currently exhibiting one or more signs or symptoms of XLH. Continuation-approve if the patient is continuing to derive benefit as determined by the prescribing physician.</p> <p>TIO-approve if the patient has a mesenchymal tumor that cannot be curatively resected or identified/localized AND the patient is currently exhibiting one or more signs or symptoms of TIO AND patient has had a baseline (prior to any TIO treatment) serum phosphorus level that was below the normal range for age AND patient has had a baseline (prior to any TIO treatment) tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender. Cont-approve if the patient is continuing to derive benefit as determined by the prescribing physician.</p>
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## CYSTEAMINE (OPHTHALMIC)

### Products Affected

- CYSTARAN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## CYSTEAMINE (ORAL)

### Products Affected

- CYSTAGON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of Cystagon and Procysbi
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cystinosis, nephropathic-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming a mutation of the CTNS gene OR white blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## DALFAMPRIDINE

### Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older (initial and continuation therapy)
<b>Prescriber Restrictions</b>	MS. If prescribed by, or in consultation with, a neurologist or MS specialist (initial and continuation).
<b>Coverage Duration</b>	Initial-4months, Continuation-1 year
<b>Other Criteria</b>	Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# DAURISMO

---

## Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, medications that will be used in combination, comorbidities
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML - approve if Daurismo will be used in combination with cytarabine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# DEFERASIROX

## Products Affected

- *deferasirox*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Serum ferritin level
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Transfusion-related chronic iron overload, initial therapy - approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy - approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## DEFERIPRONE

---

### Products Affected

- *deferiprone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Serum ferritin level
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias Initial therapy - approve. Continuation therapy - approve is the patient is benefiting from therapy as confirmed by the prescribing physician.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## DIABETIC SUPPLY - ALCOHOL PADS

---

### Products Affected

- *alcohol pads*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## DIABETIC SUPPLY - GAUZE PADS

---

### Products Affected

- GAUZE PADS 2 X 2

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No





## DIABETIC SUPPLY - NEEDLES

---

### Products Affected

- NOVO PEN NEEDLE
- PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No



## DIABETIC SUPPLY - SYRINGES

---

### Products Affected

- INSULIN SYRINGE-NEEDLE U-100  
SYRINGE 0.3 ML 29 GAUGE, 1 ML 29  
GAUGE X 1/2", 1/2 ML 28 GAUGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# DIACOMIT

---

## Products Affected

- DIACOMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	6 months and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Dravet Syndrome-Initial therapy-approve if the patient is concomitantly receiving clobazam or is unable to take clobazam due to adverse events. Dravet Syndrome-Continuation-approve if the patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## DIMETHYL FUMARATE

---

### Products Affected

- *dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# DOPTELET

## Products Affected

- DOPTELET (10 TAB PACK)
- DOPTELET (15 TAB PACK)
- DOPTELET (30 TAB PACK)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## DROXIDOPA

### Products Affected

- *droxidopa*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Medication history (as described in Other Criteria field)
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or a neurologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## DUAL OREXIN RECEPTOR ANTAGONIST

---

### Products Affected

- BELSOMRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# DUPIXENT

---

## Products Affected

- DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML
- DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML

PA Criteria	Criteria Details
Exclusion Criteria	PENDING CMS REVIEW
Required Medical Information	PENDING CMS REVIEW
Age Restrictions	PENDING CMS REVIEW
Prescriber Restrictions	PENDING CMS REVIEW
Coverage Duration	PENDING CMS REVIEW
Other Criteria	PENDING CMS REVIEW
Indications	PENDING CMS REVIEW
Off-Label Uses	PENDING CMS REVIEW
Part B Prerequisite	PENDING CMS REVIEW



## ELAPRASE

---

### Products Affected

- ELAPRASE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum or plasma OR a molecular genetic test demonstrating iduronate-2-sulfatase gene variant.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ELREXFIO

### Products Affected

- ELREXFIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# EMGALITY

## Products Affected

- EMGALITY PEN
- EMGALITY SUBCUTANEOUS SYRINGE 120 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination therapy with another cGRP inhibitor for migraine headache prevention
<b>Required Medical Information</b>	Diagnosis, number of migraine or cluster headaches per month
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Cluster headache tx-6 months, migraine prevention-1 year
<b>Other Criteria</b>	Migraine headache prevention-Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) If pt is currently taking Emgality, pt has had significant clinical benefit from the medication. Episodic cluster headache treatment-approve if the patient has between one headache every other day and eight headaches per day.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ENBREL

### Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with biologic therapy or targeted synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous therapies tried.
<b>Age Restrictions</b>	PP-4 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Initial only-RA/AS/JIA/JRA,prescribed by or in consult w/ rheumatologist. Psoriatic arthritis, prescribed by or in consultation w/ rheumatologist or dermatologist.Plaque psoriasis (PP), prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center.Behcet's disease,prescribed by or in consult w/ rheumatologist,dermatologist,ophthalmologist,gastroenterologist,or neurologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA): tried one conventional synthetic DMARD for at least 3 months (see Note 1). JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA (one of A, B, C, or D): A) patient has aggressive disease, B) tried one other systemic therapy (e.g., methotrexate [MTX], sulfasalazine, leflunomide, NSAID, or a biologic that is not a biosimilar of the requested product), C) patient will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide, or D) patient has an absolute contraindication to MTX, sulfasalazine, or leflunomide. PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent for at least 3 months, unless intolerant (e.g., MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA) [see Note 1] or B) patient has a contraindication to one oral agent for psoriasis such as MTX. GRAFT VERSUS HOST DISEASE (GVHD): approve. BEHCET'S: tried at least one conventional therapy (e.g., systemic corticosteroid, immunosuppressant, interferon alfa, mycophenolate), adalimumab, or

PA Criteria	Criteria Details
	<p>infliximab. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Note 1: a biologic that is not a biosimilar of the requested product will also count.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Graft versus host disease (GVHD), Behcet's disease
<b>Part B Prerequisite</b>	No

## ENDARI

---

### Products Affected

- *glutamine (sickle cell)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prescriber specialty
<b>Age Restrictions</b>	Greater than or equal to 5 years of age
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a physician who specializes in sickle cell disease (e.g., a hematologist)
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ENTYVIO

### Products Affected

- ENTYVIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Biologics or with Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) used for an Inflammatory Condition
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	CD/UC - adults (initial therapy)
<b>Prescriber Restrictions</b>	CD/UC initial - Prescribed by or in consultation with a gastroenterologist. (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	CD Initial - the patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient OR the patient has tried one conventional systemic therapy for Crohn's disease (e.g., azathioprine, 6-mercaptopurine, or methotrexate) OR the patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas OR patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Note: an exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried a biologic. Cont tx - had a response to Entyvio, as determined by the prescribing physician. UC initial-the patient has had a trial of one systemic agent (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone). NOTE: A trial of a biologic (e.g., an adalimumab product [e.g., Humira], an infliximab product [e.g., Remicade, Inflectra, or Renflexis], or Simponi [golimumab for SC injection]) also counts as a trial of one systemic agent for UC. Cont tx - had a response to Entyvio (for example, decreased stool frequency or rectal bleeding), as determined by the prescribing physician.
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# EPIDIOLEX

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapies
<b>Age Restrictions</b>	Patients 1 year and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Dravet Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Tuberous Sclerosis Complex-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Continuation of therapy-approve if the patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## EPKINLY

### Products Affected

- EPKINLY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma - approve if the patient has received two or more lines of systemic therapy and the medication will be given as a single agent. Classic follicular lymphoma - approve if pt has received two or more lines of systemic therapy and medication will be given as a single agent. Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma - approve if the patient has received two or more lines of systemic therapy and the medication will be given as a single agent. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL. Post-transplant lymphoproliferative disorders - approve if the patient has received two or more lines of systemic therapy and the medication will be given as a single agent.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma. Post-transplant lymphoproliferative disorders. Classic follicular lymphoma.
<b>Part B Prerequisite</b>	No

# EPOETIN ALFA

## Products Affected

- PROCRIT
- RETACRIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	MDS anemia = 18 years of age and older
<b>Prescriber Restrictions</b>	MDS anemia, myelofibrosis- prescribed by or in consultation with, a hematologist or oncologist.
<b>Coverage Duration</b>	Chemo-6m,Transfus-1m, CKD-1yr, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr
<b>Other Criteria</b>	<p>Anemia in a pt with Chronic Kidney Disease (CKD) not on dialysis- for initial therapy, approve if hemoglobin (Hb) is less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children, or for continuation of therapy in a pt currently on an erythropoiesis-stimulating agent (ESA) approve if Hb is less than or equal to 12 g/dL. Anemia in a pt with cancer due to chemotherapy- approve if pt is currently receiving myelosuppressive chemo as a non-curative treatment and (for initial therapy) Hb is less than 10.0 g/dL or (if currently on ESA) Hb is less than or equal to 12.0 g/dL. Anemia in HIV with zidovudine- for initial therapy, approve if Hb is less than 10.0 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA, approve if Hb is 12.0 g/dL or less. Surgical pts to reduce RBC transfusions - Approve if Hb is less than or equal to 13, AND surgery is elective, nonvascular and non-cardiac AND pt is unwilling or unable to donate autologous blood prior to surgery. MDS- for initial therapy, approve if Hb is less than 10 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA approve if Hb is 12.0 g/dL or less. Myelofibrosis- for Initial therapy approve if patient has a Hb less than 10 or serum erythropoietin less than or equal to 500 mU/mL, or for continuation of therapy in pt currently on ESA hemoglobin is less than or equal to 12g/dL. Anemia in patients with chronic renal failure on dialysis -</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anemia due to myelodysplastic syndrome (MDS), Myelofibrosis
<b>Part B Prerequisite</b>	No

# ERIVEDGE

## Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	BCC (La or Met) - must not have had disease progression while on Odomzo.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Basal cell carcinoma, locally advanced-patients new to therapy-approve if the patient has tried Odomzo. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has medulloblastoma, the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway. Basal cell carcinoma, metastatic (this includes primary or recurrent nodal metastases and distant metastases)-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Central nervous System Cancer
<b>Part B Prerequisite</b>	No

## ERLEADA

---

### Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) analog [for example: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets)] or if the patient has had a bilateral orchiectomy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ERLOTINIB

### Products Affected

- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Advanced or Metastatic NSCLC, approve if the patient has EGFR mutation positive non-small cell lung cancer as detected by an approved test. Note-Examples of EGFR mutation-positive non-small cell lung cancer include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. RCC, approve if the patient has recurrent or advanced non-clear cell histology RCC or if the patient had hereditary leiomyomatosis and renal cell carcinoma and erlotinib will be used in combination with bevacizumab. Bone cancer-approve if the patient has chordoma and has tried at least one previous therapy. Pancreatic cancer-approve if the medication is used in combination with gemcitabine and if the patient has locally advanced, metastatic or recurrent disease. Vulvar cancer-approve if the patient has advanced, recurrent or metastatic disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Renal Cell Carcinoma, vulvar cancer and Bone Cancer-Chordoma.
<b>Part B Prerequisite</b>	No

# EVEROLIMUS

## Products Affected

- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- *torpenz*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



# EYLEA

---

## Products Affected

- EYLEA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## FABRAZYME

### Products Affected

- FABRAZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Galafold (migalastat oral capsules) or Elfabrio (pegunigalsidase alfa intravenous infusion).
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient alpha-galactosidase A activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating a pathogenic variant in the galactosidase alpha (GLA) gene.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## FASENRA

---

### Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# FINGOLIMOD

---

## Products Affected

- *fingolimod*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of fingolimod with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	10 years and older
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## FINTEPLA

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an neurologist (initial therapy)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Dravet Syndrome-Initial therapy-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or patient has tried or is concomitantly receiving Epidiolex, Clobazam or Diacomit. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. Lennox-Gastaut Syndrome, initial-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Lennox-Gastaut Syndrome, continuation-approve if the patient is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## FIRMAGON

---

### Products Affected

- FIRMAGON KIT W DILUENT SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Patients new to therapy, are required to try Eligard or Orgovyx prior to approval of Firmagon.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## FOTIVDA

### Products Affected

- FOTIVDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Renal Cell Carcinoma (RCC)-approve if the patient has relapsed or Stage IV disease and has tried at least two other systemic regimens. Note: Examples of systemic regimens for renal cell carcinoma include axitinib tablets, axitinib + pembrolizumab injection, cabozantinib tablets, cabozantinib + nivolumab injection, sunitinib malate capsules, pazopanib tablets, sorafenib tablets, and lenvatinib capsules + everolimus.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## FRUZAQLA

### Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Colon cancer, rectal cancer, or appendiceal cancer-Approve if the patient meets the following (A and B): A.Patient has advanced or metastatic disease, AND B.Patient has previously been treated with the following (i, ii, and iii): i.Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, Note: Examples of fluoropyrimidine agents include 5-fluorouracil (5-FU) and capecitabine. AND ii.An anti-vascular endothelial growth factor (VEGF) agent, Note: Examples of anti-VEGF agents include bevacizumab. AND iii. If the tumor is RAS wild-type (KRAS wild-type and NRAS wild-type) [that is, the tumor or metastases are KRAS and NRAS mutation negative], the patient meets ONE of the following (a or b): a.According to the prescriber, anti-epidermal growth factor receptor (EGFR) therapy is NOT medically appropriate, OR b. The patient has received an anti-EGFR therapy. Note: Examples of anti-EGFR therapy includes Erbitux (cetuximab intravenous infusion) and Vectibix (panitumumab intravenous infusion).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Appendiceal cancer
<b>Part B Prerequisite</b>	No



## FULPHILA

### Products Affected

- FULPHILA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC - prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
<b>Coverage Duration</b>	Cancer pts receiving chemo-6 mo. PBPC-30 days.
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, or 3) patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients undergoing PBPC collection and therapy
<b>Part B Prerequisite</b>	No

# FYARRO

---

## Products Affected

- FYARRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Perivascular Epithelioid Cell Tumor (PEComa), Malignant-approve if the patient has locally advanced unresectable disease or metastatic disease.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# GATTEX

## Products Affected

- GATTEX 30-VIAL
- GATTEX ONE-VIAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	1 year and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist (initial and continuation)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced improvement.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# GAVRETO

## Products Affected

- GAVRETO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	NSCLC-18 years and older, thyroid cancer-12 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	NSCLC-approve if the patient has advanced, recurrent, or metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an Food and Drug Administration (FDA) approved test. Differentiated Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has RET fusion-positive or RET-mutation-positive disease AND disease requires treatment with systemic therapy AND the disease is radioactive iodine-refractory. Anaplastic thyroid cancer or Medullary Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has RET fusion-positive or RET-mutation-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Medullary Thyroid Cancer, Anaplastic Thyroid Cancer
<b>Part B Prerequisite</b>	No

# GEFITINIB

---

## Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	PENDING CMS REVIEW
Required Medical Information	PENDING CMS REVIEW
Age Restrictions	PENDING CMS REVIEW
Prescriber Restrictions	PENDING CMS REVIEW
Coverage Duration	PENDING CMS REVIEW
Other Criteria	PENDING CMS REVIEW
Indications	PENDING CMS REVIEW
Off-Label Uses	PENDING CMS REVIEW
Part B Prerequisite	PENDING CMS REVIEW

# GILOTRIF

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For NSCLC - EGFR exon deletions or mutations, or if NSCLC is squamous cell type
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	NSCLC EGFR pos - For the treatment of advanced or metastatic non small cell lung cancer (NSCLC)-approve if the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: examples of sensitizing EGFR mutation-positive NSCLC include the following mutations : exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. NSCLC metastatic squamous cell must have disease progression after treatment with platinum based chemotherapy. Head and neck cancer-approve if the patient has non-nasopharyngeal head and neck cancer and the patient has disease progression on or after platinum based chemotherapy. (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan)
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Head and neck cancer
<b>Part B Prerequisite</b>	Yes

# GLATIRAMER

## Products Affected

- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agent used for multiple sclerosis
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or after consultation with a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## GLUCAGON-LIKE PEPTIDE-1 AGONISTS

### Products Affected

- BYDUREON BCISE
- BYETTA SUBCUTANEOUS PEN INJECTOR 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML
- MOUNJARO
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	Documentation of type 2 diabetes diagnosis required (chart notes or labs).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No



## GNRH AGONIST IMPLANTS

### Products Affected

- ZOLADEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Endometriosis-18 years and older
<b>Prescriber Restrictions</b>	Prostate cancer/Breast cancer/Head and Neck/Ovarian/Uterine-prescribed by or in consultation with an oncologist. Endometriosis/abnormal uterine bleeding-prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health.
<b>Coverage Duration</b>	Abnormal uterine bleeding-2 months, Endometriosis-6 months, all other dx-1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Abnormal uterine bleeding-Zoladex 3.6mg is used as an endometrial-thinning agent prior to endometrial ablation.Endometriosis-approve Zoladex 3.6 mg. Prostate cancer-approve Zoladex 3.6 mg and/or 10.8 mg. Head and Neck Cancer - Salivary Gland Tumors: approve if patient has recurrent, unresectable, or metastatic disease AND has androgen receptor-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Zoladex 3.6mg only: head and neck cancer - salivary gland tumors, Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, and Uterine Cancer
<b>Part B Prerequisite</b>	No



## GONADOTROPIN-RELEASING HORMONE AGONISTS - ONCOLOGY

### Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- *leuprolide subcutaneous kit*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prostate cancer- prescribed by or in consultation with an oncologist or urologist. Head and neck-salivary gland tumors- prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer- salivary gland tumors (Eligard only)
Part B Prerequisite	No

## GRALISE/HORIZANT/LYRICA CR

---

### Products Affected

- *gabapentin oral tablet extended release 24 hr 300 mg, 600 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# GROWTH HORMONES

## Products Affected

- OMNITROPE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	<p>GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are less than 10ng/mL OR had at least 1 GH test and results are less than 10ng/mL and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test less than 10ng/mL or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test less than 10ng/mL OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has multiple pituitary deficiencies and pt has 3 or more pituitary hormone deficiencies or pt has had one GH test less than 10ng/mL 5.pt had a hypophysectomy. Cont-pt responding to therapy</p>
<b>Age Restrictions</b>	ISS 5 y/o or older, SGA 2 y/o or older, SBS 18 y/o or older
<b>Prescriber Restrictions</b>	GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Noonan (initial), Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist.
<b>Coverage Duration</b>	ISS - 6 mos initial, 12 months cont tx, SBS 1 month, others 12 mos
<b>Other Criteria</b>	GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage,

PA Criteria	Criteria Details
	<p>AND 3. meets one of the following - A. has known perinatal insults, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, age and gender adjusted IGF1 below the lower limits of the normal reference range AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. Cont tx - prescriber confirms response to therapy. CKD initial - CKD defined by abnormal CrCl. Noonan initial - baseline height less than 5th percentile. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile for age/gender. SGA initial -baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational age/gender and didn't have sufficient catch up growth by 2-4 y/o). Cont tx - prescriber confirms response to therapy. Cont Tx for CKD, Noonan, PW in child/adoles, SHOX, and TS - prescriber confirms response to therapy. SBS initial pt receiving specialized nutritional support. Cont tx - 2nd course if pt responded to tx with a decrease in the requirement for specialized nutritional support.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Short bowel syndrome
<b>Part B Prerequisite</b>	No

## HIGH RISK MEDICATIONS - BENZODIAZEPINES

### Products Affected

- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*
- *diazepam injection*
- *diazepam intensol*
- *diazepam oral concentrate*
- *diazepam oral solution*
- *diazepam oral tablet*
- *lorazepam injection solution*
- *lorazepam injection syringe 2 mg/ml*
- *lorazepam intensol*
- *lorazepam oral concentrate*
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Procedure-related sedation = 1mo. All other conditions = 12 months.
<b>Other Criteria</b>	All medically accepted indications other than insomnia, approve if the physician has assessed risk versus benefit in using the High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. Insomnia, may approve lorazepam if the patient has had a trial with two of the following: ramelteon, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon and the physician has assessed risk versus benefit in using the HRM in this patient and has confirmed that he/she would still like initiate/continue therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## HIGH RISK MEDICATIONS - BENZTROPINE

### Products Affected

- *benztropine oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For all medically-accepted indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing benztropine for the patient and he/she would still like to initiate/continue therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## HIGH RISK MEDICATIONS - CYCLOBENZAPRINE

### Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No





# HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

## Products Affected

- *hydroxyzine hcl oral tablet*
- *promethazine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For hydroxyzine hydrochloride, authorize use without a previous drug trial for all FDA-approved indications other than anxiety. Approve hydroxyzine hydrochloride if the patient has tried at least two other FDA-approved products for the management of anxiety. Prior to approval of promethazine and hydroxyzine, approve if the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## HIGH RISK MEDICATIONS - PHENOBARBITAL

---

### Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for use in sedation/insomnia.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the treatment of seizures, approve only if the patient is currently taking phenobarbital.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## HIGH RISK MEDICATIONS- ESTROGENS

### Products Affected

- *dotti*
- *estradiol oral*
- *estradiol transdermal patch semiweekly*
- *estradiol transdermal patch weekly*
- *estradiol-norethindrone acet*
- *fyavolv*
- *jinteli*
- *lyllana*
- *mimvey*
- *norethindrone ac-eth estradiol oral tablet*  
0.5-2.5 mg-mcg, 1-5 mg-mcg

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Previous medication use
<b>Age Restrictions</b>	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months
<b>Other Criteria</b>	For the treatment of Vulvar Vaginal Atrophy, approve if the patient has had a trial of one of the following for vulvar vaginal atrophy (brand or generic): Estradiol Vaginal Cream, Invexxy, Premarin Vaginal Cream or estradiol valerate injection. For prophylaxis of Postmenopausal Osteoporosis, approve if the patient has had a trial of one of the following (brand or generic): alendronate, ibandronate, risedronate or Raloxifene. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## IBRANCE

### Products Affected

- IBRANCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast cancer - approve recurrent or metastatic, hormone receptor positive (HR+) [i.e., estrogen receptor positive- [ER+] and/or progesterone receptor positive [PR+]] disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and Ibrance will be used in combination with anastrozole, exemestane, or letrozole 2, pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonists, or has had surgical bilateral oophorectomy, or ovarian irradiation AND meets one of the following conditions: Ibrance will be used in combination with anastrozole, exemestane, or letrozole or Ibrance will be used in combination with fulvestrant 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Ibrance with be used in combination with anastrozole, exemestane or letrozole or Ibrance will be used in combination with fulvestrant 4. Pt is postmenopausal and Ibrance will be used in combination with fulvestrant. In addition, patients new to therapy must have a trial of Kisqali, Kisqali Femara Co-Pack or Verzenio prior to approval of Ibrance. Liposarcoma-approve if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Liposarcoma
<b>Part B Prerequisite</b>	No

# ICATIBANT

## Products Affected

- *icatibant*
- *sajazir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] - Treatment of Acute Attacks, Initial Therapy-the patient has HAE type I or type II as confirmed by the following diagnostic criteria (i and ii): i. the patient has low levels of functional C1-INH protein (less than 50 percent of normal) at baseline, as defined by the laboratory reference values AND ii. the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values. Patients who have treated previous acute HAE attacks with icatibant - the patient has treated previous acute HAE type I or type II attacks with icatibant AND according to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ICLUSIG

## Products Affected

- ICLUSIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Acute lymphoblastic leukemia, Philadelphia chromosome positive or chronic myeloid leukemia-approve. GIST - approve if the patient tried all of the following therapies first to align with NCCN recommendations which include: Imatinib or Ayyakit (avapritinib tablets), AND Sunitinib or Sprycel (dasatinib tablets), AND Stivarga (regorafenib tablets), AND Qinlock (ripretinib tablets). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has ABL1 rearrangement or FGFR1 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Gastrointestinal Stromal Tumor, Myeloid/Lymphoid Neoplasms with Eosinophilia
<b>Part B Prerequisite</b>	No

## IDHIFA

---

### Products Affected

- IDHIFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	IDH2-mutation status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	AML - approve if the patient is IDH2-mutation status positive as detected by an approved test
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## ILARIS

### Products Affected

- ILARIS (PF)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	When used in combination with concurrent biologic therapy (e.g.TNF antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or riloncept.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	CAPS-4 years of age and older (initial). SJIA/HIDS/MKD/FMF/TRAPS-2 years of age and older (initial). Still's disease-18 years and older (initial) Note-patients less than 18 should be referred to criteria for systemic juvenile idiopathic arthritis. Acute gout flare-18 years of age and older
<b>Prescriber Restrictions</b>	CAPS initial- Prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist. SJIA/Still's disease (initial), Acute gout flare (initial/cont)- prescribed by or in consultation with a rheumatologist. FMF initial - rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, hematologist. HIDS/MKD/TRAPS initial - rheumatologist, nephrologist, geneticist, oncologist, hematologist.
<b>Coverage Duration</b>	Acute gout flare-6 mos, all other diagnoses-6 months initial, 1 year cont.
<b>Other Criteria</b>	For renewal of CAPS/SJIA/FMF/HIDS/MKD/TRAPS/Still's - After pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician. SJIA, initial therapy - approve if the pt has tried at least one other biologic for SJIA or started on Ilaris while in the hospital. Adult Onset Still's Disease-Initial-approve if the patient has tried at least one other biologic or started on Ilaris while in the hospital. Acute gout flare- approve if (i and ii): (i) pt has intolerance, contraindication, or lack of response to NSAIDs and colchicine for the treatment of acute gout flares OR pt is unable to be retreated with a repeat course of corticosteroids (oral or injectable) for acute gout flare, and (ii) patient is receiving or will be taking concomitant urate lowering medication for prevention of gout unless contraindicated (ex: allopurinol, febuxostat, probenecid). FMF, initial-approve if pt has tried colchicine,

PA Criteria	Criteria Details
	<p>unless contraindicated and will be taking Ilaris in combination with colchicine, unless colchicine is contraindicated or not tolerated, AND prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) pt has a history of at least one flare per month despite use of colchicine, OR was hospitalized for a severe flare. HIDS/MKD, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least three febrile acute flares within the previous 6-month period OR was hospitalized for a severe flare. TRAPS, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least six flares per year OR was hospitalized for a severe flare.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## IMATINIB

### Products Affected

- *imatinib oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported.
<b>Age Restrictions</b>	ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms/Kaposi Sarcoma/Cutaneous Melanoma-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For ALL/CML, must have Ph-positive for approval of imatinib. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or according to the prescriber, the patient cannot take Turalio. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Cutaneous melanoma-approve if the patient has an activating KIT mutation, metastatic or unresectable melanoma, and has tried at least one systemic regimen. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFR or PDGFRB rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chordoma, desmoid tumors (aggressive fibromatosis), cKit positive metastatic or unresectable cutaneous melanoma, Kaposi's Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia, GVHD, chronic.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# IMBRUVICA

## Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- IMBRUVICA ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	GVHD-1 year and older, other-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CLL- Approve. GVHD-Approve if the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi [ruxolitinib tablets]). B-cell lymphoma-approve if the patient has tried at least one systemic regimen (e.g., cisplatin, cytarabine, rituximab, oxaliplatin, gemcitabine, ifosfamide, carboplatin, etoposide, or rituximab). Central nervous system Lymphoma (primary)- approve if the patient is not a candidate for or is intolerant to high-dose methotrexate OR has tried at least one therapy (e.g., methotrexate, rituximab, vincristine, procarbazine, cytarabine, thiotepa, carmustine, intrathecal methotrexate, cytarabine, or rituximab). Hairy Cell Leukemia - approve if the patient has tried at least two systemic regimens (cladribine, Nipent [pentostatin injection], rituximab, or Pegasys [peginterferon alfa-2a subcutaneous injection]).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Central Nervous System Lymphoma (Primary), Hairy Cell Leukemia, B-Cell Lymphoma
<b>Part B Prerequisite</b>	No

## IMDELLTRA

---

### Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. SMALL CELL LUNG CANCER-patient has relapsed or refractory extensive stage disease and has previously received platinum-based chemotherapy. Note: Examples of platinum medications include cisplatin and carboplatin.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## IMJUDO

### Products Affected

- IMJUDO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	HCC, Esophageal/Esophagogastric Junction Ca, Gastric Ca-30 days, NSCLC-6 months
<b>Other Criteria</b>	<p>Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. HCC-approve if the patient has unresectable or metastatic disease or the patient is not a surgical candidate, Imjudo will be used as first-line systemic therapy in combination with Imfinzi. Non-Small Cell Lung Cancer-Approve if the patient meets ALL of the following criteria (A, B, and C): A) Patient has recurrent, advanced, or metastatic disease, AND B) Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion), AND C) Patient meets ONE of the following (i, ii, iii, or iv): i. Patient meets BOTH of the following (a and b): a) The tumor is negative for actionable molecular markers-Note: Examples of actionable molecular markers include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) genomic tumor aberrations, KRAS, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2), AND b) Imjudo is used as first-line therapy, OR ii. Patient meets both of the following (a and b): a) The tumor is positive for ONE of the following [(1), (2), or (3)]: (1) Epidermal growth factor receptor (EGFR) exon 20 mutation positive, OR (2) KRAS G12C mutation positive, OR (3) ERBB2 (HER2) mutation positive, AND b) Imjudo is used as first-line therapy, OR iii. Patient meets BOTH of the following (a and b): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) BRAF V600E mutation positive, OR (2) NTRK1/2/3 gene fusion positive, OR (3) MET exon 14 skipping mutation positive, OR (4) RET rearrangement positive, AND b)</p>

PA Criteria	Criteria Details
	<p>Imjudo is used as first-line or subsequent therapy, OR iv. Patient meets ALL of the following (a, b, and c): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) EGFR exon 19 deletion or exon 21 L858R mutation positive, OR (2) EGFR S768I, L861Q, and/or G719X mutation positive, OR (3) ALK rearrangement positive, OR (4) ROS1 rearrangement, AND b) The patient has received targeted drug therapy for the specific mutation-Note: Examples of targeted drug therapy include Gilotrif (afatinib tablets), Tagrisso (osimertinib tablets), erlotinib, Iressa (gefitinib tablets), Xalkori (crizotinib capsules), Zykadia (ceritinib capsules), Alecensa (alectinib capsules), Alunbrig (brigatinib tablets), Lorbrena (lorlatinib tablets), Rozlytrek (entrectinib capsules), or Vizimpro (dacomitinib tablets), AND c) Imjudo is used as subsequent therapy. Esophageal and Esophagogastric Junction Cancers, Gastric Cancer-approve if pt has locoregional disease AND has microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease AND Imjudo is used as neoadjuvant therapy AND Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion) AND patient is medically fit for surgery.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Esophageal and Esophagogastric Junction Cancers, Gastric Cancer
<b>Part B Prerequisite</b>	No



## INBRIJA

---

### Products Affected

- INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Asthma, COPD, other chronic underlying lung disease
<b>Required Medical Information</b>	Diagnosis, medications that will be used in combination
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient is currently taking carbidopa-levodopa and is experiencing off episodes.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# INGREZZA

## Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)
- INGREZZA SPRINKLE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	TD - Prescribed by or in consultation with a neurologist or psychiatrist. Chorea HD - prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Chorea associated with Huntington's Disease- approve if diagnosis is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## INJECTABLE TESTOSTERONE PRODUCTS

---

### Products Affected

- *testosterone cypionate*
- *testosterone enanthate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## INLYTA

### Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Advanced Renal cell carcinoma-approve. Differentiated thyroid cancer, approve if patient is refractory to radioactive iodine therapy. Soft tissue sarcoma-approve if the patient has alveolar soft part sarcoma and the medication will be used in combination with Keytruda (pembrolizumab).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma, Soft tissue sarcoma
<b>Part B Prerequisite</b>	No

## INPEFA

---

### Products Affected

- INPEFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Heart Failure, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve. Type 2 Diabetes, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve if the patient has chronic kidney disease AND has one or more cardiovascular risk factor(s).Note: Patients with heart failure should be reviewed under criteria for Heart Failure.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# INQOVI

---

## Products Affected

- INQOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Neoplasms
<b>Part B Prerequisite</b>	No

## INREBIC

---

### Products Affected

- INREBIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has intermediate-2 or high-risk disease. Myeloid/Lymphoid Neoplasms with Eosinophilia-approve if the tumor has a JAK2 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid/Lymphoid Neoplasms with Eosinophilia
<b>Part B Prerequisite</b>	No

## IVERMECTIN (ORAL)

### Products Affected

- *ivermectin oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	Pediculosis-approve if the patient has infection caused by pediculus humanus capitis (head lice), pediculus humanus corporis (body lice), or has pediculosis pubis caused by phthirus pubis (pubic lice). Scabies-approve if the patient has classic scabies, treatment resistant scabies, is unable to tolerate topical treatment, has crusted scabies or is using ivermectin tablets for prevention and/or control of scabies.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Ascariasis, Enterobiasis (pinworm infection), Hookworm-related cutaneous larva migrans, Mansonella ozzardi infection, Mansonella streptocerca infection, Pediculosis, Scabies. Trichuriasis, Wucheria bancrofti infection
<b>Part B Prerequisite</b>	No



## IVIG

---

### Products Affected

- PRIVIGEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Part B versus D determination per CMS guidance to establish if drug used for PID in pt's home.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## IWILFIN

---

### Products Affected

- IWILFIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Neuroblastoma-Approve if the patient meets the following (A, B and C): A) Patient has high-risk disease, AND B) The medication is being used to reduce the risk of relapse, AND C) Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Note: Examples of anti-GD2 immunotherapy includes Unituxin (dinutuximab intravenous infusion).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# JAKAFI

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	ALL-less than 21 years of age, GVHD-12 and older, MF/PV/CMML-2/essential thrombo/myeloid/lymphoid neoplasm/T-cell Lymphoma-18 and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For polycythemia vera patients must have tried hydroxyurea or peginterferon alfa-2a or Besremi (ropeginterferon alfa-2b-njft subcutaneous injection). ALL-approve if the mutation/pathway is Janus associated kinase (JAK)-related. GVHD, chronic-approve if the patient has tried one conventional systemic treatment for graft versus host disease (for example: prednisone, ibrutinib capsules/tablets). GVHD, acute-approve if the patient has tried one systemic corticosteroid. Atypical chronic myeloid leukemia-approve if the patient has a CSF3R mutation or a janus associated kinase 2 (JAK2) mutation. Chronic monomyelocytic leukemia-2 (CMML-2)-approve if the patient is also receiving a hypomethylating agent. Essential thrombocytopenia-approve if the patient has tried hydroxyurea, peginterferon alfa-2a or anagrelide. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the tumor has a janus associated kinase 2 (JAK2) rearrangement. T-Cell Lymphoma - approve if pt has T-cell prolymphocytic leukemia or T-cell large granular lymphocytic leukemia AND pt has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Acute lymphoblastic leukemia, atypical chronic myeloid leukemia, chronic monomyelocytic leukemia-2 (CMML-2), essential thrombocythemia, myeloid/lymphoid neoplasms, T-Cell lymphoma
<b>Part B Prerequisite</b>	No

# JAYPIRCA

## Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Mantle cell lymphoma-approve if the patient has tried at least one systemic regimen or patient is not a candidate for a systemic regimen (i.e., an elderly patient who is frail), AND the patient has tried one Bruton tyrosine kinase inhibitor (BTK) for mantle cell lymphoma. Note: Examples of a systemic regimen contain one or more of the following products: rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, Velcade (bortezomib intravenous or subcutaneous injection), lenalidomide, gemcitabine, and Venclexta (venetoclax tablets). Note: Examples of BTK inhibitors indicated for mantle cell lymphoma include Brukinsa (zanubrutinib capsules), Calquence (acalabrutinib capsules), and Imbruvica (ibrutinib capsules, tablets, and oral suspension). CLL/SLL-patient meets (A or B): A) patient has resistance or intolerance to Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules) or B) patient has relapsed or refractory disease and has tried a Bruton tyrosine kinase (BTK) inhibitor and Venclexta (venetoclax tablet)-based regimen. Examples of BTK inhibitor include: Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules). Richter's Transformation to DLBCL- pt has tried</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	at least one chemotherapy regimen or is not a candidate for a chemotherapy regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Richter's Transformation to Diffuse Large B-Cell Lymphoma
<b>Part B Prerequisite</b>	No

## JEMPERLI

### Products Affected

- JEMPERLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Endometrial cancer-approve if the patient has recurrent, advanced or metastatic disease. Mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) Solid tumors-approve if the patient has progressed on or after prior treatment and according to the prescriber, the patient does not have any satisfactory alternative treatment options. Small Bowel Adenocarcinoma-approve if the patient has dMMR or MSI-H disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation and has advanced or metastatic disease and Jemperli will be used as initial therapy when the patient has received adjuvant oxaliplatin or has a contraindication to oxaliplatin OR Jemperli is used as subsequent therapy and the patient has NOT received oxaliplatin in the adjuvant setting and the patient does NOT have a contraindication to oxaliplatin. Colon, Rectal, or Appendiceal Cancer- approve if patient has mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation AND has advanced or metastatic disease AND is being used for neoadjuvant therapy or primary or subsequent therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Small Bowel Adenocarcinoma, Colon, Rectal or Appendiceal Cancer



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No



# KADCYLA

## Products Affected

- KADCYLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	Breast Cancer-Recurrent/metastatic-1 yr, Breast Cancer-Adjuvant tx-approve 1 yr total, other-1yr
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has human epidermal growth factor receptor 2 (HER2)-positive disease and the patient is using for recurrent or metastatic breast cancer OR if using for adjuvant therapy. NSCLC-approve if the disease has activating human epidermal growth factor receptor 2 (HER2) mutations and the patient has metastatic disease. Salivary gland tumor-approve if the patient has recurrent, unresectable, or metastatic disease and the patient has human epidermal growth factor receptor 2 (HER2)-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-small cell lung cancer (NSCLC), salivary gland tumor
<b>Part B Prerequisite</b>	No

## KALYDECO

### Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with Orkambi, Trikafta or Symdeko
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	1 month of age and older
<b>Prescriber Restrictions</b>	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - must meet A, B, and C: A) pt must have one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## KANUMA

---

### Products Affected

- KANUMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient lysosomal acid lipase activity in leukocytes, fibroblasts, or liver tissue OR a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic lysosomal acid lipase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## KERENDIA

### Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with spironolactone or eplerenone
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial and continuation therapy)
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Diabetic kidney disease-initial-approve if the patient meets the following criteria (i, ii and iii): i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy AND iii. At baseline (prior to the initiation of Kerendia), patient meets all of the following (a, b, and c): a) Estimated glomerular filtration rate greater than or equal to 25 mL/min/1.73 m<sup>2</sup> AND b) Urine albumin-to-creatinine ratio greater than or equal to 30 mg/g AND c) Serum potassium level less than or equal to 5.0 mEq/L.</p> <p>Diabetic kidney disease-continuation-approve if the patient meets the following criteria (i and ii): i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

## KESIMPTA

---

### Products Affected

- KESIMPTA PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## KEYTRUDA

### Products Affected

- KEYTRUDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Melanoma - 12 and older, Glioma - less than 18 years, all others- 18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	adrenal gland tumor, anal carcinoma, extranodal NK/T-Cell Lymphoma, nasal type, Gestational trophoblastic neoplasia, mycosis fungoides/Sezary syndrome, primary cutaneous anaplastic large cell lymphoma, small cell lung cancer, soft tissue sarcoma, squamous cell skin cancer, thymic carcinoma, vulvar cancer, glioma, Kaposi sarcoma, ovarian/fallopian tube/peritoneal cancer, small bowel adenocarcinoma, thyroid carcinoma, vaginal cancer
<b>Part B Prerequisite</b>	No

# KISQALI

## Products Affected

- KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## KORLYM

### Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior surgeries
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Endogenous Cushing's Syndrome-Approve if mifepristone is being used to control hyperglycemia secondary to hypercortisolism in patients who have type 2 diabetes mellitus or glucose intolerance AND pt meets (i, ii or iii): i) patient is not a candidate for surgery or surgery has not been curative, or (ii) patient is awaiting surgery for endogenous Cushing's Syndrome or (iii) patient is awaiting therapeutic response after radiotherapy for endogenous Cushing's Syndrome.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# KOSELUGO

## Products Affected

- KOSELUGO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Neurofibromatosis Type 1-approve if prior to starting Koselugo, the patient has symptomatic, inoperable plexiform neurofibromas and if the patient is 2 to 18 years old OR if the patient is 19 years or older if the patient started on therapy with Koselugo prior to becoming 19. Circumscribed Glioma-approve if the patient has recurrent, refractory or progressive disease AND the tumor is BRAF fusion positive OR BRAF V600E activating mutation positive OR patient has neurofibromatosis type 1 mutated glioma AND this medication will be used as a single agent AND the patient is 3-21 years of age OR is greater 21 and has been previously started on therapy with Koselugo prior to becoming 21 years of age. Langerhans Cell Histiocytosis- approve if the patient meets the following criteria (A and B):</p> <p>A) Patient meets one of the following (i, ii, iii, or iv): i. Patient meets both of the following (a and b): a) Patient has multisystem Langerhans cell histiocytosis, AND b) Patient has symptomatic disease or impending organ dysfunction, OR ii. Patient has single system lung Langerhans cell histiocytosis, OR iii. Patient meets all of the following (a, b, and c): a) Patient has single system bone disease, AND b) Patient has not responded to treatment with a bisphosphonate, AND c) Patient has more than 2 bone lesions, OR iv. Patient has central nervous system disease, AND B) The medication is used as a single agent.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Circumscribed Glioma, Langerhans Cell Histiocytosis
<b>Part B Prerequisite</b>	No

# KRAZATI

---

## Products Affected

- KRAZATI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# LANREOTIDE

## Products Affected

- lanreotide subcutaneous syringe 120 mg/0.5 ml
- SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML, 90 MG/0.3 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Acromegaly-prescribed by or in consultation with an endocrinologist. Carcinoid syndrome-prescribed by or in consultation with an oncologist, endocrinologist or gastroenterologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)-approve. Carcinoid Syndrome-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pheochromocytoma/paraganglioma



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# LAPATINIB

## Products Affected

- *lapatinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which lapatinib is being used. Metastatic breast cancer, HER2 status or hormone receptor (HR) status.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	HER2-positive recurrent or metastatic breast cancer, approve if lapatinib will be used in combination with capecitabine OR trastuzumab and the patient has tried at least two prior anti-HER2 based regimens OR the medication will be used in combination with an aromatase inhibitor and and the patient has HR+ disease and the patient is a postmenopausal woman or the patient is premenopausal or perimenopausal woman and is receiving ovarian suppression/ablation with a GnRH agonist, surgical bilateral oophorectomy or ovarian irradiation OR the patient is a man and is receiving a GnRH analog. Colon or rectal cancer-approve if the patient has unresectable advanced or metastatic disease that is human epidermal receptor 2 (HER2) amplified and with wild-type RAS and BRAF disease and the patient has tried at least one chemotherapy regimen or is not a candidate for intensive therapy and the medication is used in combination with trastuzumab (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) and the patient has not been previously treated with a HER2-inhibitor. Bone Cancer-approve if the patient has recurrent chordoma and if the patient has epidermal growth-factor receptor (EGFR)-positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Bone cancer-chordoma, colon or rectal cancer, breast cancer in pre/perimenopausal women and men
<b>Part B Prerequisite</b>	Yes



## LEDIPASVIR/SOFOSBUVIR

---

### Products Affected

- LEDIPASVIR-SOFOSBUVIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with other direct acting antivirals, excluding ribavirin
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	3 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

**ConnectiCare**  
**LENALIDOMIDE**

**Products Affected**

- *lenalidomide*
- REVLIMID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis and previous therapies or drug regimens tried.
<b>Age Restrictions</b>	18 years and older (except Kaposi's Sarcoma, Castleman's Disease, CNS Lymphoma)
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Follicular lymphoma-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one prior therapy. MCL-approve -if the patient is using lenalidomide in combination with rituximab or has tried at least two other therapies or therapeutic regimens. MZL-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one other therapy or therapeutic regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). B-cell-lymphoma (other)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia and the pt has serum erythropoietin levels greater than or equal to 500 mU/mL or according to the prescriber the patient has anemia, has serum erythropoietin levels less than 500 mU/mL and patient has experienced no response or loss of response to erythropoietic stimulating agents. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve if the pt has tried at least one other therapy or regimen. CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-approve if the patient has tried at least three other regimens. Castleman's

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>disease-approve if the patient has relapsed/refractory or progressive disease. Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide is used in combination with dexamethasone.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	<p>Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma (Non-Hodgkin's Lymphoma), Myelofibrosis. Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system Lymphoma, Kaposi's sarcoma.</p>
<b>Part B Prerequisite</b>	No

## LENVIMA

### Products Affected

- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>DTC - must be refractory to radioactive iodine treatment for approval. RCC - approve if the pt meets ALL of the following criteria: 1) pt has advanced disease AND if the patient meets i or ii-i. Lenvima is is being used in combination with Keytruda OR ii. Lenvima is used in combination with Afinitor/Afinitor Disperz and the patient meets a or b-a. Patient has clear cell histology and patient has tried one antiangiogenic therapy or b. patient has non-clear cell histology. MTC-approve if the patient has tried at least one systemic therapy. Endometrial Carcinoma-Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) AND B) The medication is used in combination with Keytruda (pembrolizumab for intravenous injection) AND C)the disease has progressed on at least one prior systemic therapy AND D) The patient is not a candidate for curative surgery or radiation. HCC-approve if the patient has unresectable or metastatic disease. Thymic carcinoma-approve if the patient has tried at least one chemotherapy regimen. Melanoma - approve if the patient has unresectable or metastatic melanoma AND the medication will be used in combination with Keytruda (pembrolizumab intravenous injection) AND the patient has disease</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	progression on anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Medullary Thyroid Carcinoma (MTC), thymic carcinoma, Renal cell carcinoma with non-clear cell histology and Melanoma
<b>Part B Prerequisite</b>	No

# LIBERVANT

---

## Products Affected

- LIBERVANT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 to 5 years of age
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

# LIBTAYO

## Products Affected

- LIBTAYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous surgeries or radiation
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. CSCC-approve if the patient meets one of the following (i or ii): (i): pt has has locally advanced, recurrent, or metastatic disease and is not a candidate for curative surgery or curative radiation or (ii): pt has very-high risk, locally advanced, unresectable, or regional disease and this medication will be used as neoadjuvant therapy. Basal Cell Carcinoma-approve if the patient has locally advanced, nodal or metastatic disease. NSCLC-approve if the patient has recurrent, advanced, or metastatic disease and meets one of the following (i, ii, iii, or iv): (i): medication is used for first-line or continuation maintenance therapy AND tumor is negative for actionable mutations, or (ii): medication will be used first line AND the tumor is positive for one of EGFR exon 20 mutation, KRAS G12C mutation or ERBB2 (HER2) mutation, or (iii): medication will be used as first-line or subsequent therapy AND the tumor is positive for one of BRAF V600E mutation or NTRK1/2/3 gene fusion or MET exon 14 skipping mutation or RET rearrangement, or (iv): medication will be used as subsequent therapy AND the tumor is positive for one of EGFR S768I, L861Q, and/or G719X mutation or EGFR exon 19 deletion or exon 21 L858R or ALK rearrangement or ROS1 rearrangement AND pt has received targeted drug therapy for the specific mutation. Cervical cancer-approve if pt has local or regional recurrence or distant metastatic disease AND this medication is used

<b>PA Criteria</b>	<b>Criteria Details</b>
	as subsequent therapy. Vulvar cancer- approve if pt has advanced, recurrent, or metastatic disease AND this medication is used as subsequent therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Cervical cancer, vulvar cancer
<b>Part B Prerequisite</b>	No



# LIDOCAINE PATCH

## Products Affected

- *dermacinrx lidocan*
- *lidocaine topical adhesive patch,medicated 5 %*
- *lidocan iii*
- *lidocan iv*
- *lidocan v*
- *tridacaine ii*
- *tridacaine iii*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Diabetic neuropathic pain, chronic back pain
<b>Part B Prerequisite</b>	No

# LIVTENCITY

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with ganciclovir or valganciclovir
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	12 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist, infectious diseases specialist, oncologist, or a physician affiliated with a transplant center.
<b>Coverage Duration</b>	2 months
<b>Other Criteria</b>	Cytomegalovirus Infection, Treatment-approve if the patient meets the following criteria (A, B, and C): A) Patient weighs greater than or equal to 35 kg, AND B) Patient is post-transplant, AND Note: This includes patients who are post hematopoietic stem cell transplant or solid organ transplant. C) Patient has cytomegalovirus infection/disease that is refractory to treatment with at least one of the following: cidofovir, foscarnet, ganciclovir, or valganciclovir or patient has a significant intolerance to ganciclovir or valganciclovir.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## LONG ACTING OPIOIDS

### Products Affected

- BELBUCA
- buprenorphine
- hydromorphone oral tablet extended release 24 hr
- methadone intensol
- methadone oral concentrate
- methadone oral solution 10 mg/5 ml, 5 mg/5 ml
- methadone oral tablet 10 mg, 5 mg
- methadose oral concentrate
- morphine oral tablet extended release
- OXYCONTIN ORAL TABLET, ORAL ONLY, EXT. REL. 12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute (ie, non-chronic) pain
<b>Required Medical Information</b>	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# LONSURF

## Products Affected

- LONSURF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Gastric or Gastroesophageal Junction Adenocarcinoma, approve if the patient has been previously treated with at least two chemotherapy regimens for gastric or gastroesophageal junction adenocarcinoma. Colon and rectal cancer-approve per labeling if the patient has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type) they must also try Erbitux or Vectibix.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# LOQTORZI

## Products Affected

- LOQTORZI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Nasopharyngeal carcinoma-approve if the patient has recurrent, unresectable, oligometastatic, or metastatic disease AND the patient meets ONE of the following (i or ii): i. Patient meets BOTH of the following (a and b): a) Loqtorzi is used for first-line treatment AND b) Loqtorzi is used in combination with cisplatin and gemcitabine, OR ii. Patient meets both of the following (a and b): a) Loqtorzi is used for subsequent treatment AND b) Loqtorzi is used as a single agent.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# LORBRENA

## Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, ALK status, ROS1 status, previous therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Erdheim Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has IMT with ALK translocation. NSCLC - Approve if the patient has ALK-positive advanced or metastatic NSCLC, as detected by an approved test. In addition, patients new to therapy must also have a trial of Alecensa prior to approval of Lorbrena. NSCLC-ROS1 Rearrangement-Positive, advanced or metastatic NSCLC-approve if the patient has tried at least one of crizotinib, entrectinib or ceritinib.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-small cell lung cancer (NSCLC)-ROS1 Rearrangement-Positive, Erdheim Chester Disease, Inflammatory Myofibroblastic Tumor (IMT)
<b>Part B Prerequisite</b>	No

# LUMAKRAS

## Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 320 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. Pancreatic Adenocarcinoma- approve if patient has KRAS G12C-mutated disease, as determined by an approved test AND either (i or ii): (i) patient has locally advanced or metastatic disease and has been previously treated with at least one systemic regimen OR (ii) patient has recurrent disease after resection.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pancreatic Adenocarcinoma
<b>Part B Prerequisite</b>	No



## LUMIZYME

### Products Affected

- LUMIZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue OR patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic acid alpha-glucosidase (GAA) gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# LUNSUMIO

## Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Follicular Lymphoma-approve if the patient has received at least two lines of systemic therapy. Note: Examples of systemic therapy include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab or Gazyva (obinutuzumab intravenous infusion) and CVP (cyclophosphamide, vincristine, prednisone) plus rituximab or Gazyva.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# LUPRON DEPOT

## Products Affected

- LUPRON DEPOT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Premenstrual disorders - 18 years and older
<b>Prescriber Restrictions</b>	Prostate cancer-prescribed by/consultation with oncologist or urologist. Other cancer diagnosis- prescribed by/consultation with an oncologist. Gender dysphoria/reassignment- prescribed by/consultation with endocrinologist or physician who specializes in treatment of transgender patients
<b>Coverage Duration</b>	uterine leiomyomata - 3 months, abnormal uterine bleeding - 6 months, all others - 12 months
<b>Other Criteria</b>	Endometriosis-approve if the pt has tried one of the following, unless contraindicated: a contraceptive, an oral progesterone or depo-medroxyprogesterone injection. An exception can be made if the pt has previously tried a gonadotropin-releasing hormone [GnRH] agonist (e.g. Lupron Depot) or antagonist (e.g. Orilissa). Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease. Premenstrual disorders including PMS and PMDD- approve if pt has severe refractory premenstrual symptoms AND pt has tried an SSRI or combined oral contraceptive. Prostate cancer - for patients new to therapy requesting Lupron Depot 7.5mg, patients are required to try Orgovyx or Eligard prior to approval.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	abnormal uterine bleeding, breast cancer, gender dysphoria/gender reassignment, head and neck cancer-salivary gland tumors, ovarian cancer including fallopian tube and primary peritoneal cancers, premenstrual disorders including premenstrual syndrome and premenstrual dysphoric disorder, prophylaxis or treatment of uterine bleeding or menstrual

<b>PA Criteria</b>	<b>Criteria Details</b>
	suppression in pts with hematologic malignancy or undergoing cancer treatment or prior to bone marrow or stem cell transplant, uterine cancer
<b>Part B Prerequisite</b>	No

# LYNPARZA

## Products Affected

- LYNPARZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Maintenance monotherapy-Approve if the patient has a germline or somatic BRCA mutation-positive disease as confirmed by an approved test AND The patient is in complete or partial response to at least one platinum-based chemotherapy regimen (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine). Ovarian, fallopian tube, or primary peritoneal cancer-maintenance, combination therapy-approve if the medication is used in combination with bevacizumab, the patient has homologous recombination deficiency (HRD)-positive disease, as confirmed by an approved test and the patient is in complete or partial response to first-line platinum-based chemotherapy regimen. Breast cancer, adjuvant-approve if the patient has germline BRCA mutation-positive, HER2-negative breast cancer and the patient has tried neoadjuvant or adjuvant therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has recurrent or metastatic disease and has germline BRCA mutation-positive breast cancer. Pancreatic Cancer-maintenance therapy-approve if the patient has a germline BRCA mutation-positive metastatic disease and the disease has not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen. Prostate cancer-castration resistant-approve if the patient has metastatic disease, the medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog or the patient has had a bilateral orchiectomy, and the

PA Criteria	Criteria Details
	<p>patient meets either (i or ii): i) the patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test and the patient has been previously treated with at least one androgen receptor directed therapy or ii) the patient has a BRCA mutation and the medication is used in combination with abiraterone plus one of prednisone or prednisolone. Uterine Leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Uterine Leiomyosarcoma
<b>Part B Prerequisite</b>	No

## LYTGOBI

### Products Affected

- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease, tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an approved test and if the patient has been previously treated with at least one systemic regimen. Note: Examples of systemic regimens include gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin, capecitabine + cisplatin or oxaliplatin, gemcitabine + Abraxane (albumin-bound paclitaxel) or capecitabine or oxaliplatin, and gemcitabine + cisplatin + Abraxane.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## MAVYRET

### Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	3 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No



# MEGESTROL

## Products Affected

- *megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for weight gain for cosmetic reasons.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# MEKINIST

## Products Affected

- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Mekinist is being used. For melanoma, thyroid cancer and NSCLC must have documentation of BRAF V600 mutations
<b>Age Restrictions</b>	1 year and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Melanoma must be used in patients with BRAF V600 mutation, and patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC requires BRAF V600E Mutation and use in combination with Tafenlar. Thyroid cancer, anaplastic-patient has locally advanced or metastatic anaplastic disease AND Mekinist will be taken in combination with Tafenlar, unless intolerant AND the patient has BRAF V600-positive disease. Ovarian/fallopian tube/primary peritoneal cancer-approve if the patient has recurrent disease and the medication is used for low-grade serous carcinoma or the patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR

PA Criteria	Criteria Details
	<p>c) Glioblastoma or d) Oligodendroglioma OR iii. Melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Tafinlar (dabrafenib). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease or Rosai-Dorfman disease. Metastatic or Solid Tumors-Approve if the patient meets the following (A, B, and C): A) Patient has BRAF V600 mutation-positive disease, AND B) The medication will be taken in combination with Tafinlar (dabrafenib capsules), AND C) Patient has no satisfactory alternative treatment options. Hairy Cell Leukemia, approve if pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Tafinlar. Small bowel adenocarcinoma, approve if pt has BRAF V600E mutation-positive advanced or metastatic disease and this will be used with Tafinlar AND (i or ii): i) this will be used as initial therapy and pt has received previous FOLFOX/CAPEOX therapy in the adjuvant setting within the past 12 months or has a contraindication, or (ii) this will be used as second-line and subsequent therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Histiocytic Neoplasm, Hairy Cell Leukemia
<b>Part B Prerequisite</b>	No

# MEKTOVI

## Products Affected

- MEKTOVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, BRAF V600 status, concomitant medications
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation AND Mektovi will be used in combination with Braftovi. In addition, patients new to therapy must have a trial with Cotellic or Mekinist prior to approval of Mektovi. Histiocytic neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. multisystem disease OR, ii. pulmonary disease or, iii. central nervous system lesions. NSCLC-approve if pt has BRAF V600E mutation-positive metastatic disease AND this medication will be taken in combination with Braftovi (encorafenib capsules).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Histiocytic Neoplasms
<b>Part B Prerequisite</b>	No

# MEMANTINE

---

## Products Affected

- *memantine oral capsule, sprinkle, er 24hr*
- *memantine oral solution*
- *memantine oral tablet*
- NAMZARIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Indication for which memantine is being prescribed.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with mild to moderate vascular dementia.
<b>Part B Prerequisite</b>	No

## MEPSEVII

---

### Products Affected

- MEPSEVII

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient beta-glucuronidase activity in leukocytes, fibroblasts, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic glucuronidase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# METHYLERGONOVINE

---

## Products Affected

- *methylergonovine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## MODAFINIL/ARMODAFINIL

### Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Excessive daytime sleepiness (EDS) associated with myotonic dystrophy (modafinil only). Adjunctive/augmentation for treatment of depression in adults (modafinil only).
<b>Part B Prerequisite</b>	No



# MONJUVI

## Products Affected

- MONJUVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-Cell Lymphoma - Approve if the patient meets the following criteria: Patient has been treated with at least one prior chemotherapy regimen AND the patient is not eligible for autologous stem cell transplant AND Monjuvi will be used in combination with Revlimid (lenalidomide) OR Patient has already received 12 cycles of Monjuvi. B-cell lymphoma-Approve if the patient meets the following criteria: Patient has been treated with at least one prior chemotherapy regimen AND the patient is not eligible for autologous stem cell transplant AND Monjuvi will be used in combination with Revlimid (lenalidomide) OR Patient has already received 12 cycles of Monjuvi.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	B-Cell Lymphoma
<b>Part B Prerequisite</b>	No

## MYFEMBREE

### Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, test results
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Fibroids-Prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health
<b>Coverage Duration</b>	24 months of total therapy between Myfembree or Oriahnn
<b>Other Criteria</b>	Uterine Fibroids (Leiomyomas)-approve if the patient is premenopausal (before menopause) and is experiencing heavy menstrual bleeding associated with the uterine fibroids, the uterine fibroids have been confirmed by a pelvic ultrasound, including transvaginal ultrasonography or sonohysterography, hysteroscopy, or magnetic resonance imaging. Endometriosis-approve if the patient is premenopausal and patient has previously tried one of the following (i or ii): i. A contraceptive (e.g., combination oral contraceptives, levonorgestrel-releasing intrauterine systems, a depo-medroxyprogesterone injection), unless contraindicated OR ii. An oral progesterone (e.g., norethindrone tablets), unless contraindicated.Note: An exception to this requirement can be made if the patient has previously used a gonadotropin-releasing hormone agonist (e.g., Lupron Depot [leuprolide depot suspension]) or Orilissa (elagolix tablets).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## NAGLAZYME

### Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic arylsulfatase B gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NAYZILAM

---

## Products Affected

- NAYZILAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other medications used at the same time
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## NERLYNX

### Products Affected

- NERLYNX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Stage of cancer, HER2 status, previous or current medications tried
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Adjuvant tx-Approve for 1 year (total), advanced or metastatic disease-1 year
<b>Other Criteria</b>	Breast cancer, adjuvant therapy - approve if the patient meets all of the following criteria: patient will not be using this medication in combination with HER2 antagonists, patient has HER2-positive breast cancer AND Patient has completed one year of adjuvant therapy with trastuzumab OR could not tolerate one year of therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has HER-2 positive breast cancer, Nerlynx will be used in combination with capecitabine and the patient has tried at least two prior anti-HER2 based regimens.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NEXLETOL

## Products Affected

- NEXLETOL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and ezetimibe and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and ezetimibe and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NEXLIZET

## Products Affected

- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below).</p> <p>ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 55 mg/dL or higher or b) statin intolerant.</p> <p>PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant.</p> <p>Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene.</p> <p>Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily.</p> <p>Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of</p>



<b>PA Criteria</b>	<b>Criteria Details</b>
	atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NILUTAMIDE

---

## Products Affected

- *nilutamide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer-approve if nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NINLARO

---

## Products Affected

- NINLARO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## NITISINONE

### Products Affected

- *nitisinone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant therapy with nitisinone products
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hereditary Tyrosinemia, Type 1-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming biallelic pathogenic/likely pathogenic variants in the FAH gene OR elevated levels of succinylacetone in the serum or urine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NIVESTYM

---

## Products Affected

- NIVESTYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## NON-INJECTABLE TESTOSTERONE PRODUCTS

### Products Affected

- *testosterone transdermal gel* 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)
- *testosterone transdermal gel in metered-dose pump* 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)
- *testosterone transdermal gel in packet* 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram),
- *testosterone transdermal solution in metered pump w/app*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients.
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the

PA Criteria	Criteria Details
	individual's gender identity or gender expression.] Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-approve.Note: For a patient who has undergone gender reassignment, use this FTM criterion for hypogonadism indication.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)
<b>Part B Prerequisite</b>	No

# NUBEQA

## Products Affected

- NUBEQA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or if the patient has had a bilateral orchiectomy or if the medication is used concurrently with Firmagon. Prostate cancer-metastatic, castration sensitive-approve if (A and B): A) the medication is used in combination with docetaxel or patient has completed docetaxel therapy, and B) the medication will be used in combination with a GnRH agonist or in combination with Firmagon or if the patient had a bilateral orchiectomy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# NUCALA

## Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Asthma-6 years of age and older. EGPA/Polyps-18 years of age and older. HES-12 years and older.
<b>Prescriber Restrictions</b>	Asthma-Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA-prescribed by or in consultation with an allergist, immunologist, pulmonologist or rheumatologist. HES-prescribed by or in consultation with an allergist, immunologist, hematologist, pulmonologist or rheumatologist. Polyps-prescribed by or in consult with allergist, immunologist or Otolaryngologist.
<b>Coverage Duration</b>	Initial-Asthma/EGPA/polyps-6 months, HES-8 months. 12 months continuation.
<b>Other Criteria</b>	Asthma initial - must have blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks (prior to tx with Nucala or another monoclonal antibody therapy that may lower blood eosinophil levels) AND has received combo tx w/inhaled corticosteroid AND at least 1 additional asthma controller/maintenance med (Examples: LAMA, LABA, leukotriene receptor antagonist, monoclonal antibody) AND pt's asthma cont to be uncontrolled, or was uncontrolled prior to starting Nucala or another monoclonal antibody therapy for asthma as defined by 1 of following-pt experi 2 or more asthma exacer req tx w/systemic corticosteroids in prev yr, pt experienced 1 or more asthma exacer requiring hospitalization, urgent care visit or ED visit in the prev yr, pt has a FEV1 less than 80 percent predicted, Pt has FEV1/FVC less than 0.80, or Pt's asthma worsens upon taper of oral (systemic) corticosteroid therapy. Cont-pt responded to Nucala tx as determined by the prescribing physician AND Pt cont to receive tx with an inhaled corticosteroid. EGPA

PA Criteria	Criteria Details
	<p>initial-approve if pt has active, non-severe disease, has/had a blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks or within 6 wks prior to any monoclonal antibody that may lower blood eosinophil levels. Cont-pt responded to Nucala tx as determined by the prescribing physician.HES initial-pt has had hypereosinophilic synd for greater than or equal to 6 months AND has FIP1L1-PDGFRalpha-negative dis AND pt does NOT have identifiable non-hematologic secondary cause of hypereosinophilic synd AND prior to initiating tx with monoclonal antibody that may lower blood eosinophil levels, pt has/had a blood eosinophil level of greater than or equal to 1,000 cells per microliter. Cont-approve if the patient has responded to Nucala tx. Nasal polyps, initial-approve if pt meets ALL of the following criteria(A, B, C and D):A) pt has chronic rhinosinusitis w/nasal polyposis as evidenced by direct examination, endoscopy, or sinus CT scan AND B)pt experienced 2 or more of the following sympt for at least 6 months: nasal congest/obstruct/discharge, and/or reduction/loss of smell AND C)pt meets BOTH of the following (a and b): a)Pt has received tx with intranasal corticosteroid AND b)Pt will continue to receive tx with intranasal corticosteroid concomitantly with Nucala AND D)pt meets 1 of the following (a, b or c): a)Pt has received at least 1 course of tx with a systemic corticosteroid for 5 days or more within the previous 2 years, OR b)Pt has a contraindication to systemic corticosteroid tx, OR c)Pt had prior surgery for nasal polyps.Cont-approve if the pt has received at least 6 months of therapy, continues to receive tx with an intranasal corticosteroid and has responded to tx.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NUEDEXTA

---

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## NUPLAZID

---

### Products Affected

- NUPLAZID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# NURTEC

## Products Affected

- NURTEC ODT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention if Nurtec ODT is being taking for the preventive treatment of episodic migraine.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Migraine, Acute treatment-approve if the patient has tried at least one triptan or has a contraindication to triptans. Preventive treatment of episodic migraine-approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication) and if the patient is currently taking Nurtec ODT, the patient has had a significant clinical benefit from the medication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## NYVEPRIA

### Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
<b>Coverage Duration</b>	Cancer pts receiving chemo-6 mo. PBPC-1 mo
<b>Other Criteria</b>	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, or 3) patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients undergoing PBPC collection and therapy
<b>Part B Prerequisite</b>	No

# OCALIVA

## Products Affected

- OCALIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Prescriber specialty, lab values, prior medications used for diagnosis and length of trials
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial)
<b>Coverage Duration</b>	6 months initial, 1 year cont.
<b>Other Criteria</b>	Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies, including sp100 or gp210, if AMA is negative c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)). Patients new to therapy and continuing therapy must not have cirrhosis or must have compensated cirrhosis without evidence of portal hypertension.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## OCTREOTIDE INJECTABLE

### Products Affected

- *octreotide acetate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-presc/consult with oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma
<b>Part B Prerequisite</b>	No



## ODOMZO

### Products Affected

- ODOMZO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	BCC - Must not have had disease progression while on Erivedge (vismodegib).
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve, if the disease is limited to nodal metastases. (Note-This includes primary or recurrent nodal metastases. A patient with distant metastasis does not meet this requirement.)
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Metastatic BCC
<b>Part B Prerequisite</b>	No

## OFEV

### Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF) [A and B]: A) diagnosis confirmed by presence of usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) or surgical lung biopsy and B) forced vital capacity (FVC) greater than or equal to 40 percent of the predicted value. INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (A and B): A) diagnosis confirmed by HRCT and B) FVC greater than or equal to 40 percent of the predicted value. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE (all of A, B and C): A) FVC greater than or equal to 45 percent of the predicted value, B) fibrosing lung disease impacting more than 10 percent of lung volume on HRCT, and C) clinical signs of progression.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# OGSIVEO

---

## Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## OJEMDA

---

### Products Affected

- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)
- OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	6 months of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	PEDIATRIC LOW GRADE GLIOMA-patient has relapsed or refractory disease and the tumor is positive for one of the following: BRAF fusion, BRAF rearrangement or BRAF V600 mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## OJJAARA

---

### Products Affected

- OJJAARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Myelofibrosis-approve if the patient has intermediate-risk or high-risk disease and (a or b): a) the patient has anemia, defined as hemoglobin less than 10g/dL and has symptomatic splenomegaly and/or constitutional symptoms, or b) the patient has platelet count greater than or equal to 50x10 <sup>9</sup> /L.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ONUREG

---

### Products Affected

- ONUREG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML - Approve if the medication is used for post-remission maintenance therapy AND the patient has intermediate or poor-risk cytogenetics AND allogeneic hematopoietic stem cell transplant is not planned.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## OPDIVO

### Products Affected

- OPDIVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	colon/rectal-12 years and older, pediatric hodgkin lymphoma-less than 18 years old, All other (except gestational trophoblastic)-18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	Adjuvant treatment of melanoma-approve up to 1 year total, all other dx-1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	anal carcinoma, cervical carcinoma, endometrial carcinoma, extranodal NK/T-Cell Lymphoma, gestational trophoblastic neoplasia, merkel cell carcinoma, neuroendocrine tumors, pediatric hodgkin lymphoma, small bowel adenocarcinoma, small cell lung cancer, vulvar cancer, ampullary adenocarcinoma, bone cancer, diffuse high-grade gliomas, Kaposi sarcoma, primary mediastinal large B-cell lymphoma, biliary tract cancers, soft tissue sarcoma
<b>Part B Prerequisite</b>	No

# OPDUALAG

## Products Affected

- OPDUALAG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	12 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Melanoma-approve if the patient is greater than or equal to 40 kg and either (i or ii): (i) the patient has unresectable or metastatic disease or (ii) medication is used as neoadjuvant therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# OPSUMIT

---

## Products Affected

- OPSUMIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	PAH WHO group, right heart catheterization results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1 patients are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# OPSYNVI

---

## Products Affected

- OPSYNVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with guanylate cyclase stimulators
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1-approve if patient has had a right-heart catheterization to confirm the diagnosis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ORENCIA

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist.
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). PsA-approve. Juvenile idiopathic arthritis (JIA) [or Juvenile Rheumatoid Arthritis (JRA)]-approve if the patient has tried one other agent for this condition or the patient will be starting on Orencia concurrently with methotrexate, sulfasalazine or leflunomide or the patient has an absolute contraindication to methotrexate, sulfasalazine or leflunomide or the patient has aggressive disease. Cont tx - responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ORENCIA IV

### Products Affected

- ORENCIA (WITH MALTOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	GVHD-2 years and other
<b>Prescriber Restrictions</b>	Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist. GVHD-prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). PsA-approve. Juvenile idiopathic arthritis (JIA) [or Juvenile Rheumatoid Arthritis (JRA)]-approve if the patient has tried one other agent for this condition or the patient will be starting on Orencia concurrently with methotrexate, sulfasalazine or leflunomide or the patient has an absolute contraindication to methotrexate, sulfasalazine or leflunomide or the patient has aggressive disease. Cont tx - responded to therapy. GVHD-approve if Orencia is being used for prevention of acute graft-versus host disease, patient will also receive a calcinuerin inhibitor for prevention of acute graft-versus-host disease, patient will also receive methotrexate for prevention of acute graft-versus-host disease, patient will undergo hematopoietic stem cell transplanation from one of the following donors: matched unrelated donor OR 1-allele-mismatched unrelated donor.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# ORGOVYX

---

## Products Affected

- ORGOVYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Prostate Cancer-approve.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ORKAMBI

## Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Combination use with Kalydeco, Trikafta or Symdeko.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	1 year of age and older
<b>Prescriber Restrictions</b>	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt mees A, B and C: A) pt has two copies of the F508del mutation in the CTFR gene, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ORSERDU

### Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast cancer in postmenopausal women or Men-approve if the patient meets the following criteria (A, B, C, D, and E): A) Patient has recurrent or metastatic disease, AND B) Patient has estrogen receptor positive (ER+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has estrogen receptor 1 gene (ESR1)-mutated disease, AND E) Patient has tried at least one endocrine therapy. Note: Examples of endocrine therapy include fulvestrant, anastrozole, exemestane, letrozole, and tamoxifen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# OZEZLA

## Products Affected

- OZEZLA MG (51), 10 MG (4)-20 MG (4)-30 MG
- OZEZLA STARTER ORAL (47)
- TABLETS,DOSE PACK 10 MG (4)- 20

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

# OXERVATE

---

## Products Affected

- OXERVATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment duration greater than 16 weeks per affected eye(s)
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by an ophthalmologist or an optometrist.
<b>Coverage Duration</b>	Initial-8 weeks, continuation-approve for an additional 8 weeks
<b>Other Criteria</b>	Patients who have already received Oxervate-approve if the patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PADCEV

### Products Affected

- PADCEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Urothelial carcinoma-approve if the patient has locally advanced or metastatic disease and meets either (i or ii): (i): Padcev is used as first-line therapy and will be used in combination with Keytruda (pembrolizumab intravenous infusion), or (ii): Padcev is used as subsequent therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PANRETIN

---

### Products Affected

- PANRETIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a dermatologist, oncologist, or infectious disease specialist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Kaposi Sarcoma-approve if the patient is not receiving systemic therapy for Kaposi Sarcoma.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PEMAZYRE

### Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test AND the patient has been previously treated with at least one systemic therapy regimen. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement, as detected by an approved test and the cancer is in chronic phase or blast phase.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PENICILLAMINE

### Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Wilson's Disease-Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cystinuria-approve. Wilson's disease-approve if diagnosis is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, d): a) Presence of Kayser-Fleischer rings, b) Serum ceruloplasmin level less than 20 mg/dL, c) Liver biopsy findings consistent with Wilson's disease, d) 24-hour urinary copper greater than 40 mcg/24 hours.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PHENYL BUTYRATE

### Products Affected

- *sodium phenylbutyrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant therapy with more than one phenylbutyrate product
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
<b>Coverage Duration</b>	Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval
<b>Other Criteria</b>	Urea cycle disorders-approve if genetic testing confirmed a mutation resulting in a urea cycle disorder or if the patient has hyperammonemia diagnosed with an ammonia level above the upper limit of the normal reference range for the reporting laboratory.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PHEOCHROMOCYTOMA

### Products Affected

- *metyrosine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior medication trials
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial and continuation therapy for metyrosine)
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	If the requested drug is metyrosine for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). If the requested drug is metyrosine for continuation therapy, approve if the patient is currently receiving metyrosine or has received metyrosine in the past.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

### Products Affected

- *alyq*
- *sildenafil (pulmonary arterial hypertension) intravenous solution 10 mg/12.5 ml*
- *sildenafil (pulmonary arterial hypertension) oral tablet 20 mg*
- *tadalafil (pulm. hypertension)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use With Guanylate Cyclase Stimulators.
<b>Required Medical Information</b>	Diagnosis, right heart cath results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# PIQRAY

---

## Products Affected

- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X 1), 300 MG/DAY (150 MG X 2), 300 MG/DAY (150 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	PENDING CMS REVIEW
Required Medical Information	PENDING CMS REVIEW
Age Restrictions	PENDING CMS REVIEW
Prescriber Restrictions	PENDING CMS REVIEW
Coverage Duration	PENDING CMS REVIEW
Other Criteria	PENDING CMS REVIEW
Indications	PENDING CMS REVIEW
Off-Label Uses	PENDING CMS REVIEW
Part B Prerequisite	PENDING CMS REVIEW

## PIRFENIDONE

### Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## PLEGRIDY

---

### Products Affected

- PLEGRIDY INTRAMUSCULAR
- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use of with other disease-modifying agents used for multiple sclerosis (MS).
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist or an MS specialist.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## POLIVY

### Products Affected

- POLIVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma/High-Grade B-Cell Lymphoma-Approve if the patient has International Prognostic Index score of greater than or equal to 2 and will use Polivy as first line therapy OR the patient has been treated with at least one prior chemotherapy regimen. Note: Diffuse large B-cell lymphoma includes histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma. B-Cell Lymphoma (Examples include HIV-related B-cell lymphoma and post-transplant lymphoproliferative disorders) - approve if the patient has been treated with at least one prior chemotherapy regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	B-Cell Lymphoma
<b>Part B Prerequisite</b>	No

# POMALYST

## Products Affected

- POMALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Kaposi Sarcoma/MM-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	CNS Lymphoma-approve if the patient has relapsed or refractory disease. Kaposi Sarcoma-Approve if the patient meets one of the following (i or ii): i. patient is Human Immunodeficiency Virus (HIV)-negative OR ii. patient meets both of the following (a and b): a) The patient is Human Immunodeficiency Virus (HIV)-positive AND b) The patient continues to receive highly active antiretroviral therapy (HAART). MM-approve if the patient has received at least one other Revlimid (lenalidomide tablets)-containing regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Systemic Light Chain Amyloidosis, Central Nervous System (CNS) Lymphoma
<b>Part B Prerequisite</b>	No



## POSACONAZOLE (ORAL)

---

### Products Affected

- *posaconazole oral tablet, delayed release (dr/ec)*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Aspergillus/Candida prophylaxis, mucormycosis-6 mo, all others-3 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	mucomycosis - maintenance, fusariosis, invasive - treatment fungal infections (systemic) in patients with human immunodeficiency virus (HIV) infections (e.g., histoplasmosis, coccidioidomycosis) - treatment.
<b>Part B Prerequisite</b>	No

# POTELIGEO

---

## Products Affected

- POTELIGEO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Mycosis fungoides/Sezary-prescribed by, or in consultation with an oncologist or dermatologist. ATLL-prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Mycosis Fungoides/Sezary Syndrome-Approve. ATLL-patient has relapsed or refractory disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Adults with T-cell leukemia/lymphoma (ATLL)
<b>Part B Prerequisite</b>	No



# PREVYMIS

---

## Products Affected

- PREVYMIS INTRAVENOUS
- PREVYMIS ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# PROLIA

## Products Affected

- PROLIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with other medications for osteoporosis
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	<p>Treatment of postmenopausal osteoporosis/Treatment of osteoporosis in men (to increase bone mass) [a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression], approve if the patient meets one of the following: 1. has had inadequate response after 12 months of therapy with an oral bisphosphonate, had osteoporotic fracture or fragility fracture while receiving an oral bisphosphonate, or intolerability to an oral bisphosphonate, OR 2. the patient cannot take an oral bisphosphonate because they cannot swallow or have difficulty swallowing, they cannot remain in an upright position, or they have a pre-existing GI medical condition, OR 3. pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR 4. the patient has severe renal impairment (eg, creatinine clearance less than 35 mL/min) or chronic kidney disease, or if the patient has an osteoporotic fracture or fragility fracture . Treatment of bone loss in patient at high risk for fracture receiving ADT for nonmetastatic prostate cancer, approve if the patient has prostate cancer that is not metastatic to the bone and the patient is receiving ADT (eg, leuprolide, triptorelin, goserelin) or the patient has undergone a bilateral orchiectomy. Treatment of bone loss (to increase bone mass) in patients at high risk for fracture receiving adjuvant AI therapy for breast cancer, approve if the patient has breast cancer that is not metastatic to the bone and in receiving concurrent AI therapy (eg, anastrozole, letrozole,</p>

PA Criteria	Criteria Details
	<p>exemestane). Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# PROMACTA

---

## Products Affected

- PROMACTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## PYRIMETHAMINE

### Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient's immune status (Toxoplasma gondii Encephalitis, chronic maintenance and prophylaxis, primary)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis
<b>Part B Prerequisite</b>	No

# QINLOCK

## Products Affected

- QINLOCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies tried
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Gastrointestinal stromal tumor (GIST)-approve if the patient has tried imatinib or avapritinib tablets, AND the patient meets one of the following criteria (i, ii, or iii): i. Patient has tried sunitinib and regorafenib tablets, OR ii. Patient has tried dasatinib tablets, OR iii. Patient is intolerant of sunitinib. Melanoma, cutaneous-approve if the patient has metastatic or unresectable disease, AND the patient has an activating KIT mutation, AND the patient has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Melanoma, cutaneous
<b>Part B Prerequisite</b>	No

# QULIPTA

## Products Affected

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Preventive treatment of episodic migraine-approve if the patient meets (A and B): A) has greater than or equal to 4 and less than 15 migraine headache days per month (prior to initiating a migraine-preventative medication, and B) if the pt is currently taking Qulipta, the pt has had significant clinical benefit. Chronic migraine prevention-approve if the patient has greater than or equal to 15 migraine headache days per month (prior to initiating a migraine-preventative medication).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# RADICAVA ORS

## Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT SUSP

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	ALSFRS-R score, FVC %, time elapsed since diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS (initial and continuation).
<b>Coverage Duration</b>	Initial, 6 months. Continuation, 6 months
<b>Other Criteria</b>	ALS, initial therapy - approve if the patient meets ALL of the following criteria: 1. According to the prescribing physician, the patient has a definite or probable diagnosis of ALS, based on the application of the El Escorial or the revised Airlie house diagnostic criteria AND 2. Patient has a score of two points or more on each item of the ALS Functional Rating Scale - Revised (ALSFRS-R) [ie, has retained most or all activities of daily living], AND 3. Patient has a percent predicted FVC greater than or equal to 80% (ie, has normal respiratory function), AND 4. Patient has been diagnosed with ALS for less than or equal to 2 years. 5. Patient has received or is currently receiving riluzole tablets. Note-a trial of Tiglutik or Exservan would also count. ALS, continuation therapy - approve if, according to the prescribing physician, the patient continues to benefit from therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## RECLAST

### Products Affected

- *zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Medications for Osteoporosis (e.g., other bisphosphonates, Evenity, Prolia, Forteo/Bonsity, Tymlos, calcitonin nasal spray)
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Paget's 1 month. Others 12 months.
<b>Other Criteria</b>	Tx of osteo in post menopausal pt or osteo in men (a man defined as an individual with biological traits of man, regardless of the individual's gender identity/gender expression), must meet ONE of the following: pt had inadequate response after 12 mo (eg, ongoing and sign loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or pt experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot swallow or has difficulty swallowing or pt cannot remain in upright position post oral bisphos admin or pt has pre-existing GI condition (eg, pt with esophageal lesions/ulcers, or abnormal of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt had an osteo fracture or a fragility fracture OR pt has tried IV Reclast (zoledronic acid). Tx of PMO may have also tried IV Boniva (ibandronate) for approval. Prevent or tx of GIO, approve if: pt is initiating or cont therapy with systemic glucocorticoids, AND had an inadequate response after 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or pt had an osteo fracture or fragility fracture while on therapy or pt experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot

PA Criteria	Criteria Details
	<p>swallow or has difficulty swallowing or pt cannot remain in an upright position post oral bisphos administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), or has tried Reclast OR patient had an osteo fracture or a fragility fracture. Tx of Paget's disease, approve if pt has elevations in serum alkaline phos of two times higher than the upper limit of the age-specific normal reference range, OR pt is symptomatic (eg, bone pain, hearing loss, osteoarthritis), OR pt is at risk for complications from their disease (eg, immobilization, bone deformity, fractures, nerve compression syndrome). Prevent of PMO - meets 1 of the following had inadequate response after trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or patient experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphos admin or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions/ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried Reclast or the patient has had an osteo fracture or fragility fracture.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# RELEUKO

---

## Products Affected

- RELEUKO SUBCUTANEOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## REMICADE

### Products Affected

- REMICADE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medication, previous medications tried
<b>Age Restrictions</b>	CD and UC, Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	All dx-initial therapy only-Prescribed by or in consult w/RA/AS/Still's/JIA/JRA-rheumatol.Plaque Psor/Pyoderma gangrenosum/HS-dermatol.Psoriatic Arthritis-rheumatol or dermatol.CD/UC-gastroenterol.Uveitis-ophthalmol.GVHD-transplant center, oncol, or hematol.Behcet's- rheumatol, dermatol,ophthalmol, gastroenterol, or neurol.Sarcoidosis-pulmonol, ophthalmol, or dermatol, cardio/neuro.
<b>Coverage Duration</b>	FDAind ini-3 mo,cont1yr,GVHD ini-1 mo,cont-3 mo,Pyo Gang-ini4 mo,cont1 yr,others-ini 3mo,cont-12 mo
<b>Other Criteria</b>	INITIAL THERAPY: RHEUMATOID ARTHRITIS: tried one conventional synthetic DMARD for at least 3 months (e.g., MTX, leflunomide, hydroxychloroquine, sulfasalazine. 3-month trial of a biologic also counts). CROHN'S DISEASE [one of A, B, C, or D]: A) tried or currently taking corticosteroid (CS) or CS is contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine [AZA], 6-mercaptopurine [6-MP], MTX. Trial of a biologic also counts.), C) had ileocolonic resection, or D) enterocutaneous (perianal or abdominal) or rectovaginal fistulas. ULCERATIVE COLITIS (A or B): A) tried or intolerant to a systemic therapy (e.g., 6-MP, AZA, cyclosporine [CSA], tacrolimus, or a CS. A biologic also counts.) or B) has pouchitis and tried therapy with an antibiotic, probiotic, CS enema, or mesalamine (Rowasa) enema. BEHCET'S (A or B): A) tried one conventional therapy (e.g., systemic CS, immunosuppressants such as AZA, MTX, mycophenolate, CSA, tacrolimus, chlorambucil, cyclophosphamide, interferon alfa. TNF inhibitor also counts.) or B) ophthalmic manifestations. STILL'S DISEASE

PA Criteria	Criteria Details
	<p>(A and B): A) tried one CS and B) tried one DMARD for at least 2 months or intolerant (e.g., MTX. Trial of a biologic also counts.) UVEITIS: tried periocular, intraocular or systemic CS or immunosuppressive (e.g., MTX, mycophenolate, CSA. Trial of a biologic also counts.) SARCOIDOSIS (A and B): A) tried one CS and B) tried one immunosuppressant (e.g., MTX, AZA, leflunomide, mycophenolate, hydroxychloroquine, chloroquine.) PYODERMA GANGRENOSUM (A or B): A) tried one systemic CS or B) tried one immunosuppressant for at least 2 months or intolerant (e.g., mycophenolate, CSA). HIDRADENITIS SUPPURATIVA: Tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics, isotretinoin). GRAFT VS HOST DISEASE: Tried one conventional systemic treatment (e.g., CS, antithymocyte globulin, CSA, tacrolimus, mycophenolate.) JUVENILE IDIOPATHIC ARTHRITIS: (A or B): A) tried one systemic medication (e.g., MTX, sulfasalazine, leflunomide, NSAID. Trial of a biologic also counts.) or B) has aggressive disease. PLAQUE PSORIASIS (A or B): A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Trial of a biologic will also count) or B) contraindication to MTX. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Behcet's disease (BD). Still's disease (SD). Uveitis (UV). Pyoderma gangrenosum (PG). Hidradenitis suppurativa (HS). Graft-versus-host disease (GVHD). Juvenile Idiopathic Arthritis (JIA). Sarcoidosis
<b>Part B Prerequisite</b>	No

## REMODULIN

### Products Affected

- *treprostinil sodium*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Oral or Inhaled Prostacyclin Agents Used for Pulmonary Hypertension.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH WHO Group 1, prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation).
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Pulmonary Arterial Hypertension (PAH) [World Health Organization (WHO) Group 1], Initial Therapy- Approve if the patient meets all of the following criteria (i, ii, iii, and iv): i. Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND ii. Patient meets the following criteria (a and b): a) Patient has had a right heart catheterization, AND b) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH, AND iii. Patient meets ONE of the following criteria (a or b): a) Patient is in Functional Class III or IV, OR b) Patient is in Functional Class II and meets ONE of the following criteria [(1) or (2)]: (1) Patient has tried or is currently receiving one oral agent for PAH, OR (2) Patient has tried one inhaled or parenteral prostacyclin product for PAH, AND iv. Patient with idiopathic PAH must meet ONE of the following criteria (a, b, c, d, or e): a) Patient meets both of the following criteria [(1) and (2)]: (1) the patient has had an acute response to vasodilator testing that occurred during the right heart catheterization, AND (2) Patient has tried one calcium channel blocker (CCB) therapy, OR b) According to the prescriber, the patient did not have an acute response to vasodilator testing, OR c) According to the prescriber, the patient cannot undergo a vasodilator test, OR d) Patient cannot take CCB therapy, OR e) Patient has tried one CCB. Continuation-Approve if the patient meets ALL of the following</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>conditions (a and b): a) Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND b) Patient meets the following criteria [(1) and (2)]: (1) Patient has had a right heart catheterization, AND (2) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# REPATHA

---

## Products Affected

- REPATHA
- REPATHA SURECLICK
- REPATHA PUSHTRONEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW



## RETEVMO

---

### Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	PENDING CMS REVIEW
Required Medical Information	PENDING CMS REVIEW
Age Restrictions	PENDING CMS REVIEW
Prescriber Restrictions	PENDING CMS REVIEW
Coverage Duration	PENDING CMS REVIEW
Other Criteria	PENDING CMS REVIEW
Indications	PENDING CMS REVIEW
Off-Label Uses	PENDING CMS REVIEW
Part B Prerequisite	PENDING CMS REVIEW

## REZDIFFRA

---

### Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## REZLIDHIA

---

### Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Acute myeloid leukemia-approve if the patient has relapsed or refractory disease and the patient has isocitrate dehydrogenase-1 (IDH1) mutation positive disease as detected by an approved test.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# REZUROCK

---

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	12 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Graft-versus-host disease-approve if the patient has chronic graft-versus-host disease and has tried at least two conventional systemic treatments (e.g., ibrutinib, cyclosporine) for chronic graft-versus-host disease.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# RILUZOLE

---

## Products Affected

- *riluzole*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# RINVOQ

---

## Products Affected

- RINVOQ ORAL TABLET EXTENDED  
RELEASE 24 HR 15 MG, 30 MG, 45 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## RINVOQ LQ

### Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic DMARD, other potent immunosuppressants, other janus kinase inhibitors, or a biologic immunomodulator.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	PsA-2 years and older (initial therapy)
<b>Prescriber Restrictions</b>	JIA-prescribed by or in consultation with a rheumatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or a dermatologist (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: JUVENILE IDIOPATHIC ARTHRITIS (JIA)/ PSORIATIC ARTHRITIS (PsA) - 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial. CONTINUATION THERAPY: ALL INDICATIONS - patient responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ROFLUMILAST (ORAL)

### Products Affected

- *roflumilast*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Chronic Obstructive Pulmonary Disease (COPD), medications tried.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# ROZLYTREK

## Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	NSCLC-18 years and older, Solid Tumors-1 month and older, Pediatric Diffuse High-Grade Glioma-less than 18 years old
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Solid Tumors-Approve if the patient's tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease and the mutation was detected by an approved test. Pediatric Diffuse High-Grade Glioma- approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the medication is used either as adjuvant therapy or for recurrent or progressive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pediatric Diffuse High-Grade Glioma
<b>Part B Prerequisite</b>	No

## RUBRACA

### Products Affected

- RUBRACA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Rubraca is being used. BRCA-mutation (germline or somatic) status. Other medications tried for the diagnosis provided
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Maintenance Therapy of Ovarian, Fallopian tube or Primary peritoneal cancer-Approve if the patient is in complete or partial response after a platinum-based chemotherapy regimen and the patient is in complete or partial response to first-line primary treatment or if the patient has recurrent disease and has a BRCA mutation. Castration-Resistant Prostate Cancer - Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has metastatic disease that is BRCA-mutation positive (germline and/or somatic) AND B) The patient meets one of the following criteria (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy AND C) The patient has been previously treated with at least one androgen receptor-directed therapy AND D) The patient meets one of the following criteria (i or ii): i. The patient has been previously treated with at least one taxane-based chemotherapy OR ii. The patient is not a candidate or is intolerant to taxane-based chemotherapy. Pancreatic adenocarcinoma-approve if pt has a BRCA mutation or PALB2 mutation AND pt has tried platinum-based chemotherapy AND has not had disease progression following the most recent platinum-based chemotherapy. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Uterine Leiomyosarcoma, Pancreatic Adenocarcinoma
<b>Part B Prerequisite</b>	No

## RUFINAMIDE

---

### Products Affected

- *rufinamide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Patients 1 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Initial therapy-approve if rufinamide is being used for adjunctive treatment. Continuation-approve if the patient is responding to therapy
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Treatment-Refractory Seizures/Epilepsy
<b>Part B Prerequisite</b>	No

## RUXIENCE

---

### Products Affected

- RUXIENCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

# RYBREVANT

## Products Affected

- RYBREVANT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Small Cell Lung Cancer (NSCLC) - approve if pt has locally advanced or metastatic disease AND either (A or B): (A) the pt has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, EGFR exon 19 deletion, or EGFR exon 21 L858R mutation, as detected by an approved test OR pt meets both of the following (a and b): a) medication is used as subsequent therapy AND b) pt has EGFR S768I, L861Q, and/or G719X mutation.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# RYDAPT

## Products Affected

- RYDAPT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For AML, FLT3 status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML -approve if the patient is FLT3-mutation positive as detected by an approved test. Myeloid or lymphoid Neoplasms with eosinophilia-approve if the patient has an FGFR1 rearrangement or has an FLT3 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid or lymphoid Neoplasms with eosinophilia
<b>Part B Prerequisite</b>	No

## RYTELO

### Products Affected

- RYTELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist or oncologist (initial)
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL THERAPY: MYELODYSPLASTIC SYNDROME-All of (i, ii, iii, iv, and v): i.Low- to intermediate-1 risk myelodysplastic syndrome (MDS), Note: MDS risk category is determined using the International Prognostic Scoring System (IPSS). AND, ii.Transfusion-dependent anemia, defined as requiring transfusion of greater than or equal to 4 red blood cell units over an 8-week period, AND iii. Has not responded, lost response to, or is ineligible for erythropoiesis-stimulating agents, Note: Examples of erythropoiesis-stimulating agents (ESA): epoetin alfa product (e.g., Epogen, Procrit, or Retacrit), a darbepoetin alfa product (e.g., Aranesp), or a methoxy polyethylene glycol-epoetin beta product (e.g., Mircera). AND, iv. Does NOT have deletion 5q [del(5q)] cytogenic abnormalities, AND v.Rytelo will NOT be used in combination with an ESA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# SANDOSTATIN LAR

## Products Affected

- SANDOSTATIN LAR DEPOT  
INTRAMUSCULAR SUSPENSION,  
EXTENDED RELEASE RECON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous treatments/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Acromegaly-prescr/consult w/endocrinologist. All neuroendocrine tumors-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist or neurosurgeon.Thymoma/Thymic carcinoma-prescr/consult w/oncologist
<b>Coverage Duration</b>	Enterocutaneous fistula - 3 months, all others - 1 year
<b>Other Criteria</b>	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptides-secreting tumors [VIPomas], insulinomas)-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Pheochromocytoma/paraganglioma, Meningioma, Thymoma and thymic carcinoma, enterocutaneous fistulas
<b>Part B Prerequisite</b>	No



# SAPROPTERIN

---

## Products Affected

- *sapropterin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## SARCLISA

### Products Affected

- SARCLISA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if pt meets (A, B, or C): A) the requested medication will be used as primary therapy in combination with bortezomib, lenalidomide, and dexamethasone, or B) the requested medication will be used in combination with Pomalyst and dexamethasone and the patient has tried at least TWO prior regimens for multiple myeloma and a proteasome inhibitor was a component of at least one previous regimen and Revlimid was a component of at least one previous regimen, or C) medication will be used in combination with Kyprolis and dexamethasone and pt has tried at least one prior regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## SCSEMBLIX

### Products Affected

- SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Chronic Myeloid Leukemia (CML)-approve if the patient meets the following (A and B): A) Patient has Philadelphia chromosome-positive chronic myeloid leukemia, AND B) Patient meets one of the following (i or ii): i. The chronic myeloid leukemia is T315I-positive, OR ii. Patient has tried at least two other tyrosine kinase inhibitors indicated for use in Philadelphia chromosome-positive chronic myeloid leukemia. Note: Examples of tyrosine kinase inhibitors include imatinib tablets, Bosulif (bosutinib tablets), Iclusig (ponatinib tablets), Sprycel (dasatinib tablets), and Tasigna (nilotinib capsules). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has an ABL1 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Myeloid/Lymphoid Neoplasms with Eosinophilia
<b>Part B Prerequisite</b>	No

## SIGNIFOR

---

### Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy)
<b>Coverage Duration</b>	Cushing's disease/syndrome-Initial therapy - 4 months, Continuation therapy - 1 year.
<b>Other Criteria</b>	Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## SIRTURO

### Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients weighing less than 15 kg
<b>Required Medical Information</b>	Diagnosis, concomitant therapy
<b>Age Restrictions</b>	Patients 5 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with an infectious diseases specialist
<b>Coverage Duration</b>	9 months
<b>Other Criteria</b>	Tuberculosis (Pulmonary)-Approve if the patient has multidrug-resistant tuberculosis and the requested medication is prescribed as part of a combination regimen with other anti-tuberculosis agents
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# SKYRIZI

## Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis, Previous medication use
<b>Age Restrictions</b>	PP-18 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	PP-Prescribed by or in consultation with a dermatologist (initial therapy), PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy), CD-presc/consult-gastro (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or PUVA) for at least 3 months, unless intolerant. (Note: a 3-month trial or previous intolerance to at least one biologic also counts) or B) contraindication to MTX. PSORIATIC ARTHRITIS (PsA): approve. CROHN'S DISEASE (CD) [one of A, B, C, or D]: A) tried or is currently taking corticosteroids, unless contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-mercaptopurine, MTX) [Notes: a trial of a biologic that is not a biosimilar of Skyrizi also counts. A trial of mesalamine does not count as a systemic agent], C) patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or D) patient had ileocolonic resection to reduce the chance of CD recurrence. ALL INDICATIONS: Patient must be receiving induction dosing with Skyrizi IV within 3 months of initiating therapy with Skyrizi subcutaneous. CONTINUATION THERAPY: ALL INDICATIONS: patient has responded to therapy.
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## SKYRIZI IV

### Products Affected

- SKYRIZI INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis, Previous medication use
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Approve for 3 doses
<b>Other Criteria</b>	<p>Crohn's Disease- approve if this medication will be used as induction therapy AND the pt meets one of the following (i, ii, iii, or iv): (i) pt has tried or is currently taking a systemic corticosteroid, or a systemic corticosteroid is contraindicated in this patient, or (ii) pt has tried one other conventional systemic therapy for Crohn's disease (ex: azathioprine, 6-mercaptopurine, or methotrexate. Mesalamine does not count. An exception can be made if pt tried at least one biologic OTHER than the requested medication/biosimilar of the requested medication.) or (iii) pt has enterocutaneous (perianal or abdominal) or rectovaginal fistulas or (iv) pt had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Ulcerative colitis- approve if this medication will be used as induction therapy AND pt meets one of the following (i or ii): i) pt tried one systemic therapy (ex: 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A trial of one biologic other than the requested medication also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count.) or ii) pt has pouchitis and has tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema. (Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema.)</p>



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## SOFOSBUVIR/VELPATASVIR

---

### Products Affected

- SOFOSBUVIR-VELPATASVIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Combination use with other direct acting antivirals, excluding ribavirin.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	3 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied according to AASLD guidelines.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

# SOLARAZE

---

## Products Affected

- *diclofenac sodium topical gel 3 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 6 months.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# SOMAVERT

## Products Affected

- SOMAVERT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapy, concomitant therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## SORAFENIB

### Products Affected

- *sorafenib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>Bone cancer, approve if the patient has recurrent chordoma or has osteosarcoma and has tried one standard chemotherapy regimen. GIST, approve if the patient has tried TWO of the following: imatinib mesylate, avapritinib, sunitinib, dasatinib, ripretinib or regorafenib. Differentiated (ie, papillary, follicular, oncocytic) thyroid carcinoma (DTC), approve if the patient is refractory to radioactive iodine treatment. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. AML - Approve if disease is FLT3-ITD mutation positive as detected by an approved test and the medication is used in combination with azacitidine or decitabine or patient has had an allogeneic stem cell transplant and is in remission. Renal cell carcinoma (RCC)-approve if the patient has relapsed or advanced clear cell histology and the patient has tried at least one systemic therapy (e.g., Inlyta, Votrient, Sutent Cabometyx). Ovarian, fallopian tube, primary peritoneal cancer-approve if the patient has platinum resistant disease and sorafenib is used in combination with topotecan. HCC-approve if the patient has unresectable or metastatic disease. Soft tissue sarcoma-approve if the patient has angiosarcoma or desmoid tumors (aggressive fibromatosis) or solitary fibrous tumor/hemangiopericytoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement. Please note for all diagnoses: Part B before Part D Step Therapy applies only to beneficiaries enrolled in an MA-PD plan</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Bone cancer, Soft tissue sarcoma, gastrointestinal stromal tumors (GIST), medullary thyroid carcinoma, Acute Myeloid Leukemia, ovarian, fallopian tube, primary peritoneal cancer, myeloid/lymphoid neoplasms with eosinophilia
<b>Part B Prerequisite</b>	Yes

## SOTYKTU

### Products Affected

- SOTYKTU

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other biologics or with targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Concurrent use with other potent immunosuppressants, including methotrexate.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a dermatologist (initial)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of a biologic will also count) or B) contraindication to MTX. CONTINUATION THERAPY: patient had a response to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# SPRAVATO

## Products Affected

- SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by a psychiatrist
<b>Coverage Duration</b>	MDD w/Acute Suicidal Ideation or Behavior - 2 months, Treatment-Resistant Depression - 6 months
<b>Other Criteria</b>	Major Depressive Disorder with Acute Suicidal Ideation or Behavior: approve if the patient has major depressive disorder that is considered to be severe, AND if the patient is concomitantly receiving at least one oral antidepressant, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks. Treatment-Resistant Depression: approve if the patient has demonstrated nonresponse (less than or equal to 25 percent improvement in depression symptoms or scores) to at least two different antidepressants, each from a different pharmacologic class and each antidepressant was used at therapeutic dosages for at least 6 weeks in the current episode of depression, AND patient is concomitantly receiving at least one oral antidepressant, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks, AND patient's history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

## SPRYCEL

### Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Sprycel is being used. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For melanoma, cutaneous- KIT mutation and previous therapies.
<b>Age Restrictions</b>	GIST/bone cancer/ melanoma, cutaneous-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	For CML, patient must have Ph-positive CML. For ALL, patient must have Ph-positive ALL. For Bone Cancer-approve if patient has chondrosarcoma or chordoma. GIST - approve if the patient has tried imatinib or avapritinib. For melanoma, cutaneous - approve if patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	GIST, bone cancer, melanoma cutaneous
<b>Part B Prerequisite</b>	No

# STELARA

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION
- STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis, concurrent medications, previous drugs tried.
<b>Age Restrictions</b>	PP-6 years and older (initial therapy).
<b>Prescriber Restrictions</b>	Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>INITIAL THERAPY for STELARA SC: PLAQUE PSORIASIS (PP) [A or B]: A) tried one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, psoralen plus PUVA) for at least 3 months, unless intolerant or B) contraindication to MTX. (Note: a 3-month trial or intolerance of at least one biologic that is not Stelara or a Stelara biosimilar also counts.) CROHN'S DISEASE (CD) [A and B]: A) receiving/received single IV loading dose within 2 months of initiating therapy with Stelara SC, and B) (a, b, c or d): a) tried or is currently taking corticosteroids (CS), or CS are contraindicated, b) tried one conventional systemic therapy, c) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or d) had ileocolonic resection to reduce the chance of CD recurrence.</p> <p>ULCERATIVE COLITIS (UC) [A and B]: A) receiving/received single IV loading dose within 2 months of initiating therapy with Stelara SC and B) meets one of the following (a or b): a) tried one systemic agent or b) has pouchitis and tried an antibiotic, probiotic, CS enema or mesalamine enema. INDUCTION THERAPY for STELARA IV: UC [A or B]: A) tried one systemic agent or B) has pouchitis and has tried an antibiotic, probiotic, CS enema or mesalamine enema. CD, approve single dose of IV if meets A, B, C, or D: A) tried or is currently taking CS, or CS are</p>

PA Criteria	Criteria Details
	<p>contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-MP, MTX, certolizumab, vedolizumab, adalimumab, infliximab), C) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or D) had ileocolonic resection to reduce the chance of Crohn's disease recurrence. CONTINUATION THERAPY: PP/PsA/CD/UC: patient has responded to therapy.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## STELARA IV

### Products Affected

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Approve a single dose
<b>Other Criteria</b>	INDUCTION THERAPY for STELARA IV: UC [A or B]: A) tried one systemic agent or B) has pouchitis and has tried an antibiotic, probiotic, CS enema or mesalamine enema. Crohn's Disease [A, B, C, or D]: A) tried or is currently taking CS, or CS are contraindicated, B) tried one other conventional systemic therapy (e.g., azathioprine, 6-MP, MTX, certolizumab, vedolizumab, adalimumb, infliximab), C) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or D) had ileocolonic resection to reduce the chance of Crohn's disease recurrence.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# STIVARGA

## Products Affected

- STIVARGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Stivarga is being used. Prior therapies tried. For metastatic CRC, KRAS/NRAS mutation status.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For GIST, patient must have previously been treated with imatinib or Ayvakit and sunitinib or Sprycel. For HCC, patient must have previously been treated with at least one systemic regimen. Soft tissue sarcoma, advanced or metastatic disease-approve if the patient has non-adipocytic sarcoma, angiosarcoma, or pleomorphic rhabdomyosarcoma. Bone Cancer-approve if the patient has relapsed/refractory or metastatic disease AND the patient has tried one systemic chemotherapy regimen AND pt has Ewing sarcoma or osteosarcoma. Colon and Rectal cancer/Appendiceal cancer-approve if the patient has advanced or metastatic disease, has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient meets one of the following (i or ii): i. patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type), the patient has tried Erbitux or Vectibix or the patient's tumor did not originate on the left side of the colon (from the splenic fixture to rectum) or ii. the patient's tumor or metastases has a RAS mutation (either KRAS mutation or NRAS mutation). Glioblastoma-approve if the patient has recurrent or progressive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Soft tissue Sarcoma, Bone Cancer, Glioblastoma, Appendiceal cancer



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No



# STRENSIQ

## Products Affected

- STRENSIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	Disease onset-less than or equal to 18
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of hypophosphatasia or related disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Hypophosphatasia - Perinatal/Infantile- and Juvenile-Onset-Patient must meet both A and B for approval. A) Diagnosis is supported by one of the following (i, ii, or iii): i. Molecular genetic testing documenting tissue non-specific alkaline phosphatase (ALPL) gene variants OR ii. Low baseline serum alkaline phosphatase activity OR iii. An elevated level of a tissue non-specific alkaline phosphatase substrate (i.e., serum pyridoxal 5'-phosphate, serum or urinary inorganic pyrophosphate, urinary phosphoethanolamine) AND B) Patient meets one of the following (i or ii): i. Patient currently has, or has a history of clinical manifestations consistent with hypophosphatasia (e.g., skeletal abnormalities, premature tooth loss, muscle weakness, poor feeding, failure to thrive, respiratory problems, Vitamin B6-dependent seizures) OR ii. Patient has a family history (parent or sibling) of hypophosphatasia without current clinical manifestations of hypophosphatasia
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## SUCRAID

### Products Affected

- SUCRAID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient meets the following criteria (A and B): A) The diagnosis is established by one of the following (i or ii): i. Patient has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by ALL of the following (a, b, c, and d): a) Decreased (usually absent) sucrase (normal reference: greater than 25 U/g protein), b) Decreased or normal isomaltase (palatinase) [normal reference: greater than 5 U/g protein], c) Decreased maltase (normal reference: greater than 100 U/g protein), d) Decreased or normal lactase (normal reference: greater than 15 U/g protein) OR ii. Patient has a molecular genetic test demonstrating homozygous or compound heterozygous pathogenic or likely pathogenic sucrase-isomaltase gene variant AND B) Patient has symptomatic congenital sucrose-isomaltase deficiency (e.g., diarrhea, bloating, abdominal cramping).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## SUNITINIB

### Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Gastrointestinal stromal tumors (GIST), approve if the patient has tried imatinib or Ayvakit or if the patient has succinate dehydrogenase (SDH)-deficient GIST. Chordoma, approve if the patient has recurrent disease. Differentiated thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. Meningioma, approve if the patient has recurrent or progressive disease. Thymic carcinoma - has tried at least one systemic chemotherapy. Renal Cell Carcinoma (RCC) - approve if the patient has relapsed or advanced disease. Neuroendocrine tumors of the pancreas-approve for advanced or metastatic disease. Pheochromocytoma/paraganglioma-approve if the patient has unresectable or metastatic disease. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chordoma, angiosarcoma, solitary fibrous tumor/hemangiopericytoma, alveolar soft part sarcoma (ASPS), differentiated (ie, papillary, follicular, and oncocytic carcinoma) thyroid carcinoma, medullary thyroid carcinoma, meningioma, thymic carcinoma, pheochromocytoma/paraganglioma, myeloid/lymphoid neoplasms with eosinophilia, GIST-unresectable succinate dehydrogenase (SDH)-deficient GIST, or use after avapritinib.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

## SYMDEKO

### Products Affected

- SYMDEKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients with unknown CFTR gene mutations, Combination therapy with Orkambi, Kalydeco or Trikafta
<b>Required Medical Information</b>	Diagnosis, specific CFTR gene mutations
<b>Age Restrictions</b>	Six years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt meets A, B and C: A) pt has at least one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# SYMLIN

## Products Affected

- SYMLINPEN 120
- SYMLINPEN 60

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TABRECTA

## Products Affected

- TABRECTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has advanced or metastatic disease AND the tumor is positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping or high-level MET amplification, as detected by an approved test.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-small cell lung cancer with high-level MET amplification.
<b>Part B Prerequisite</b>	No

# TADALAFIL

---

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Indication for which tadalafil is being prescribed.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 mos.
<b>Other Criteria</b>	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed as once daily dosing, to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# TAFAMIDIS

## Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with Onpattro or Tegsedi or Wainua. Concurrent use of Vyndaqel and Vyndamax.
<b>Required Medical Information</b>	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cardiomyopathy of Wild-Type or Hereditary Transthyretin Amyloidosis-approve if the diagnosis was confirmed by one of the following (i, ii or iii): i. A technetium pyrophosphate scan (i.e., nuclear scintigraphy), ii. Amyloid deposits are identified on cardiac biopsy OR iii. patient had genetic testing which, according to the prescriber, identified a TTR mutation AND Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TAFINLAR

## Products Affected

- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Tafinlar is being used. BRAF V600 mutations
<b>Age Restrictions</b>	1 year and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Melanoma with BRAF V600 mutation AND patient has unresectable, advanced (including Stage III or Stage IV disease) or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC, must have BRAF V600E mutation. Thyroid Cancer, anaplastic-must have BRAF V600-positive disease AND Tafinlar will be taken in combination with Mekinist, unless intolerant AND the patient has locally advanced or metastatic anaplastic disease. Thyroid Cancer, differentiated (i.e., papillary, follicular, or Hurthle cell) AND the patient has disease that is refractory to radioactive iodine therapy AND the patient has BRAF-positive disease. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Mekinist. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b, c, or d): a) glioma OR b) Isocitrate dehydrogenase-2 (IDH2)-mutant astrocytoma OR c) Glioblastoma OR d)Oligodendroglioma OR iii. Melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND

PA Criteria	Criteria Details
	<p>medication will be taken in combination with Mekinist (trametinib tablets). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following (a, b, or c): a) Multisystem disease OR b) Pulmonary disease OR c) Central nervous system lesions OR patient has Erdheim Chester disease AND patient has BRAF V600-mutation positive disease. Metastatic or solid tumors-approve if BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets) AND patient has no satisfactory alternative treatment options. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-approve if the patient meets the following (A, B, and C): A) Patient has recurrent disease, AND B) Patient has BRAF V600 mutation-positive disease, AND C) The medication will be taken in combination with Mekinist (trametinib tablets). Hairy Cell Leukemia, approve if pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Mekinist. Small bowel adenocarcinoma, approve if pt has BRAF V600E mutation-positive advanced or metastatic disease and this will be used with Mekinist AND (i or ii): i) this will be used as initial therapy and pt has received previous FOLFOX/CAPEOX therapy in the adjuvant setting within the past 12 months or has a contraindication, or (ii) this will be used as second-line and subsequent therapy.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Patients with Differentiated Thyroid Cancer, Biliary tract cancer, central nervous system cancer, histiocytic neoplasm, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, hairy cell leukemia, small bowel adenocarcinoma
<b>Part B Prerequisite</b>	No

# TAGRISSO

## Products Affected

- TAGRISSO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>NSCLC-EGFR Mutation Positive (other than EGFR T790M-Positive Mutation)- approve if the patient has advanced or metastatic disease, has EGFR mutation-positive NSCLC as detected by an approved test. Note-examples of EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. NSCLC-EGFR T790M mutation positive-approve if the patient has metastatic EGFR T790M mutation-positive NSCLC as detected by an approved test and has progressed on treatment with at least one of the EGFR tyrosine kinase inhibitors. NSCLC-Post resection-approve if the patient has completely resected disease and has received previous adjuvant chemotherapy or if the patient is ineligible to receive platinum based chemotherapy and the patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TALVEY

## Products Affected

- TALVEY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TALZENNA

## Products Affected

- TALZENNA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Recurrent or metastatic breast cancer-approve if the patient has germline BRCA mutation-positive disease. In addition, patients new to therapy are required to try Lynparza prior to approval of Talzenna. Prostate cancer - approve if the patient has metastatic castration resistant prostate cancer, AND is using this medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy AND the patient has homologous recombination repair (HRR) gene-mutated disease [Note: HRR gene mutations include ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C] AND the medication is used in combination with Xtandi (enzalutamide capsules and tablets). In addition, patients new to therapy with BRCA-mutated-positive prostate cancer are required to try Lynparza prior to approval of Talzenna.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TASIGNA

## Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Tasigna is being used. For indication of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For indication of gastrointestinal stromal tumor (GIST) and melanoma, cutaneous, prior therapies tried. For melanoma, cutaneous, KIT mutation status.
<b>Age Restrictions</b>	ALL/GIST/Myeloid/lymphoid neoplasms/melanoma, cutaneous-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Acute lymphoblastic leukemia, philadelphia chromosome positive or chronic myeloid leukemia- approve. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. Pigmented villonodular synovitis/tenosynovial giant cell tumor-approve if the patient has tried Turalio or cannot take Turalio, according to the prescriber. For melanoma, cutaneous - approve if the patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Philadelphia positive Acute Lymphoblastic Leukemia (ALL) and Gastrointestinal Stromal Tumor (GIST), Pigmented villonodular synovitis/tenosynovial giant cell tumor, Myeloid/Lymphoid neoplasms with Eosinophilia, melanoma cutaneous.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No



# TAZAROTENE

---

## Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Cosmetic uses
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TAZVERIK

## Products Affected

- TAZVERIK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Epithelioid Sarcoma-16 years and older, Follicular Lymphoma-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Epithelioid Sarcoma-approve if the patient has metastatic or locally advanced disease and the patient is not eligible for complete resection. Follicular Lymphoma-approve if the patient has relapsed or refractory disease and there are no appropriate alternative therapies or the patient has tried at least two prior systemic therapies.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TECVAYLI

---

## Products Affected

- TECVAYLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Multiple Myeloma-approve if the patient has tried at least four systemic regimens which must include at least one drug from each of the following classes: proteasome inhibitor, immunomodulatory drug and Anti-CD38 monoclonal antibody
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## TEPMETKO

---

### Products Affected

- TEPMETKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	NSCLC-approve if the patient has advanced or metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations or patient has high-level MET amplification, as detected by an approved test.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Non-small cell lung cancer with high-level MET amplification.
<b>Part B Prerequisite</b>	No

# TERIPARATIDE

## Products Affected

- TERIPARATIDE SUBCUTANEOUS  
PEN INJECTOR 20 MCG/DOSE  
(620MCG/2.48ML)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with other medications for osteoporosis
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime.
<b>Other Criteria</b>	<p>INITIAL THERAPY: Postmenopausal Osteoporosis (PMO) Treatment, Increase Bone Mass in Men (see Note 1 below) with Primary or Hypogonadal Osteoporosis, and Treatment of Glucocorticosteroid-Induced Osteoporosis (GIO): (one of A, B, C, D or E): A) tried one oral bisphosphonate or cannot take due to swallowing difficulties or inability to remain upright after administration, B) pre-existing gastrointestinal condition (e.g., esophageal lesions/ulcers, abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), C) tried an IV bisphosphonate (PMO-ibandronate or zoledronic acid, all other diagnoses-zoledronic acid), D) severe renal impairment (creatinine clearance [CrCL] less than 35 mL/min) or chronic kidney disease (CKD), or E) patient had an osteoporotic fracture or fragility fracture at any time in the past.</p> <p>CONTINUATION THERAPY: ALL INDICATIONS: if the patient has taken teriparatide for two years, approve if the patient is at high risk for fracture. Examples of high risk for fracture include a previous osteoporotic fracture or fragility fracture, receipt of medications that increase the risk of osteoporosis, advanced age, and very low bone mineral density. Note 1: a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.</p>



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TETRABENAZINE

## Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
<b>Part B Prerequisite</b>	No

## THALOMID

### Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	MM, myelofibrosis-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapson, acitretin [Soriatane]). Myelofibrosis, approve if according to the prescriber the patient has anemia and has serum erythropoietin levels greater than or equal to 500 mU/mL or if the patient has serum erythropoietin level less than 500 mU/mL and experienced no response or loss of response to erythropoietic stimulating agents. Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and has relapsed or refractory disease. Castleman's disease-approve if the patient has multicentric Castleman's disease, and is negative for the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8).
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Discoid lupus erythematosus or cutaneous lupus erythematosus, Myelofibrosis, Prurigo nodularis, Recurrent aphthous ulcers or aphthous stomatitis, Kaposi's Sarcoma, Castleman's Disease.
<b>Part B Prerequisite</b>	No

# TIBSOVO

## Products Affected

- TIBSOVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, IDH1 Status
<b>Age Restrictions</b>	All diagnoses (except chondrosarcoma)-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML- approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive, as detected by an approved test. Cholangiocarcinoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive and has been previously treated with at least one chemotherapy regimen (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). Chondrosarcoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive. Central nervous system cancer-approve if the patient has recurrent or progressive disease, AND patient has World Health Organization (WHO) grade 2 or 3 oligodendroglioma, OR Patient has WHO grade 2 astrocytoma. Myelodysplastic Syndrome-approve if patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease AND relapsed or refractory disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Chondrosarcoma, Central nervous system cancer
<b>Part B Prerequisite</b>	Yes

# TIVDAK

---

## Products Affected

- TIVDAK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cervical cancer-approve if the patient has tried at least one chemotherapy agent.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## TOBRAMYCIN (NEBULIZATION)

### Products Affected

- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Bronchiectasis, Non-cystic fibrosis-18 years and older
<b>Prescriber Restrictions</b>	CF-prescr/consult w/pulm/phys specializes in tx of CF.Bronchiectasis, non CF-prescr/consult w/pulm
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cystic fibrosis/Bronchiectasis, non-cystic fibrosis-approve if the patient has pseudomonas aeruginosa in the culture of the airway.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Bronchiectasis, non-cystic fibrosis
<b>Part B Prerequisite</b>	No

## TOLVAPTAN

### Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with Jynarque.
<b>Required Medical Information</b>	Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion).
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 30 days for initial therapy, 3 months for continuation of therapy
<b>Other Criteria</b>	Hyponatremia, initial therapy (including new starts, patients on therapy for less than 30 days, and patients restarting therapy) - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on tolvaptan and has received less than 30 days of therapy. Hyponatremia, continuation of therapy for patients established on therapy for at least 30 days - approve if the serum sodium level has increased from baseline (prior to initiating the requested drug) OR if the patient experienced improvement in at least one symptom, such as nausea, vomiting, headache, lethargy, or confusion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## TOPICAL AGENTS FOR ATOPIC DERMATITIS

### Products Affected

- *pimecrolimus*
- *tacrolimus topical*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## TOPICAL RETINOID PRODUCTS

---

### Products Affected

- *tretinoin topical*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for cosmetic use.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## TOPIRAMATE/ZONISAMIDE

---

### Products Affected

- EPRONTIA
- *topiramate oral capsule, sprinkle*
- *topiramate oral tablet*
- ZONISADE
- *zonisamide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for weight loss or smoking cessation.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## TRANSDERMAL FENTANYL

### Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute (i.e., non-chronic) pain.
<b>Required Medical Information</b>	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, sickle cell disease, in hospice or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

## TRANSMUCOSAL FENTANYL DRUGS

### Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 12 months.
<b>Other Criteria</b>	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TRELSTAR

---

## Products Affected

- TRELSTAR INTRAMUSCULAR  
SUSPENSION FOR RECONSTITUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist or urologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Patients new to therapy, are required to try Eligard or Orgovyx prior to approval of Trelstar.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TREMFYA

## Products Affected

- TREMFYA SUBCUTANEOUS AUTO-INJECTOR
- TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	PP- 18 years of age and older (initial therapy)
<b>Prescriber Restrictions</b>	PP- Prescribed by or in consultation with a dermatologist (initial therapy only). PsA- prescribed by or in consultation with a dermatologist or rheumatologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	PP, initial therapy - approve if the pt meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: a biologic that is not a biosimilar of the requested product will also count) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. PP/PsA continuation of therapy - approve if the pt is responding to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## TRIENTINE

### Products Affected

- *trientine oral capsule 250 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician.
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	For Wilson's Disease, approve if the patient meets A and B: A) Diagnosis of Wilson's disease is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, or d): a. Presence of Kayser-Fleischer rings, OR b. Serum ceruloplasmin levels less than 20mg/dL, OR c. Liver biopsy findings consistent with Wilson's disease, OR d. 24-hour urinary copper greater than 40 micrograms/24 hours, AND B) Patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant, OR 6) the patient has been started on therapy with trientine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# TRIKAFTA

## Products Affected

- TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL
- TRIKAFTA ORAL TABLETS, SEQUENTIAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Patients with unknown CFTR gene mutations. Combination therapy with Orkambi, Kalydeco or Symdeko.
<b>Required Medical Information</b>	Diagnosis, specific CFTR gene mutations, concurrent medications
<b>Age Restrictions</b>	2 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	CF - Approve if the pt meets A, B and C: A) pt has at least one mutation in the CFTR gene that is considered to be pathogenic or likely pathogenic, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal CFTR function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two CFTR mutations or (iii) abnormal nasal potential difference.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# TRODELVY

## Products Affected

- TRODELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has recurrent or metastatic, human epidermal growth factor receptor (HER2) negative breast cancer and patient meets (a or b): a) patient has hormone receptor (HR) negative disease AND has tried at least two systemic regimens, OR b) patient has HR positive disease, has tried endocrine therapy, has tried a cyclin-dependent kinase(CDK) 4/6 inhibitor and has tried at least two systemic chemotherapy regimens . Urothelial Cancer-approve if the patient has locally advanced or metastatic urothelial cancer AND has tried at least one systemic chemotherapy AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TRUQAP

## Products Affected

- TRUQAP

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast Cancer-Approve if the patient meets the following (A, B, C, D and E): A) Patient has locally advanced or metastatic disease, AND B) Patient has hormone receptor positive (HR+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has at least one phosphatidylinositol 3-kinase (PIK3CA), serine/threonine protein kinase (AKT1), or phosphatase and tensin homolog (PTEN)-alteration, AND E) Patient meets one of the following (i or ii): i. Patient has had progression with at least one endocrine-based regimen in the metastatic setting (Note: Examples of endocrine therapy include anastrozole, exemestane, and letrozole.) and has had progression with at least one cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting (Note: Examples of CDK4/6 inhibitor include: Ibrance (palbociclib tablets or capsules), Verzenio (abemaciclib tablets), Kisqali (ribociclib tablets), Kisqali Femara Co-Pack (ribociclib and letrozole tablets) OR ii. Patient has recurrence on or within 12 months of completing adjuvant endocrine therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# TUKYSA

## Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Breast Cancer-approve if the patient has recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, has received at least one prior anti-HER2-based regimen in the metastatic setting and Tukysa is used in combination with trastuzumab and capecitabine. Colon/Rectal Cancer-approve if the requested medication is used in combination with trastuzumab, patient has unresectable or metastatic disease, human epidermal growth factor receptor 2 (HER2)-amplified disease, AND Patient's tumor or metastases are wild-type RAS (KRAS wild-type and NRAS wild-type). Biliary tract cancer- approve if the patient meets all of (a, b, c, and d): a) unresectable or metastatic disease, b) HER2 positive disease, c) tried at least one systemic regimen, d) will use in combination with trastuzumab.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Biliary tract cancer
<b>Part B Prerequisite</b>	No

# TURALIO

## Products Affected

- TURALIO ORAL CAPSULE 125 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)-approve if, according to the prescriber, the tumor is not amenable to improvement with surgery. Histiocytic Neoplasms-approve if the patient has a colony stimulating factor 1 receptor (CSF1R) mutation AND has one of the following conditions (i, ii, or iii): i. Langerhans cell histiocytosis OR ii. Erdheim-Chester disease OR iii. Rosai-Dorfman disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Histiocytic Neoplasms
<b>Part B Prerequisite</b>	No

## TYENNE IV

### Products Affected

- TYENNE INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or targeted synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>INITIAL THERAPY- RHEUMATOID ARTHRITIS (RA) [A OR B]: A) Try TWO of the following: Enbrel, a preferred adalimumab product, Rinvoq, Oencia or Xeljanz. (Note: if the patient has not tried TWO of these drugs listed, previous trial(s) with the following drugs can count towards meeting the try TWO requirement: Cimzia, infliximab, Simponi (IV/SC), Kevzara or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A OR B]: A) Try TWO of the following: Enbrel, Oencia, Rinvoq, Xeljanz, a preferred adalimumab product, (Note: if they have had a trial with infliximab, Kevzara or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): Try one other systemic agent (eg, a corticosteroid [oral, IV], a conventional synthetic DMARD [eg, MTX, leflunomide, sulfasalazine], Kineret (anakinra), or Ilaris (canakinumab for SC injection), or a 1-month trial of a nonsteroidal anti-inflammatory drug [NSAID]). GIANT CELL ARTERITIS: Try one systemic corticosteroid. CYTOKINE RELEASE SYNDROME ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY-approve. Please Note: preferred adalimumab products</p>

PA Criteria	Criteria Details
	Humira (NDCs starting with -00074), Cyltezo, Yuflyma. CONTINUATION THERAPY-RA, PJIA, SJIA, GCA;patient has responded to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# UBRELVY

---

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Migraine, Acute treatment-approve
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## UPTRAVI

### Products Affected

- UPTRAVI ORAL TABLET
- UPTRAVI ORAL TABLETS,DOSE PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent Use with Other Inhaled or Parenteral Prostacyclin Agents Used for Pulmonary Hypertension.
<b>Required Medical Information</b>	Confirmation of right heart catheterization, medication history (as described in Other Criteria)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	PAH must be prescribed by, or in consultation with, a cardiologist or a pulmonologist.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Patient new to therapy must meet a) OR b): a) tried one or is currently taking one oral therapy for PAH for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# VALCHLOR

## Products Affected

- VALCHLOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Cutaneous lymphoma-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve. Adult T-Cell Leukemia/Lymphoma-approve if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma. Langerhans cell histiocytosis-approve if the patient has unifocal Langerhans cell histiocytosis with isolated skin disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Adults with T-cell leukemia/lymphoma, Langerhans Cell Histiocytosis
<b>Part B Prerequisite</b>	No

# VALTOCO

## Products Affected

- VALTOCO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, other medications used at the same time
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiseizure medication(s).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# VANCOMYCIN

---

## Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 weeks
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# VANFLYTA

## Products Affected

- VANFLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Acute Myeloid Leukemia: approve if the patient has FLT3-ITD mutation-positive disease as detected by an approved test and this medication is being used for induction, re-induction, consolidation, or maintenance treatment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# VENCLEXTA

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapy
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML-approve if used in combination with azacitidine, decitabine, or cytarabine. CLL/SLL- approve. Mantle Cell Lymphoma- approve if the patient has tried at least one systemic regimen. Multiple Myeloma- approve if the patient has t (11,14) translocation AND has tried at least one systemic regimen for multiple myeloma AND Venclexta will be used in combination with dexamethasone. Systemic light chain amyloidosis-approve if the patient has t (11, 14) translocation and has tried at least one systemic regimen. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Mantle Cell Lymphoma, waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, multiple myeloma, systemic light chain amyloidosis
<b>Part B Prerequisite</b>	No

# VERZENIO

## Products Affected

- VERZENIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Breast cancer: HR status, HER2 status, previous medications/therapies tried, concomitant therapy, menopausal status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Breast Cancer, Early-Approve if pt meets (A,B,C and D): A)Pt has HR+disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt has node-positive disease at high risk of recurrence AND D)Pt meets ONE of the following (i or ii): i.Verzenio will be used in combo w/anastrozole, exemestane, or letrozole AND pt meets one of the following (a,b, or c): a)Pt is a postmenopausal woman, OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist, OR 2-Pt has had surgical bilateral oophorectomy or ovarian irradiation, OR c)Pt is a man and pt is receiving a GnRH analog, OR ii.Verzenio will be used in combo with tamoxifen AND pt meets one of the following (a or b): a)Pt is a postmenopausal woman or man OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Patient has had surgical bilateral oophorectomy or ovarian irradiation. Breast Cancer-Recurrent or Metastatic in Women-Approve if pt meets (A, B, C and D): A) Pt has HR+ disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets ONE of the following criteria (i or ii): i.Pt is a postmenopausal woman, OR ii.Pt is a pre/perimenopausal woman and meets one of the following (a or b): a)Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR b)Pt has had surgical bilateral oophorectomy or ovarian irradiation, AND D)Pt meets ONE of the</p>

PA Criteria	Criteria Details
	<p>following criteria (i, ii, or iii): i.Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c)Pt has tried chemotherapy for metastatic breast cancer.Breast Cancer-Recurrent or Metastatic in Men-Approve if pt meets the following criteria (A,B and C): A)Pt has HR+ disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets ONE of the following criteria (i, ii, or iii): i.Pt meets BOTH of the following conditions (a and b): a)Pt is receiving a GnRH analog, AND b)Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.Pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c)Pt has tried chemotherapy for metastatic breast cancer. Endometrial cancer- approve if pt meets all of (A, B, And C): A) pt has recurrent or metastatic disease, and B) pt has estrogen receptor (ER)-positive tumors, and C) pt will be using in combination with letrozole.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Endometrial cancer
<b>Part B Prerequisite</b>	No

# VIGABATRIN

## Products Affected

- *vigabatrín*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, medication history (complex partial seizures)
<b>Age Restrictions</b>	Refractory complex partial seizures - patients 2 years of age or older. Infantile spasms - patients less than or equal to 2 years of age
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a neurologist
<b>Coverage Duration</b>	Infantile spasms- 6 months. Treatment-Refractory Partial Seizures- initial 3 months, cont 1 year
<b>Other Criteria</b>	Infantile spasms-requested medication is being used as monotherapy. Treatment refractory complex partial seizures initial-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs. Treatment refractory complex partial seizures continuation- the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## VIMIZIM

### Products Affected

- VIMIZIM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, genetic and lab test results
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine-6-sulfatase activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic N-acetylgalactosamine-6-sulfatase gene variants.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# VITRAKVI

## Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, NTRK gene fusion status
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Solid tumors - approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## VIZIMPRO

---

### Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, EGFR status, exon deletions or substitutions
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	NSCLC-approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## VONJO

### Products Affected

- VONJO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Myelofibrosis (MF), including primary MF, post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient meets either (A, B, or C): (A) the patient has a platelet count of less than $50 \times 10^9 /L$ (less than 50,000/mcL) and meets one of the following criteria (a or b): a) Patient has intermediate-risk or high-risk disease and is not a candidate for transplant, or b) Patient has lower-risk disease OR (B) Patient has a platelet count of greater than or equal to $50 \times 10^9 /L$ (greater than or equal to 50,000/mcL) and meets all of the following criteria (a, b and c): a) Patient has high-risk disease, AND b) Patient is not a candidate for transplant, AND c) Patient has tried Jakafi (ruxolitinib tablets) or Inrebic (fedratinib capsules) OR (C) patient has myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## VORICONAZOLE (ORAL)

### Products Affected

- *voriconazole*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Aspergillus-Prophy, systemic w/risk neutropenia-Prophy, systemic w/HIV-Prophy/Tx-6 mo, others-3 mo
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Aspergillus Infections - prophylaxis, oropharyngeal candidiasis (fluconazole-refractory) - treatment, candidia endophthalmitis - treatment, blastomycosis - treatment, fungal infections (systemic) in patients at risk of neutropenia - prophylaxis, fungal infections (systemic) in patients with human immunodeficiency virus (HIV) - prophylaxis or treatment.
<b>Part B Prerequisite</b>	No

# VOSEVI

---

## Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
<b>Coverage Duration</b>	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Indications consistent with current AASLD/IDSA guidance
<b>Part B Prerequisite</b>	No

# VOTRIENT

## Products Affected

- *pazopanib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Soft tissue sarcoma other than GIST-approve if the patient has advanced or metastatic disease and has ONE of the following: alveolar soft part sarcoma, angiosarcoma, desmoid tumors (aggressive fibromatosis, dermatofibrosarcoma protuberans with fibrosarcomatous transformation, non-adipocytic sarcoma or pleomorphic rhabdomyosarcoma. Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Uterine sarcoma, approve if the patient has recurrent or metastatic disease. Renal Cell Carcinoma, Clear Cell or non-Clear Cell histology-approved if the patient has relapsed or advanced disease or VonHippel-Lindau disease. Ovarian Cancer (ie, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) - approve if the patient has persistent or recurrent disease. GIST - approve if the patient has succinate dehydrogenase (SDH)-deficient GIST OR the patient has tried TWO of the following: Gleevec, Ayvakit, Sutent, Sprycel, Qinlock or Stivarga. Medullary Thyroid Carcinoma, approve if the patient has tried at least one systemic therapy. Bone cancer-approve if the patient has chondrosarcoma and has metastatic widespread disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Differentiated (ie, papillary, follicular, oncocytic carcinoma) thyroid carcinoma. Uterine sarcoma, Epithelial Ovarian, Fallopian Tube, or

<b>PA Criteria</b>	<b>Criteria Details</b>
	Primary Peritoneal Cancer, Gastrointestinal Stromal Tumor (GIST), Medullary thyroid carcinoma, bone cancer.
<b>Part B Prerequisite</b>	No



# VOWST

---

## Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	Prevention of recurrence of clostridioides difficile infection (CDI)-approve if the patient has completed a bowel prep, will not eat or drink for at least 8 hours prior to the first dose and will complete their antibacterial treatment for recurrent CDI 2-4 days before initiating treatment with Vowst and Vowst will not be used for the TREATMENT of CDI.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# VUMERITY

## Products Affected

- VUMERITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
<b>Required Medical Information</b>	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
<b>Coverage Duration</b>	Authorization will be for 1 year.
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## WELIREG

### Products Affected

- WELIREG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Renal Cell Carcinoma- approve if pt has advanced disease AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor AND has tried at least one a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). [Note: Examples of PD-1 inhibitor or PD-L1 inhibitor include: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), and Bavencio (avelumab intravenous infusion). Examples of VEGF-TKI include Cabometyx (cabozantinib tablets), Lenvima (lenvatinib capsules), Inlyta (axitinib tablets), Fotivda (tivozanib capsules), pazopanib, sunitinib, and sorafenib.] Van Hippel-Lindau Disease-approve if the patient meets the following (A, B, and C): A) Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing, B) Does not require immediate surgery and C) Patient requires therapy for ONE of the following conditions (i, ii, iii, or iv): i. Central nervous system hemangioblastomas, OR ii. Pancreatic neuroendocrine tumors, OR iii. Renal cell carcinoma, OR iv. Retinal hemangioblastoma.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# XALKORI

## Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Anaplastic large cell lymphoma/IMT-patients greater than or equal to 1 year of age. All other diagnoses-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test and patients new to therapy must have a trial of Alecensa prior to approval of Xalkori. Metastatic non-small cell lung cancer, approve if the patient has ROS1 rearrangement positive disease, as detected by an approved test. Anaplastic Large Cell Lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Histiocytic neoplasm-approve if the patient has ALK rearrangement/fusion-positive disease and meets one of the following criteria (i, ii, or iii): (i. Patient has Langerhans cell histiocytosis, OR ii. Patient has Erdheim-Chester disease OR iii. Patient has Rosai-Dorfman disease. NSCLC with MET mutation-approve if the patient has high level MET amplification or MET exon 14 skipping mutation. Inflammatory Myofibroblastic Tumor-approve if the patient has ALK positive disease and the patient has advanced, recurrent or metastatic disease or the tumor is inoperable. Melanoma, cutaneous-approve if the patient has ALK fusion disease or ROS1 fusion disease.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	NSCLC with high level MET amplification or MET Exon 14 skipping mutation, Histiocytic neoplasms, melanoma, cutaneous.
<b>Part B Prerequisite</b>	No

## XDEMVY

---

### Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

# XELJANZ

---

## Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ XR
- XELJANZ ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	PENDING CMS REVIEW
<b>Required Medical Information</b>	PENDING CMS REVIEW
<b>Age Restrictions</b>	PENDING CMS REVIEW
<b>Prescriber Restrictions</b>	PENDING CMS REVIEW
<b>Coverage Duration</b>	PENDING CMS REVIEW
<b>Other Criteria</b>	PENDING CMS REVIEW
<b>Indications</b>	PENDING CMS REVIEW
<b>Off-Label Uses</b>	PENDING CMS REVIEW
<b>Part B Prerequisite</b>	PENDING CMS REVIEW

## XERMELO

### Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous therapy, concomitant therapy
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Initial therapy - approve if the patient meets ALL of the following criteria: 1) patient has been on long-acting somatostatin analog (SSA) therapy (eg, Somatuline Depot [lanreotide for injection]) AND 2) while on long-acting SSA therapy (prior to starting Xermelo), the patient continues to have at least four bowel movements per day, AND 3) Xermelo will be used concomitantly with a long-acting SSA therapy. Continuation therapy - approve if the patient is continuing to take Xermelo concomitantly with a long-acting SSA therapy for carcinoid syndrome diarrhea.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



# XIAFLEX

## Products Affected

- XIAFLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Retreatment for Peyronie's Disease (i.e., treatment beyond eight injections).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Dupuytren's Contracture-administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture. Peyronie's Disease -administered by a healthcare provider experienced in the treatment of male urological diseases.
<b>Coverage Duration</b>	Dupuytren's Contracture-3 months, Peyronie's Disease-6 months
<b>Other Criteria</b>	Dupuytren's Contracture-at baseline (prior to initial injection of Xiaflex), the patient had contracture of a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint of at least 20 degrees AND the patient will not be treated with more than a total of three injections (maximum) per affected cord as part of the current treatment course. Peyronie's Disease-the patient meets ONE of the following (i or ii): i. at baseline (prior to use of Xiaflex), the patient has a penile curvature deformity of at least 30 degrees OR in a patient who has received prior treatment with Xiaflex, the patient has a penile curvature deformity of at least 15 degrees AND the patient has not previously been treated with a complete course (8 injections) of Xiaflex for Peyronie's disease.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## XIFAXAN

### Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Traveler's diarrhea - 12 years of age or older. Hepatic encephalopathy, irritable bowel syndrome with diarrhea - 18 years of age or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Hep Enceph-6mo, IBS/diarrhea-14days, Traveler's Diarr-3days, Sm intest bacterial overgrowth-14days
<b>Other Criteria</b>	Hepatic Encephalopathy-approve Xifaxan 550 mg tablets if the patient has previously had overt hepatic encephalopathy and the requested medication will be used concomitantly with lactulose, unless the patient has a contraindication or significant intolerance to treatment with lactulose. Irritable bowel syndrome with diarrhea-approve Xifaxan 550 mg tablets. Travelers Diarrhea-approve Xifaxan 200 mg tablets if the patient is afebrile and does not have blood in the stool. Small intestine bacterial overgrowth-approve Xifaxan 200mg or 550 mg tablets if the diagnosis has been confirmed by a glucose hydrogen breath test, lactulose hydrogen breath test, or small bowel aspiration and culture.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Small intestine bacterial overgrowth
<b>Part B Prerequisite</b>	No

# XOLAIR

## Products Affected

- XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML
- XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML
- XOLAIR SUBCUTANEOUS RECON SOLN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with another monoclonal antibody therapy.
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older
<b>Prescriber Restrictions</b>	Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist
<b>Coverage Duration</b>	asthma/CIU-Initial tx 4 months, Polyps-initial-6 months, continued tx 12 months, Food allergy-1 yr
<b>Other Criteria</b>	MODERATE TO SEVERE PERSISTENT ASTHMA (A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, and B) baseline positive skin test or in vitro test for 1 or more perennial or seasonal aeroallergens C) received at least 3 months of combination therapy with an inhaled corticosteroid (ICS) and additional asthma controller/maintenance medication (e.g., LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody) [see Exception 1 below] and D) asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody and meets one of the following (a, b, c, d, or e): a) experienced two or more asthma exacerbations requiring systemic CSs in the past year, b) experienced one or more asthma exacerbation requiring hospitalization/urgent care visit/emergency department visit in the past year, c) forced expiratory volume in 1 second (FEV1) less than 80% predicted, d) FEV1/forced vital capacity (FVC) less than 0.80, or e) asthma worsens upon tapering of oral CS. CHRONIC RHINOSINUSITIS WITH

PA Criteria	Criteria Details
	<p>NASAL POLYPS (CRwNP) [all of A, B, C, D, and E]: A) diagnosis by direct exam, endoscopy, or sinus CT scan, B) baseline (prior to Xolair or another monoclonal antibody that may lower IgE) IgE at least 30 IU/ml, C) at least two of the following symptoms for 6 months: nasal congestion, obstruction, discharge, reduction/loss of smell, D) tried intranasal CS and will continue in combination with Xolair, and E) one of the following (a, b, or c): a) had systemic CS at least 5 days in past 2 years, b) contraindication to systemic CS, or c) had nasal polyp surgery. CHRONIC IDIOPATHIC URTICARIA (CIU): urticaria more than 6 weeks prior to treatment with Xolair with symptoms present more than 3 days per week despite daily non-sedating H1-antihistamine therapy. IgE-MEDIATED FOOD ALLERGY (all of A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, B) positive skin prick test and positive in vitro test for IgE to one or more foods, C) history of allergic reaction that met all of the following (a, b, and c): a) signs and symptoms of a significant systemic allergic reaction, b) reaction occurred within a short period of time following a known ingestion of the food, and c) prescriber deemed this reaction significant enough to require a prescription for an epinephrine auto-injector, and D) patient has been prescribed an epinephrine auto-injector.</p> <p>CONTINUATION THERAPY: ASTHMA: patient responded to therapy and continues to receive an ICS. CRwNP: patient responded after 6 months of therapy and continues intranasal CS. CIU: patient responded to therapy.</p> <p>Exception 1: an exception to the requirement of a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# XOSPATA

## Products Affected

- XOSPATA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, FLT3-mutation status
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	AML - approve if the patient has relapsed or refractory disease AND the disease is FLT3-mutation positive as detected by an approved test. Lymphoid, Myeloid Neoplasms-approve if the patient has eosinophilia and the disease is FLT3-mutation positive as detected by an approved test.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Lymphoid, Myeloid Neoplasms
<b>Part B Prerequisite</b>	No

## XPOVIO

### Products Affected

- XPOVIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	<p>Multiple Myeloma-Approve if the patient meets the following (A and B):</p> <p>A) The medication will be taken in combination with dexamethasone AND</p> <p>B) Patient meets one of the following (i, ii, or iii): i. Patient has tried at least four prior regimens for multiple myeloma OR ii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with bortezomib OR iii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with Darzalex (daratumumab infusion), Darzlaex Faspro (daratumumab and hyaluronidase-fihj injection), or Pomalyst (pomalidomide capsules). Note: Examples include bortezomib/Revlimid (lenalidomide capsules)/dexamethasone, Kyprolis (carfilzomib infusion)/Revlimid/dexamethasone, Darzalex (daratumumab injection)/bortezomib or Kyprolis/dexamethasone, or other regimens containing a proteasome inhibitor, immunomodulatory drug, and/or anti-CD38 monoclonal antibody. Diffuse large B-cell lymphoma Note:this includes patients with histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma)-approve if the patient has been treated with at least two prior systemic therapies.</p>
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off-Label Uses</b>	Treatment of multiple myeloma in combination with daratumumb or pomalidomide
<b>Part B Prerequisite</b>	No

# XTANDI

## Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis for which Xtandi is being used.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Prostate cancer-castration-resistant [Metastatic or Non-metastatic] and Prostate cancer-metastatic, castration sensitive-approve if Xtandi will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or the medication is concurrently used with Firmagon or if the patient has had a bilateral orchiectomy. Prostate cancer- Non-Metastatic, Castration-Sensitive - approve if pt has biochemical recurrence and is at high risk for metastasis. [Note: High-risk biochemical recurrence is defined as prostate-specific antigen (PSA) doubling time less than or equal to 9 months.]
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## XYREM

### Products Affected

- SODIUM OXYBATE (PREFERRED NDCS STARTING WITH 00054)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with Xywav, Wakix or Sunosi
<b>Required Medical Information</b>	Medication history (as described in Other Criteria field)
<b>Age Restrictions</b>	7 years and older
<b>Prescriber Restrictions</b>	Prescribed by a sleep specialist physician or a Neurologist
<b>Coverage Duration</b>	12 months.
<b>Other Criteria</b>	For Excessive daytime sleepiness (EDS) in patients with narcolepsy, 18 years and older - approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). For EDS in patients with narcolepsy, less than 18 years old-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextramphetamine) or modafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Cataplexy treatment in patients with narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ZEJULA

### Products Affected

- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Ovarian, fallopian tube, or primary peritoneal cancer, maintenance therapy - approve if the patient is in complete or partial response after platinum-based chemotherapy regimen and if the patient is new to therapy they must have a trial of Lynparza prior to approval of Zejula. Patients who have had a complete or partial response to first-line platinum based chemotherapy and do not have BRCA altered disease are not required to try Lynparza. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen. In addition, patients new to therapy must have a trial of Lynparza prior to approval of Zejula. Ovarian, fallopian tube or primary peritoneal cancer in the treatment setting-approve.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Uterine Leiomyosarcoma, Ovarian, fallopian tube or primary peritoneal cancer-treatment
<b>Part B Prerequisite</b>	No

## ZELBORAF

### Products Affected

- ZELBORAF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	BRAFV600 mutation status required.
<b>Age Restrictions</b>	All diagnoses (except CNS cancer)-18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Melanoma, patient new to therapy must have BRAFV600 mutation for approval AND have unresectable, advanced or metastatic melanoma. HCL - must have tried at least one other systemic therapy for hairy cell leukemia OR is unable to tolerate purine analogs and Zelboraf will be used in combination with Gazyva (obinutuzumab intravenous infusion) as initial therapy. Thyroid Cancer-patient has disease that is refractory to radioactive iodine therapy. Erdheim-Chester disease, in patients with BRAF V600 mutation-approve. Central Nervous System Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Ganglioglioma OR ii. Recurrent or progressive disease for one of the following conditions (a or b): a) glioma OR b) Glioblastoma OR iii. Melanoma with brain metastases AND the medication with be taken in combination with Cotellic (cobimetinib tablets). Histiocytic Neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. Multisystem disease OR ii. Pulmonary disease OR iii. Central nervous system lesions AND the patient has BRAF V600-mutation positive disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
<b>Off-Label Uses</b>	Patients with Hairy Cell Leukemia, Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Differentiated thyroid carcinoma (i.e., papillary, follicular, or Hurthle cell) with BRAF-positive disease, Central Nervous System Cancer, Histiocytic Neoplasm
<b>Part B Prerequisite</b>	No

## ZEPOSIA

### Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS-Concurrent use with other disease-modifying agents used for multiple sclerosis.UC- Concurrent Use with a Biologic or with a Targeted Synthetic Disease-modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	UC-18 years and older
<b>Prescriber Restrictions</b>	MS-Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. UC-Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	MS-approve. Ulcerative Colitis, initial-approve if the patient has tried an adalimumab product [i.e., Humira, Cyltezo, Hyrimoz (NDCs starting with 61314-), adalimumab-adaz, adalimumab-adbm]. Note-a trial of Simponi SC, a non-preferred adalimumab product or infliximab would also count). Cont tx-approve if the patient has been established on Zeposia.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ZEPZELCA

---

### Products Affected

- ZEPZELCA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Small cell lung cancer-approve if the patient has metastatic disease and has previously received platinum-based chemotherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

## ZOLINZA

---

### Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

## ZTALMY

### Products Affected

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	2 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder-approve if the patient has a molecularly confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and patient has tried or is concomitantly receiving two other antiepileptic drugs.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No



## ZURZUVAE

### Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Previous treatment with Zurzuvae during the current episode of postpartum depression
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a psychiatrist or an obstetrician-gynecologist
<b>Coverage Duration</b>	14 days
<b>Other Criteria</b>	Postpartum depression-approve if the patient meets the following (A, B and C): A.Patient meets BOTH of the following (i and ii): i. Patient has been diagnosed with severe depression, AND ii. Symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery, AND B. Patient is less than or equal to 12 months postpartum, AND C. Patient is not currently pregnant.
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ZYDELIG

---

## Products Affected

- ZYDELIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	CLL/SLL-approve if the patient has tried at least one systemic regimen.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	small lymphocytic lymphoma
<b>Part B Prerequisite</b>	No

## ZYKADIA

### Products Affected

- ZYKADIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Erdheim-Chester Disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. NSCLC, ALK positive-approve if the patient has advanced or metastatic disease that is ALK positive as detected by an approved test and for patients new to therapy must have a trial of Alecensa prior to approval of Zykadia. NSCLC, ROS1 Rearrangement-approve if the patient has advanced or metastatic disease.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation. Patients with NSCLC with ROS1 Rearrangement. Erdheim-Chester disease.
<b>Part B Prerequisite</b>	No

## ZYMFENTRA

### Products Affected

- ZYMFENTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with a biologic or with a targeted synthetic disease-modifying antirheumatic drug (DMARD).
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older (initial therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist (initial therapy)
<b>Coverage Duration</b>	Approve through end of plan year
<b>Other Criteria</b>	<p>Crohn's Disease, initial therapy-Approve if the patient meets the following (i. and ii.): i.The patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra, AND ii. Patient meets ONE of the following (a, b, c, or d): a) Patient has tried or is currently taking systemic corticosteroids, or corticosteroids are contraindicated in this patient, Note: Examples of corticosteroids are prednisone and methylprednisolone. OR b) Patient has tried one conventional systemic therapy for Crohn's disease, Note: Examples of conventional systemic therapy for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate. An exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. OR c) Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, OR d) Patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). Crohn's Disease, continuation-approve if the patient has had a response to therapy.</p> <p>Ulcerative Colitis, initial therapy-Approve if the patient meets ALL of the following (i, ii, iii, and iv): i.The patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with</p>

PA Criteria	Criteria Details
	<p>Zymfentra, AND ii. Patient meets ONE of the following (a or b): a) Patient had a trial of one systemic agent or was intolerant to one of these agents for ulcerative colitis, Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a mesalamine product does not count as a systemic therapy for ulcerative colitis. A previous trial of one biologic other than the requested medication also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count. OR b) Patient meets BOTH of the following [(1) and (2)]: (1) Patient has pouchitis AND (2) Patient has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine enema). Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema (Cortenema, generics). Ulcerative Colitis, continuation-approve if the patient has had a response to therapy.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Part B Prerequisite</b>	No

# ZYNLONTA

---

## Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Large B-Cell Lymphoma, HIV-Related B-Cell Lymphoma and post-transplant lymphoproliferative disorder-approve if the patient has tried at least two systemic regimens.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	HIV-related B-Cell Lymphoma, Post-transplant lymphoproliferative disorders
<b>Part B Prerequisite</b>	No

## ZYNYZ

### Products Affected

- ZYNYZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Merkel Cell Carcinoma-approve if the patient has not received prior systemic therapy for Merkel cell carcinoma and if the patient has metastatic disease or has locally advanced disease or recurrent regional disease. Anal carcinoma- approve if pt has either locally recurrent persistent disease or metastatic disease AND medication is used for subsequent treatment.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Anal carcinoma
<b>Part B Prerequisite</b>	No

## ZYTIGA

### Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Authorization will be for 1 year
<b>Other Criteria</b>	<p>Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is used concurrently used with a gonadotropin-releasing hormone (GnRH) agonist, or the medication is concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)-approve if the medication is used in combination with prednisone and the medication is concurrently used with a gonadotropin-releasing hormone agonist or concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A) abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i, ii or iii): i. abiraterone with prednisone is used in combination with gonadotropin-releasing hormone (GnRH) agonist OR ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with prednisone, the medication will be used in combination with external beam radiation therapy and the patient meets one of the following criteria (i, ii or iii): i. abiraterone is used in combination with gonadotropin-releasing hormone (GnRH) agonist OR</p>



PA Criteria	Criteria Details
	ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-radical prostatectomy-approve if the medication is used in combination with prednisone, the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy, patient has pelvic recurrence, the medication will be used concurrently with GnRH agonist, Firmagon or the patient has had a bilateral orchiectomy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off-Label Uses</b>	Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer-radical prostatectomy
<b>Part B Prerequisite</b>	No

## PART B VERSUS PART D

---

### Products Affected

- ABELCET INTRAVENOUS SUSPENSION
- ABRAXANE INTRAVENOUS SUSPENSION FOR RECONSTITUTION
- *acetylcysteine solution*
- *acyclovir sodium intravenous solution*
- ADCETRIS INTRAVENOUS RECON SOLN
- *albuterol sulfate inhalation solution for nebulization*
- ALIQOPA INTRAVENOUS RECON SOLN
- *amiodarone intravenous solution*
- *amphotericin b injection recon soln*
- *aprepitant oral capsule*
- *aprepitant oral capsule, dose pack*
- *arformoterol inhalation solution for nebulization*
- *arsenic trioxide intravenous solution*
- *azacitidine injection recon soln*
- *azathioprine oral tablet 50 mg*
- *azathioprine sodium injection recon soln*
- BAVENCIO INTRAVENOUS SOLUTION
- BELEODAQ INTRAVENOUS RECON SOLN
- *bendamustine intravenous recon soln*
- BENDEKA INTRAVENOUS SOLUTION
- BESPONSA INTRAVENOUS RECON SOLN
- *bleomycin injection recon soln*
- BLINCYTO INTRAVENOUS KIT
- BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG
- *bortezomib injection recon soln 3.5 mg*
- *budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml*
- *busulfan intravenous solution*
- *carboplatin intravenous solution*
- *carmustine intravenous recon soln 100 mg*
- *cidofovir intravenous solution*
- *cisplatin intravenous solution*
- *cladribine intravenous solution*
- CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 4.25%/D10W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 4.25%/D5W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 5%-D20W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION
- *clofarabine intravenous solution*
- *cromolyn inhalation solution for nebulization*
- *cyclophosphamide intravenous recon soln*
- *cyclophosphamide oral capsule*
- CYCLOPHOSPHAMIDE ORAL TABLET
- *cyclosporine modified oral capsule*
- *cyclosporine modified oral solution*
- *cyclosporine oral capsule*
- CYRAMZA INTRAVENOUS SOLUTION
- *cytarabine (pf) injection solution*
- *cytarabine injection solution*
- *dacarbazine intravenous recon soln*
- *dactinomycin intravenous recon soln*
- DANYELZA INTRAVENOUS SOLUTION
- DARZALEX INTRAVENOUS SOLUTION

- *daunorubicin intravenous solution*
- *decitabine intravenous recon soln*
- *deferoxamine injection recon soln*
- *dexrazoxane hcl intravenous recon soln*
- *dobutamine in d5w intravenous parenteral solution 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml)*
- *dobutamine intravenous solution*
- *docetaxel intravenous solution*
- *dopamine in 5 % dextrose intravenous solution*
- *dopamine intravenous solution 200 mg/5 ml (40 mg/ml), 400 mg/10 ml (40 mg/ml)*
- *doxorubicin intravenous recon soln*
- *doxorubicin intravenous solution*
- *doxorubicin, peg-liposomal intravenous suspension*
- *dronabinol oral capsule*
- ELZONRIS INTRAVENOUS SOLUTION
- EPLICITI INTRAVENOUS RECON SOLN
- ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION
- ENGERIX-B (PF) INTRAMUSCULAR SYRINGE
- ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE
- ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR
- *epirubicin intravenous solution 200 mg/100 ml*
- ERBITUX INTRAVENOUS SOLUTION
- *eribulin intravenous solution*
- ERWINASE INJECTION RECON SOLN
- ETOPOPHOS INTRAVENOUS RECON SOLN
- *etoposide intravenous solution*
- *everolimus (immunosuppressive) oral tablet*
- *floxuridine injection recon soln*
- *fludarabine intravenous recon soln*
- *fludarabine intravenous solution*
- *flurouracil intravenous solution*
- *formoterol fumarate inhalation solution for nebulization*
- *fulvestrant intramuscular syringe*
- *ganciclovir sodium intravenous recon soln*
- *ganciclovir sodium intravenous solution*
- GAZYVA INTRAVENOUS SOLUTION
- *gemcitabine intravenous recon soln*
- *gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)*
- GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML
- *gengraf oral capsule*
- *gengraf oral solution*
- *granisetron hcl oral tablet*
- HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE
- HIZENTRA SUBCUTANEOUS SOLUTION
- HIZENTRA SUBCUTANEOUS SYRINGE
- *idarubicin intravenous solution*
- *ifosfamide intravenous recon soln*
- *ifosfamide intravenous solution*
- IMFINZI INTRAVENOUS SOLUTION
- *intralipid intravenous emulsion 20 %*
- *ipratropium bromide inhalation solution*
- *ipratropium-albuterol inhalation solution for nebulization*
- *irinotecan intravenous solution*
- ISTODAX INTRAVENOUS RECON SOLN
- IXEMPRA INTRAVENOUS RECON SOLN
- JEVTANA INTRAVENOUS SOLUTION
- JYLAMVO ORAL SOLUTION
- JYNNEOS (PF) SUBCUTANEOUS SUSPENSION
- KHAPZORY INTRAVENOUS RECON SOLN 175 MG
- KIMMTRAK INTRAVENOUS SOLUTION
- KYPROLIS INTRAVENOUS RECON SOLN
- *levoleucovorin calcium intravenous recon soln*

- *levoleucovorin calcium intravenous solution*
- MARGENZA INTRAVENOUS SOLUTION
- *melphalan hcl intravenous recon soln*
- *mesna intravenous solution*
- *methotrexate sodium (pf) injection recon soln*
- *methotrexate sodium (pf) injection solution*
- *methotrexate sodium injection solution*
- *methotrexate sodium oral tablet*
- *methylprednisolone oral tablet*
- *milrinone in 5 % dextrose intravenous piggyback*
- *milrinone intravenous solution*
- *mitomycin intravenous recon soln*
- *mitoxantrone intravenous concentrate*
- *mycophenolate mofetil (hcl) intravenous recon soln*
- *mycophenolate mofetil oral capsule*
- *mycophenolate mofetil oral suspension for reconstitution*
- *mycophenolate mofetil oral tablet*
- *mycophenolate sodium oral tablet, delayed release (dr/ec)*
- MYHIBBIN ORAL SUSPENSION
- MYLOTARG INTRAVENOUS RECON SOLN
- *nelarabine intravenous solution*
- *nitroglycerin in 5 % dextrose intravenous solution 100 mg/250 ml (400 mcg/ml), 25 mg/250 ml (100 mcg/ml), 50 mg/250 ml (200 mcg/ml)*
- *nitroglycerin intravenous solution*
- NULOJIX INTRAVENOUS RECON SOLN
- ONCASPAR INJECTION SOLUTION
- *ondansetron hcl oral solution*
- *ondansetron hcl oral tablet 4 mg, 8 mg*
- *ondansetron oral tablet, disintegrating 4 mg, 8 mg*
- ONIVYDE INTRAVENOUS DISPERSION
- *oxaliplatin intravenous recon soln*
- *oxaliplatin intravenous solution*
- *paclitaxel intravenous concentrate*
- *paraplatin intravenous solution*
- *pemetrexed disodium intravenous recon soln*
- *pentamidine inhalation recon soln*
- PERJETA INTRAVENOUS SOLUTION
- PLENAMINE INTRAVENOUS PARENTERAL SOLUTION
- *plerixafor subcutaneous solution*
- PORTRAZZA INTRAVENOUS SOLUTION
- PRALATREXATE INTRAVENOUS SOLUTION
- PREHEVBRIO (PF) INTRAMUSCULAR SUSPENSION
- *premasol 10 % intravenous parenteral solution*
- PROGRAF INTRAVENOUS SOLUTION
- PROGRAF ORAL GRANULES IN PACKET
- PULMOZYME INHALATION SOLUTION
- RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION
- RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE
- *romidepsin intravenous recon soln*
- RYLAZE INTRAMUSCULAR SOLUTION
- SIMULECT INTRAVENOUS RECON SOLN
- *sirolimus oral solution*
- *sirolimus oral tablet*
- *sodium nitroprusside intravenous solution*
- *tacrolimus oral capsule*
- TECENTRIQ INTRAVENOUS SOLUTION
- TEMODAR INTRAVENOUS RECON SOLN
- *temsirolimus intravenous recon soln*
- *thiotepa injection recon soln*
- TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION
- *topotecan intravenous recon soln*
- *topotecan intravenous solution*

- *travasol 10 % intravenous parenteral solution*
- TRAZIMERA INTRAVENOUS RECON SOLN
- TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION
- TYVASO INHALATION SOLUTION FOR NEBULIZATION
- TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION
- TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION
- TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION
- UNITUXIN INTRAVENOUS SOLUTION
- *valrubicin intravesical solution*
- VARUBI ORAL TABLET
- VECTIBIX INTRAVENOUS SOLUTION
- *veletri intravenous recon soln*
- *vinblastine intravenous solution*
- *vincristine intravenous solution*
- *vinorelbine intravenous solution*
- VYXEOS INTRAVENOUS RECON SOLN
- XGEVA SUBCUTANEOUS SOLUTION
- YERVOY INTRAVENOUS SOLUTION
- YONDELIS INTRAVENOUS RECON SOLN
- ZALTRAP INTRAVENOUS SOLUTION
- ZANOSAR INTRAVENOUS RECON SOLN
- ZIRABEV INTRAVENOUS SOLUTION
- *zoledronic acid intravenous solution*
- *zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml*

### **Details**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

## Index

### A

ABELCET INTRAVENOUS	
SUSPENSION .....	417
abiraterone oral tablet 250 mg, 500 mg	415, 416
ABRAXANE INTRAVENOUS	
SUSPENSION FOR	
RECONSTITUTION .....	417
acetylcysteine solution .....	417
ACTEMRA ACTPEN .....	3, 4
ACTEMRA INTRAVENOUS .....	1, 2
ACTEMRA SUBCUTANEOUS .....	3, 4
ACTIMMUNE .....	5
acyclovir sodium intravenous solution ...	417
acyclovir topical ointment .....	6
ADBRY .....	9
ADCETRIS INTRAVENOUS RECON	
SOLN .....	417
ADEMPAS .....	10
ADSTILADRIN .....	11
AIMOVIQ AUTOINJECTOR .....	12
AKEEGA .....	13
albuterol sulfate inhalation solution for	
nebulization .....	417
alcohol pads .....	78
ALDURAZYME .....	14
ALECENSA .....	15
ALIQOPA INTRAVENOUS RECON	
SOLN .....	417
alosetron .....	16
ALUNBRIG ORAL TABLET 180 MG, 30	
MG, 90 MG .....	18
ALUNBRIG ORAL TABLETS,DOSE	
PACK .....	18
alyq .....	256
ambrisentan .....	40
amikacin injection solution 1,000 mg/4 ml,	
500 mg/2 ml .....	20, 21
amiodarone intravenous solution .....	417
amphotericin b injection recon soln .....	417
ampicillin sodium .....	20, 21
ampicillin-sulbactam .....	20, 21
ANKTIVA .....	19

aprepitant oral capsule .....	417
aprepitant oral capsule,dose pack .....	417
ARCALYST .....	23
arformoterol inhalation solution for	
nebulization .....	417
ARIKAYCE .....	24
armodafinil .....	207
arsenic trioxide intravenous solution .....	417
ASPARLAS .....	25
ASSURE ID INSULIN SAFETY	
SYRINGE 1 ML 29 GAUGE X 1/2 .....	80
AUGTYRO .....	27
AVONEX INTRAMUSCULAR PEN	
INJECTOR KIT .....	28
AVONEX INTRAMUSCULAR SYRINGE	
KIT .....	28
AYVAKIT .....	29
azacitidine injection recon soln .....	417
azathioprine oral tablet 50 mg .....	417
azathioprine sodium injection recon soln	417
azithromycin intravenous .....	20, 21
aztreonam .....	20, 21
<b>B</b>	
BALVERSA .....	30
BAVENCIO INTRAVENOUS SOLUTION	
.....	417
BELBUCA .....	186, 187
BELEODAQ INTRAVENOUS RECON	
SOLN .....	417
BELSOMRA .....	86
bendamustine intravenous recon soln .....	417
BENDEKA INTRAVENOUS SOLUTION	
.....	417
BENLYSTA .....	31, 32, 33
benztropine oral .....	126
BESPONSIA INTRAVENOUS RECON	
SOLN .....	417
BESREMI .....	34
BETASERON SUBCUTANEOUS KIT ..	35
bexarotene .....	36, 37
BICILLIN L-A .....	20, 21
bleomycin injection recon soln .....	417
BLINCYTO INTRAVENOUS KIT .....	417

BORTEZOMIB INJECTION RECON	
SOLN 1 MG, 2.5 MG .....	417
bortezomib injection recon soln 3.5 mg..	417
bosentan .....	40
BOSULIF ORAL CAPSULE 100 MG, 400	
MG .....	41
BOSULIF ORAL TABLET 100 MG, 400	
MG, 500 MG.....	41
BRAFTOVI.....	42
BRIUMVI .....	43
BRUKINSA .....	44
budesonide inhalation suspension for	
nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1	
mg/2 ml .....	417
buprenorphine .....	186, 187
busulfan intravenous solution .....	417
BYDUREON BCISE.....	119
BYETTA SUBCUTANEOUS PEN	
INJECTOR 10 MCG/DOSE(250	
MCG/ML) 2.4 ML, 5 MCG/DOSE (250	
MCG/ML) 1.2 ML .....	119
<b>C</b>	
CABLIVI INJECTION KIT .....	46
CABOMETYX .....	47
CALQUENCE .....	48
CALQUENCE (ACALABRUTINIB MAL)	
.....	48
CAPRELSA ORAL TABLET 100 MG, 300	
MG .....	49
carboplatin intravenous solution .....	417
carglumic acid.....	50
carmustine intravenous recon soln 100 mg	
.....	417
CAYSTON.....	51
cefoxitin .....	20, 21
cefoxitin in dextrose (iso-osm) .....	20, 21
ceftazidime.....	20, 21
cefuroxime sodium injection recon soln 750	
mg .....	20, 21
cefuroxime sodium intravenous.....	20, 21
CEPROTIN (BLUE BAR).....	52
CEPROTIN (GREEN BAR).....	52
CHEMET .....	53
CIBINQO.....	54, 55
cidofovir intravenous solution .....	417
CIMERLI .....	56
CIMZIA POWDER FOR RECONST	57, 58
CIMZIA STARTER KIT.....	57, 58
CIMZIA SUBCUTANEOUS SYRINGE	
KIT 400 MG/2 ML (200 MG/ML X 2)	57,
58	
cinacalcet.....	59
CINRYZE .....	45
ciprofloxacin in 5 % dextrose .....	20, 21
cisplatin intravenous solution .....	417
cladribine intravenous solution.....	417
clindamycin in 5 % dextrose.....	20, 21
clindamycin phosphate injection.....	20, 21
CLINIMIX 4.25%/D10W SULFITE FREE	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 4.25%/D5W SULFITE FREE	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 5%/D15W SULFITE FREE	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 5%-D20W SULFITE FREE	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 6%-D5W (SULFITE-FREE)	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 8%-D10W(SULFITE-FREE)	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
CLINIMIX 8%-D14W(SULFITE-FREE)	
INTRAVENOUS PARENTERAL	
SOLUTION.....	417
clobazam oral suspension .....	60
clobazam oral tablet .....	60
clofarabine intravenous solution .....	417
clomid .....	61
clorazepate dipotassium oral tablet 15 mg,	
3.75 mg, 7.5 mg .....	125
colistin (colistimethate na).....	20, 21
COLUMVI.....	62, 63
COMETRIQ ORAL CAPSULE 100	
MG/DAY(80 MG X1-20 MG X1), 140	
MG/DAY(80 MG X1-20 MG X3), 60	
MG/DAY (20 MG X 3/DAY).....	64
COPIKTRA.....	65

COSENTYX (2 SYRINGES).....	66	decitabine intravenous recon soln.....	418
COSENTYX INTRAVENOUS.....	67	deferasirox.....	76
COSENTYX PEN.....	66	deferiprone.....	77
COSENTYX PEN (2 PENS).....	66	deferoxamine injection recon soln.....	418
COSENTYX SUBCUTANEOUS		dermacinrx lidocan.....	184
SYRINGE 150 MG/ML, 75 MG/0.5 ML		dexrazoxane hcl intravenous recon soln .	418
.....	66	DIACOMIT.....	82
COSENTYX UNOREADY PEN.....	66	diazepam injection.....	125
COTELLIC.....	68	diazepam intensol.....	125
CRESEMBA ORAL.....	69	diazepam oral concentrate.....	125
cromolyn inhalation solution for		diazepam oral solution.....	125
nebulization.....	417	diazepam oral tablet.....	125
CRYSVITA.....	70, 71	diclofenac sodium topical gel 3 %.....	307
cyclobenzaprine oral tablet 10 mg, 5 mg	127	dimethyl fumarate oral capsule, delayed	
cyclophosphamide intravenous recon soln		release(dr/ec) 120 mg, 120 mg (14)- 240	
.....	417	mg (46), 240 mg.....	83
cyclophosphamide oral capsule.....	417	dobutamine in d5w intravenous parenteral	
CYCLOPHOSPHAMIDE ORAL TABLET		solution 1,000 mg/250 ml (4,000	
.....	417	mcg/ml), 250 mg/250 ml (1 mg/ml), 500	
cyclosporine modified oral capsule.....	417	mg/250 ml (2,000 mcg/ml).....	418
cyclosporine modified oral solution.....	417	dobutamine intravenous solution.....	418
cyclosporine oral capsule.....	417	docetaxel intravenous solution.....	418
CYLTEZO(CF) PEN.....	7, 8	dopamine in 5 % dextrose intravenous	
CYLTEZO(CF) PEN CROHN'S-UC-HS7, 8		solution.....	418
CYLTEZO(CF) PEN PSORIASIS-UV ..	7, 8	dopamine intravenous solution 200 mg/5 ml	
CYLTEZO(CF) SUBCUTANEOUS		(40 mg/ml), 400 mg/10 ml (40 mg/ml)	418
SYRINGE KIT 10 MG/0.2 ML, 20		DOPTELET (10 TAB PACK).....	84
MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8		DOPTELET (15 TAB PACK).....	84
ML.....	7, 8	DOPTELET (30 TAB PACK).....	84
CYRAMZA INTRAVENOUS SOLUTION		dotti.....	130
.....	417	doxorubicin intravenous recon soln.....	418
CYSTAGON.....	73	doxorubicin intravenous solution.....	418
CYSTARAN.....	72	doxorubicin, peg-liposomal intravenous	
cytarabine (pf) injection solution.....	417	suspension.....	418
cytarabine injection solution.....	417	doxy-100.....	20, 21
<b>D</b>		doxycycline hyclate intravenous.....	20, 21
dacarbazine intravenous recon soln.....	417	dronabinol oral capsule.....	418
dactinomycin intravenous recon soln.....	417	droxidopa.....	85
dalfampridine.....	74	DUPIXENT PEN SUBCUTANEOUS PEN	
DANYELZA INTRAVENOUS		INJECTOR 200 MG/1.14 ML, 300 MG/2	
SOLUTION.....	417	ML.....	87
DARZALEX INTRAVENOUS SOLUTION		DUPIXENT SYRINGE SUBCUTANEOUS	
.....	417	SYRINGE 100 MG/0.67 ML, 200	
daunorubicin intravenous solution.....	418	MG/1.14 ML, 300 MG/2 ML.....	87
DAURISMO ORAL TABLET 100 MG, 25		<b>E</b>	
MG.....	75	ELAPRASE.....	88



ELIGARD.....	121	estradiol transdermal patch weekly.....	130
ELIGARD (3 MONTH).....	121	estradiol-norethindrone acet.....	130
ELIGARD (4 MONTH).....	121	ETOPOPHOS INTRAVENOUS RECON	
ELIGARD (6 MONTH).....	121	SOLN .....	418
ELREXFIO .....	89	etoposide intravenous solution.....	418
ELZONRIS INTRAVENOUS SOLUTION		everolimus (antineoplastic) oral tablet....	103
.....	418	everolimus (antineoplastic) oral tablet for	
EMGALITY PEN.....	90	suspension 2 mg, 3 mg, 5 mg.....	103
EMGALITY SYRINGE		everolimus (immunosuppressive) oral tablet	
SUBCUTANEOUS SYRINGE 120		.....	418
MG/ML.....	90	EYLEA .....	104
EMPLICITI INTRAVENOUS RECON		<b>F</b>	
SOLN .....	418	FABRAZYME.....	105
ENBREL MINI.....	91, 92	FASENRA PEN.....	106
ENBREL SUBCUTANEOUS SOLUTION		FASENRA SUBCUTANEOUS SYRINGE	
.....	91, 92	10 MG/0.5 ML, 30 MG/ML .....	106
ENBREL SUBCUTANEOUS SYRINGE91,		fentanyl citrate buccal lozenge on a handle	
92		.....	354
ENBREL SURECLICK.....	91, 92	fentanyl transdermal patch 72 hour 100	
ENGERIX-B (PF) INTRAMUSCULAR		mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr,	
SUSPENSION .....	418	75 mcg/hr .....	352, 353
ENGERIX-B (PF) INTRAMUSCULAR		fingolimod.....	107
SYRINGE .....	418	FINTEPLA.....	108
ENGERIX-B PEDIATRIC (PF)		FIRMAGON KIT W DILUENT SYRINGE	
INTRAMUSCULAR SYRINGE.....	418	.....	109
ENTYVIO.....	94, 95	floxuridine injection recon soln .....	418
ENVARBUS XR ORAL TABLET		fluconazole in nacl (iso-osm).....	22
EXTENDED RELEASE 24 HR .....	418	fludarabine intravenous recon soln .....	418
EPIDIOLEX.....	96	fludarabine intravenous solution.....	418
epirubicin intravenous solution 200 mg/100		fluorouracil intravenous solution .....	418
ml .....	418	formoterol fumarate inhalation solution for	
EPKINLY .....	97	nebulization.....	418
EPRONTIA.....	351	FOTIVDA .....	110
ERBITUX INTRAVENOUS SOLUTION		FRUZAQLA ORAL CAPSULE 1 MG, 5	
.....	418	MG .....	111
eribulin intravenous solution.....	418	FULPHILA .....	112
ERIVEDGE.....	100	fulvestrant intramuscular syringe.....	418
ERLEADA ORAL TABLET 240 MG, 60		FYARRO .....	113
MG .....	101	fyavolv .....	130
erlotinib oral tablet 100 mg, 150 mg, 25 mg		<b>G</b>	
.....	102	gabapentin oral tablet extended release 24 hr	
ertapenem.....	20, 21	300 mg, 600 mg .....	122
ERWINASE INJECTION RECON SOLN		ganciclovir sodium intravenous recon soln	
.....	418	.....	418
estradiol oral.....	130	ganciclovir sodium intravenous solution	418
estradiol transdermal patch semiweekly .	130	GATTEX 30-VIAL.....	114

GATTEX ONE-VIAL .....	114	MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML.....	7, 8
GAUZE PAD TOPICAL BANDAGE 2 X 2 .....	79	HUMIRA(CF) PEN (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML..	7, 8
GAVRETO .....	115	HUMIRA(CF) PEN CROHNS-UC-HS (PREFERRED NDCS STARTING WITH 00074) .....	7, 8
GAZYVA INTRAVENOUS SOLUTION .....	418	HUMIRA(CF) PEN PEDIATRIC UC (PREFERRED NDCS STARTING WITH 00074) .....	7, 8
gefitinib .....	116	HUMIRA(CF) PEN PSOR-UV-ADOL HS (PREFERRED NDCS STARTING WITH 00074) .....	7, 8
gemcitabine intravenous recon soln.....	418	hydromorphone oral tablet extended release 24 hr .....	186, 187
gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) .....	418	hydroxyzine hcl oral tablet.....	128
GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML .....	418	<b>I</b>	
gengraf oral capsule .....	418	ibandronate intravenous .....	38, 39
gengraf oral solution .....	418	IBRANCE .....	131, 132
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml.....	20, 21	icatibant.....	133
gentamicin injection solution 40 mg/ml ..	20, 21	ICLUSIG.....	134
gentamicin sulfate (ped) (pf).....	20, 21	idarubicin intravenous solution.....	418
GILOTRIF .....	117	IDHIFA.....	135
glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml .....	118	ifosfamide intravenous recon soln .....	418
glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml .....	118	ifosfamide intravenous solution.....	418
glutamine (sickle cell).....	93	ILARIS (PF).....	136, 137
granisetron hcl oral tablet.....	418	imatinib oral tablet 100 mg, 400 mg	138, 139
<b>H</b>		IMBRUVICA ORAL CAPSULE 140 MG, 70 MG .....	140
HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE .....	418	IMBRUVICA ORAL SUSPENSION.....	140
HIZENTRA SUBCUTANEOUS SOLUTION.....	418	IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG.....	140
HIZENTRA SUBCUTANEOUS SYRINGE .....	418	IMDELLTRA .....	141
HUMIRA (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML .....	7, 8	IMFINZI INTRAVENOUS SOLUTION	418
HUMIRA PEN (PREFERRED NDCS STARTING WITH 00074).....	7, 8	imipenem-cilastatin.....	20, 21
HUMIRA(CF) (PREFERRED NDCS STARTING WITH 00074) SUBCUTANEOUS SYRINGE KIT 10		IMJUDO .....	142, 143
		INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE .....	144
		INGREZZA.....	145
		INGREZZA INITIATION PK(TARDIV) .....	145
		INGREZZA SPRINKLE .....	145
		INLYTA ORAL TABLET 1 MG, 5 MG	147
		INPEFA.....	148

INQOVI .....	149	KOSELUGO .....	169, 170
INREBIC.....	150	KRAZATI.....	171
INSULIN SYRINGE-NEEDLE U-100		KYPROLIS INTRAVENOUS RECON	
SYRINGE 0.3 ML 29 GAUGE, 1 ML 29		SOLN .....	418
GAUGE X 1/2.....	81	<b>L</b>	
intralipid intravenous emulsion 20 % .....	418	lanreotide subcutaneous syringe 120 mg/0.5	
ipratropium bromide inhalation solution	418	ml .....	172, 173
ipratropium-albuterol inhalation solution for		lapatinib.....	174, 175
nebulization.....	418	LEDIPASVIR-SOFOSBUVIR.....	176
irinotecan intravenous solution .....	418	lenalidomide.....	177, 178
ISTODAX INTRAVENOUS RECON		LENVIMA ORAL CAPSULE 10 MG/DAY	
SOLN .....	418	(10 MG X 1), 12 MG/DAY (4 MG X 3),	
ivermectin oral .....	151	14 MG/DAY(10 MG X 1-4 MG X 1), 18	
IWILFIN .....	153	MG/DAY (10 MG X 1-4 MG X2), 20	
IXEMPRA INTRAVENOUS RECON		MG/DAY (10 MG X 2), 24 MG/DAY(10	
SOLN .....	418	MG X 2-4 MG X 1), 4 MG, 8 MG/DAY	
<b>J</b>		(4 MG X 2).....	179, 180
JAKAFI.....	154, 155	leuprolide subcutaneous kit.....	121
JAYPIRCA ORAL TABLET 100 MG, 50		levofloxacin in d5w.....	20, 21
MG .....	156, 157	levofloxacin intravenous.....	20, 21
JEMPERLI.....	158, 159	levoleucovorin calcium intravenous recon	
JEVTANA INTRAVENOUS SOLUTION		soln.....	418
.....	418	levoleucovorin calcium intravenous solution	
jinteli .....	130	.....	419
JYLAMVO ORAL SOLUTION.....	418	LIBERVANT.....	181
JYNNEOS (PF) SUBCUTANEOUS		LIBTAYO .....	182, 183
SUSPENSION .....	418	lidocaine topical adhesive patch,medicated 5	
<b>K</b>		% .....	184
KADCYLA.....	160	lidocan iii .....	184
KALYDECO.....	161	lidocan iv.....	184
KANUMA.....	162	lidocan v.....	184
KERENDIA .....	163, 164	lincomycin.....	20, 21
KESIMPTA PEN .....	165	linezolid in dextrose 5%.....	20, 21
KEYTRUDA.....	166	linezolid-0.9% sodium chloride .....	20, 21
KHAPZORY INTRAVENOUS RECON		LIVTENCITY.....	185
SOLN 175 MG.....	418	LONSURF .....	188
KIMMTRAK INTRAVENOUS		LOQTORZI.....	189
SOLUTION.....	418	lorazepam injection solution.....	125
KISQALI FEMARA CO-PACK ORAL		lorazepam injection syringe 2 mg/ml.....	125
TABLET 200 MG/DAY(200 MG X 1)-		lorazepam intensol .....	125
2.5 MG, 400 MG/DAY(200 MG X 2)-2.5		lorazepam oral concentrate .....	125
MG, 600 MG/DAY(200 MG X 3)-2.5		lorazepam oral tablet 0.5 mg, 1 mg, 2 mg	
MG .....	167	.....	125
KISQALI ORAL TABLET 200 MG/DAY		LORBRENA ORAL TABLET 100 MG, 25	
(200 MG X 1), 400 MG/DAY (200 MG X		MG .....	190
2), 600 MG/DAY (200 MG X 3).....	167		

LUMAKRAS ORAL TABLET 120 MG,  
320 MG ..... 191  
LUMIZYME ..... 192  
LUNSUMIO ..... 193  
LUPRON DEPOT..... 194, 195  
lyllana..... 130  
LYNPARZA ..... 196, 197  
LYTGOBI ORAL TABLET 12 MG/DAY  
(4 MG X 3), 16 MG/DAY (4 MG X 4),  
20 MG/DAY (4 MG X 5) ..... 198

**M**

MARGENZA INTRAVENOUS  
SOLUTION..... 419  
MAVYRET ORAL PELLETS IN PACKET  
..... 199  
MAVYRET ORAL TABLET..... 199  
megestrol oral suspension 400 mg/10 ml (10  
ml), 400 mg/10 ml (40 mg/ml), 625 mg/5  
ml (125 mg/ml) ..... 200  
megestrol oral tablet..... 200  
MEKINIST ORAL RECON SOLN 201, 202  
MEKINIST ORAL TABLET 0.5 MG, 2  
MG ..... 201, 202  
MEKTOVI ..... 203  
melphalan hcl intravenous recon soln.... 419  
memantine oral capsule,sprinkle,er 24hr 204  
memantine oral solution..... 204  
memantine oral tablet..... 204  
MEPSEVII ..... 205  
meropenem intravenous recon soln 1 gram,  
500 mg ..... 20, 21  
mesna intravenous solution..... 419  
methadone intensol ..... 186, 187  
methadone oral concentrate ..... 186, 187  
methadone oral solution 10 mg/5 ml, 5 mg/5  
ml ..... 186, 187  
methadone oral tablet 10 mg, 5 mg. 186, 187  
methadose oral concentrate..... 186, 187  
methotrexate sodium (pf) injection recon  
soln..... 419  
methotrexate sodium (pf) injection solution  
..... 419  
methotrexate sodium injection solution .. 419  
methotrexate sodium oral tablet..... 419  
methylergonovine oral ..... 206  
methylprednisolone oral tablet..... 419

metro i.v. .... 20, 21  
metronidazole in nacl (iso-osm)..... 20, 21  
metyrosine..... 255  
mifepristone oral tablet 300 mg ..... 168  
milrinone in 5 % dextrose intravenous  
piggyback..... 419  
milrinone intravenous solution ..... 419  
mimvey ..... 130  
mitomycin intravenous recon soln ..... 419  
mitoxantrone intravenous concentrate .... 419  
modafinil oral tablet 100 mg, 200 mg..... 207  
MONJUVI..... 208  
morphine oral tablet extended release.... 186,  
187  
MOUNJARO ..... 119  
moxifloxacin-sod.chloride(iso)..... 20, 21  
mycophenolate mofetil (hcl) intravenous  
recon soln..... 419  
mycophenolate mofetil oral capsule ..... 419  
mycophenolate mofetil oral suspension for  
reconstitution..... 419  
mycophenolate mofetil oral tablet ..... 419  
mycophenolate sodium oral tablet,delayed  
release (dr/ec)..... 419  
MYFEMBREE..... 209  
MYHIBBIN ORAL SUSPENSION ..... 419  
MYLOTARG INTRAVENOUS RECON  
SOLN ..... 419

**N**

nafcillin in dextrose (iso-osm) intravenous  
piggyback 2 gram/100 ml ..... 20, 21  
nafcillin injection ..... 20, 21  
NAGLAZYME ..... 210  
NAMZARIC ..... 204  
NAYZILAM..... 211  
nelarabine intravenous solution ..... 419  
NERLYNX ..... 212  
NEXLETOL..... 213, 214  
NEXLIZET ..... 215, 216  
nilutamide ..... 217  
NINLARO..... 218  
nitisinone..... 219  
nitroglycerin in 5 % dextrose intravenous  
solution 100 mg/250 ml (400 mcg/ml), 25  
mg/250 ml (100 mcg/ml), 50 mg/250 ml  
(200 mcg/ml)..... 419

nitroglycerin intravenous solution .....	419	ORENCIA SUBCUTANEOUS SYRINGE	
NIVESTYM.....	220	125 MG/ML, 50 MG/0.4 ML, 87.5	
norethindrone ac-eth estradiol oral tablet		MG/0.7 ML .....	242
0.5-2.5 mg-mcg, 1-5 mg-mcg .....	130	ORGOVYX.....	245
NUBEQA.....	223	ORKAMBI ORAL GRANULES IN	
NUCALA SUBCUTANEOUS AUTO-		PACKET .....	246
INJECTOR.....	224, 225	ORKAMBI ORAL TABLET .....	246
NUCALA SUBCUTANEOUS RECON		ORSERDU ORAL TABLET 345 MG, 86	
SOLN .....	224, 225	MG .....	247
NUCALA SUBCUTANEOUS SYRINGE		OTEZLA .....	248
100 MG/ML, 40 MG/0.4 ML .....	224, 225	OTEZLA STARTER ORAL	
NUDEXTA.....	226	TABLETS,DOSE PACK 10 MG (4)- 20	
NULOJIX INTRAVENOUS RECON		MG (51), 10 MG (4)-20 MG (4)-30 MG	
SOLN .....	419	(47).....	248
NUPLAZID.....	227	oxacillin.....	20, 21
NURTEC ODT .....	228	oxacillin in dextrose(iso-osm).....	20, 21
NYVEPRIA .....	229	oxaliplatin intravenous recon soln .....	419
<b>O</b>		oxaliplatin intravenous solution.....	419
OCALIVA.....	230	OXERVATE.....	249
octreotide acetate .....	231	OXYCONTIN ORAL TABLET,ORAL	
ODOMZO .....	232	ONLY,EXT.REL.12 HR 10 MG, 15 MG,	
OFEV .....	233	20 MG, 30 MG, 40 MG, 60 MG, 80 MG	
OGSIVEO ORAL TABLET 100 MG, 150		.....	186, 187
MG, 50 MG.....	234	OZEMPIC SUBCUTANEOUS PEN	
OJEMDA ORAL SUSPENSION FOR		INJECTOR 0.25 MG OR 0.5 MG (2	
RECONSTITUTION .....	235	MG/3 ML), 1 MG/DOSE (4 MG/3 ML),	
OJEMDA ORAL TABLET 400 MG/WEEK		2 MG/DOSE (8 MG/3 ML) .....	119
(100 MG X 4), 500 MG/WEEK (100 MG		<b>P</b>	
X 5), 600 MG/WEEK (100 MG X 6) .	235	paclitaxel intravenous concentrate.....	419
OJJAARA .....	236	PADCEV.....	250
OMNITROPE .....	123, 124	PANRETIN.....	251
ONCASPAR INJECTION SOLUTION.	419	paraplatin intravenous solution.....	419
ondansetron hcl oral solution .....	419	pazopanib .....	382, 383
ondansetron hcl oral tablet 4 mg, 8 mg...	419	PEMAZYRE.....	252
ondansetron oral tablet,disintegrating 4 mg,		pemetrexed disodium intravenous recon soln	
8 mg .....	419	.....	419
ONIVYDE INTRAVENOUS DISPERSION		PEN NEEDLE, DIABETIC NEEDLE 29	
.....	419	GAUGE X 1/2.....	80
ONUREG .....	237	penicillamine oral tablet.....	253
OPDIVO .....	238	PENICILLIN G POT IN DEXTROSE	
OPDUALAG.....	239	INTRAVENOUS PIGGYBACK 2	
OPSUMIT .....	240	MILLION UNIT/50 ML, 3 MILLION	
OPSYNVI .....	241	UNIT/50 ML .....	20, 21
ORENCIA (WITH MALTOSE).....	243, 244	penicillin g potassium .....	20, 21
ORENCIA CLICKJECT.....	242	penicillin g sodium.....	20, 21
		pentamidine inhalation recon soln .....	419

PERJETA INTRAVENOUS SOLUTION	
.....	419
pfizerpen-g .....	20, 21
phenobarbital.....	129
pimecrolimus.....	349
PIQRAY ORAL TABLET 200 MG/DAY	
(200 MG X 1), 250 MG/DAY (200 MG	
X1-50 MG X1), 300 MG/DAY (150 MG	
X 2) .....	257
pirfenidone oral capsule.....	258
pirfenidone oral tablet 267 mg, 801 mg..	258
PLEGRIDY INTRAMUSCULAR .....	259
PLEGRIDY SUBCUTANEOUS PEN	
INJECTOR 125 MCG/0.5 ML, 63	
MCG/0.5 ML- 94 MCG/0.5 ML.....	259
PLEGRIDY SUBCUTANEOUS SYRINGE	
125 MCG/0.5 ML, 63 MCG/0.5 ML- 94	
MCG/0.5 ML .....	259
PLENAMINE INTRAVENOUS	
PARENTERAL SOLUTION.....	419
plerixafor subcutaneous solution .....	419
POLIVY .....	260
POMALYST .....	261
PORTRAZZA INTRAVENOUS	
SOLUTION.....	419
posaconazole oral tablet,delayed release	
(dr/ec).....	262
POTELIGEO.....	263
PRALATREXATE INTRAVENOUS	
SOLUTION.....	419
PREHEVBRIO (PF) INTRAMUSCULAR	
SUSPENSION .....	419
premasol 10 % intravenous parenteral	
solution.....	419
PREVYMIS INTRAVENOUS.....	264
PREVYMIS ORAL .....	264
PRIVIGEN.....	152
PROCRIT.....	98, 99
PROGRAF INTRAVENOUS SOLUTION	
.....	419
PROGRAF ORAL GRANULES IN	
PACKET .....	419
PROLASTIN-C INTRAVENOUS	
SOLUTION.....	17
PROLIA .....	265, 266
PROMACTA .....	267
promethazine oral.....	128
PULMOZYME INHALATION	
SOLUTION.....	419
pyrimethamine .....	268
<b>Q</b>	
QINLOCK.....	269
QULIPTA .....	270
<b>R</b>	
RADICAVA ORS.....	271
RADICAVA ORS STARTER KIT SUSP	
.....	271
RECOMBIVAX HB (PF)	
INTRAMUSCULAR SUSPENSION. 419	
RECOMBIVAX HB (PF)	
INTRAMUSCULAR SYRINGE.....	419
RELEUKO SUBCUTANEOUS.....	274
REMICADE.....	275, 276
REPATHA .....	279
REPATHA PUSHTRONEX.....	279
REPATHA SURECLICK.....	279
RETACRIT .....	98, 99
RETEVMO ORAL CAPSULE 40 MG, 80	
MG .....	280
RETEVMO ORAL TABLET 120 MG, 160	
MG, 40 MG, 80 MG .....	280
REVLIMID .....	177, 178
REZDIFFRA.....	281
REZLIDHIA .....	282
REZUROCK .....	283
riluzole .....	284
RINVOQ LQ.....	286
RINVOQ ORAL TABLET EXTENDED	
RELEASE 24 HR 15 MG, 30 MG, 45	
MG .....	285
roflumilast.....	287
romidepsin intravenous recon soln .....	419
ROZLYTREK ORAL CAPSULE 100 MG,	
200 MG .....	288
ROZLYTREK ORAL PELLETS IN	
PACKET .....	288
RUBRACA .....	289, 290
rufinamide.....	291
RUXIENCE .....	292
RYBELSUS .....	119
RYBREVANT .....	293
RYDAPT.....	294

RYLAZE INTRAMUSCULAR SOLUTION.....	419	SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3).....	312, 313
RYTELO.....	295	SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG	314
<b>S</b>		STELARA INTRAVENOUS .....	317
sajazir .....	133	STELARA SUBCUTANEOUS SOLUTION.....	315, 316
SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON .....	296	STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .....	315, 316
sapropterin.....	297	STIVARGA .....	318, 319
SARCLISA .....	298	STRENSIQ .....	320
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG.....	299	STREPTOMYCIN .....	20, 21
SIGNIFOR .....	300	SUCRAID.....	321
sildenafil (pulmonary arterial hypertension) intravenous solution 10 mg/12.5 ml....	256	sulfamethoxazole-trimethoprim intravenous .....	20, 21
sildenafil (pulmonary arterial hypertension) oral tablet 20 mg .....	256	sunitinib malate.....	322, 323
SIMULECT INTRAVENOUS RECON SOLN .....	419	SYMDEKO.....	324
sirolimus oral solution.....	419	SYMLINPEN 120.....	325
sirolimus oral tablet.....	419	SYMLINPEN 60.....	325
SIRTURO .....	301	SYMPAZAN.....	60
SKYRIZI INTRAVENOUS .....	304, 305	<b>T</b>	
SKYRIZI SUBCUTANEOUS PEN INJECTOR.....	302, 303	TABRECTA .....	326
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML .....	302, 303	tacrolimus oral capsule .....	419
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) .....	302, 303	tacrolimus topical.....	349
sodium nitroprusside intravenous solution .....	419	tadalafil (pulm. hypertension).....	256
SODIUM OXYBATE (PREFERRED NDCS STARTING WITH 00054) .....	400	tadalafil oral tablet 2.5 mg, 5 mg .....	327
sodium phenylbutyrate.....	254	TAFINLAR ORAL CAPSULE .....	329, 330
SOFOSBUVIR-VELPATASVIR.....	306	TAFINLAR ORAL TABLET FOR SUSPENSION .....	329, 330
SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML, 90 MG/0.3 ML .....	172, 173	TAGRISO.....	331
SOMAVERT.....	308	TALVEY.....	332
sorafenib.....	309, 310	TALZENNA .....	333
SOTYKTU .....	311	TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG.....	334, 335
		tazarotene topical cream .....	336
		tazarotene topical gel .....	336
		tazicef.....	20, 21
		TAZVERIK.....	337
		TECENTRIQ INTRAVENOUS SOLUTION.....	419
		TECVAYLI.....	338
		TEFLARO.....	20, 21
		TEMODAR INTRAVENOUS RECON SOLN .....	419
		temsirolimus intravenous recon soln .....	419

TEPMETKO .....	339	TREMFYA SUBCUTANEOUS AUTO-INJECTOR.....	356
teriflunomide.....	26	TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML.....	356
TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML).....	340, 341	treprostinil sodium .....	277, 278
testosterone cypionate.....	146	tretinoin topical.....	350
testosterone enanthate .....	146	tridacaine ii.....	184
testosterone transdermal gel.....	221, 222	tridacaine iii .....	184
testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %).....	221, 222	trientine oral capsule 250 mg.....	357, 358
testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram), 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram) .....	221, 222	TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL .....	359
testosterone transdermal solution in metered pump w/app.....	221, 222	TRIKAFTA ORAL TABLETS, SEQUENTIAL.....	359
tetrabenazine oral tablet 12.5 mg, 25 mg	342	TRODELVY .....	360
THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG .....	343, 344	TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION.....	420
thiotepa injection recon soln .....	419	TRULICITY .....	119
TIBSOVO .....	345	TRUQAP.....	361
TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION .....	419	TUKYSA ORAL TABLET 150 MG, 50 MG .....	362
tigecycline .....	20, 21	TURALIO ORAL CAPSULE 125 MG..	363
TIVDAK .....	346	TYENNE AUTOINJECTOR.....	3, 4
tobramycin in 0.225 % nacl .....	347	TYENNE INTRAVENOUS .....	364, 365
tobramycin inhalation .....	347	TYENNE SUBCUTANEOUS.....	3, 4
tobramycin sulfate injection recon soln ...	20, 21	TYVASO INHALATION SOLUTION FOR NEBULIZATION .....	420
tobramycin sulfate injection solution..	20, 21	TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION .....	420
tolvaptan.....	348	TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION .	420
topiramate oral capsule, sprinkle .....	351	TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION .	420
topiramate oral tablet .....	351	<b>U</b>	
topotecan intravenous recon soln.....	419	UBRELVY.....	366
topotecan intravenous solution .....	419	UNITUXIN INTRAVENOUS SOLUTION .....	420
torpenz.....	103	UPTRAVI ORAL TABLET.....	367
travasol 10 % intravenous parenteral solution.....	420	UPTRAVI ORAL TABLETS,DOSE PACK .....	367
TRAZIMERA INTRAVENOUS RECON SOLN .....	420	<b>V</b>	
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION .....	355	VALCHLOR.....	368
		valrubicin intravesical solution.....	420
		VALTOCO .....	369
		VANCOMYCIN IN 0.9 % SODIUM CHL INTRAVENOUS PIGGYBACK 1	





GRAM/200 ML, 500 MG/100 ML, 750  
MG/150 ML ..... 20, 21  
vancomycin intravenous recon soln 1,000  
mg, 10 gram, 5 gram, 500 mg, 750 mg 20,  
21  
vancomycin oral capsule 125 mg, 250 mg  
..... 370  
VANFLYTA ..... 371  
VARUBI ORAL TABLET ..... 420  
VECTIBIX INTRAVENOUS SOLUTION  
..... 420  
veletri intravenous recon soln ..... 420  
VENCLEXTA ORAL TABLET 10 MG,  
100 MG, 50 MG..... 372  
VENCLEXTA STARTING PACK ..... 372  
VERZENIO..... 373, 374  
VIBATIV INTRAVENOUS RECON SOLN  
750 MG ..... 20, 21  
vigabatrin ..... 375  
vigadrone..... 375  
vigpoder ..... 375  
VIMIZIM ..... 376  
vinblastine intravenous solution ..... 420  
vincristine intravenous solution ..... 420  
vinorelbine intravenous solution..... 420  
VITRAKVI ORAL CAPSULE 100 MG, 25  
MG ..... 377  
VITRAKVI ORAL SOLUTION ..... 377  
VIZIMPRO ..... 378  
VONJO ..... 379  
voriconazole..... 22, 380  
VOSEVI..... 381  
VOWST ..... 384  
VUMERITY ..... 385  
VYNDAMAX..... 328  
VYXEOS INTRAVENOUS RECON SOLN  
..... 420

**W**  
WELIREG..... 386

**X**  
XALKORI ORAL CAPSULE..... 387, 388  
XALKORI ORAL PELLETT 150 MG, 20  
MG, 50 MG..... 387, 388  
XDEMVY ..... 389  
XELJANZ ORAL SOLUTION ..... 390  
XELJANZ ORAL TABLET ..... 390

XELJANZ XR ..... 390  
XERMELO ..... 391  
XGEVA SUBCUTANEOUS SOLUTION  
..... 420  
XIAFLEX ..... 392  
XIFAXAN ORAL TABLET 200 MG, 550  
MG ..... 393  
XOLAIR SUBCUTANEOUS AUTO-  
INJECTOR 150 MG/ML, 300 MG/2 ML,  
75 MG/0.5 ML ..... 394, 395  
XOLAIR SUBCUTANEOUS RECON  
SOLN ..... 394, 395  
XOLAIR SUBCUTANEOUS SYRINGE  
150 MG/ML, 300 MG/2 ML, 75 MG/0.5  
ML..... 394, 395  
XOSPATA ..... 396  
XPOVIO ..... 397, 398  
XTANDI ORAL CAPSULE..... 399  
XTANDI ORAL TABLET 40 MG, 80 MG  
..... 399

**Y**  
YERVOY INTRAVENOUS SOLUTION  
..... 420  
YONDELIS INTRAVENOUS RECON  
SOLN ..... 420  
YUFLYMA(CF) AI CROHN'S-UC-HS. 7, 8  
YUFLYMA(CF) AUTOINJECTOR  
SUBCUTANEOUS AUTO-INJECTOR,  
KIT 40 MG/0.4 ML, 80 MG/0.8 ML.. 7, 8  
YUFLYMA(CF) SUBCUTANEOUS  
SYRINGE KIT 20 MG/0.2 ML, 40  
MG/0.4 ML..... 7, 8

**Z**  
ZALTRAP INTRAVENOUS SOLUTION  
..... 420  
ZANOSAR INTRAVENOUS RECON  
SOLN ..... 420  
ZEJULA ORAL TABLET..... 401  
ZELBORAF..... 402, 403  
ZEPOSIA ..... 404  
ZEPOSIA STARTER KIT (28-DAY).... 404  
ZEPOSIA STARTER PACK (7-DAY).. 404  
ZEPZELCA..... 405  
ZIRABEV INTRAVENOUS SOLUTION  
..... 420  
ZOLADEX..... 120



zoledronic acid intravenous solution .....	420
zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml .....	420
zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml .....	272, 273
ZOLINZA .....	406
ZONISADE.....	351
zonisamide .....	351

ZTALMY .....	407
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....	408
ZYDELIG .....	409
ZYKADIA .....	410
ZYMFENTRA .....	411, 412
ZYNLONTA.....	413
ZYNYZ.....	414



ConnectiCare, Inc. is an HMO-POS plan with a Medicare contract. ConnectiCare Insurance Company, Inc. is an HMO-POS D-SNP plan with a Medicare contract and a contract with the Connecticut Medicaid Program. Enrollment in a ConnectiCare Medicare plan depends on contract renewal. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2026.

This document includes ConnectiCare Medicare Plan's partial formulary as of January 1, 2025. For a complete, updated formulary, please visit our website at [www.connecticare.com/Medicare](http://www.connecticare.com/Medicare) or call the Member Services number below.

For alternative formats or language, please call Member Services toll free at:

ConnectiCare's Member Services at 800-224-2273. From Oct. 1 through March 31: 8 a.m. to 8 p.m., seven days a week. From April 1 through Sept. 30: 8 a.m. to 8 p.m., Monday through Saturday.

TTY users should call 711.

25285 v7